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Abstract
G protein-coupled receptor kinase 2 (GRK2) phosphorylates and desensitises 
activated G protein-coupled receptors (GPCRs). In this thesis, I identify ezrin, a 
member of the ezrin-radixin-moesin (ERM) family of actin/plasma membrane cross­
linkers, as a novel non-GPCR substrate of GRK2. GRK2 phosphorylates ezrin 
within a 53 amino acid region that encompasses the phosphorylation site required for 
ezrin activation, threonine-567. Two lines of evidence indicate that GRK2 acts as an 
effector of activated GPCRs through phosphorylation of ERM proteins. Firstly, in 
Hep2 cells muscarinic Ml receptor (MlMR) activation promotes cytoskeletal 
reorganisation and membrane ruffling. This ruffling response is ERM-dependent 
and is accompanied by ERM protein phosphorylation. Inhibition of GRK2, but not 
Rho kinase, protein kinase C or cAMP-dependent protein kinase, prevents ERM 
protein phosphorylation and membrane ruffling. Secondly, agonist-induced 
internalisation of the ^-adrenergic receptor (p2AR) and Ml MR is accompanied by 
ERM protein phosphorylation and localisation of phosphorylated ERM proteins to 
receptor-containing endosomal vesicles. The Na+/H+ exchanger regulatory factor, 
however, is not required for co-localisation of phosphorylated ERM proteins to the 
p2AR. Inhibition of ezrin function impedes p2AR internalisation, further linking 
GPCR activation, GRK activity and ezrin function. However, ERM protein 
phosphorylation does not occur following M2 muscarinic receptor (M2MR) 
activation and ERM proteins do not colocalise with internalised M2MR, suggesting 
that ERM proteins may be required for the internalisation of a subset of GPCRs. 
Overall, my results indicate that GRK2 serves not only to attenuate but also to 
transduce some GPCR-mediated signals.
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Abbreviations used in this thesis
aAR: a-adrenergic receptor
p2AR: p2 -adrenergic receptor
PARK: P-adrenergic receptor kinase
pARs: p-adrenergic receptors
Abpl: actin binding protein 1
Ach: acetylcholine
ACK: activated Cdc42-associated tyrosine kinase
ADP: adenosine diphosphate
Arf: ADP-ribosylation factor
ASK1: apoptosis signal-regulating kinase 1
ATP: adenosine triphosphate
AT1aR: angiotensin 1A receptor
BM: binding medium
Ca2+: calcium
cAMP: cyclic adenosine monophosphate
CBP: calcium-binding protein
CCPs: clathrin coated pits
CCV: clathrin-coated vesicle
C-ERMAD: carboxy-ERM association domain
cGMP: cyclic guanosine monophosphate
DMEM: Dulbecco’s Modified Eagle Medium
DNA: deoxyribonucleic acid
EEA1: Early endosome antigen 1
EGF: epidermal growth factor
ERK: extracellular signal-regulated kinase
ERM: ezrin-radixin-moesin
ETbR: endothelin B receptor
EVH1: Enabled/V ASP-1 domain
F-actin: filamentous actin
FCS: foetal calf serum
FERM: 4.1, ezrin, radixin, moesin
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G protein: GTP-binding protein
G-actin: globular actin
GAP: GTPase activating protein
GDI: guanine nucleotide dissociation inhibitor
GEF: guanine nucleotide exchange factor
GIT: GRK interactor
GPCR: G protein-coupled receptor
GRK: G protein-coupled receptor kinase
GST: glutathione S transferase
GTP: guanosine triphosphate
HiplR: Hungtingtin interacting protein 1R
hKOR: human k opioid receptor
Iso: isoproterenol
JNK3: c-Jun amino-terminal kinase 3
LAMP1: lysosomal-associated membrane protein 1
LDL: low density lipoprotein
LPA: lysophosphatidic acid
Ml MR: Ml muscarinic receptor
M2MR: M2 muscarinic receptor
M3MR: M3 muscarinic receptor
MAPK: mitogen-activated protein kinase
MEK1: MAPK/ERK kinase 1
MRCK: myotonic dystrophy kinase-related Cdc42-binding kinase
mRNA: messenger RNA
N-ERMAD: amino-ERM association domain
NHERF: Na+/H+ exchanger regulatory factor
NSF: TV-ethylmaleimide-sensitive factor
P: phosphate
PAR2: proteinase-activated receptor 2
PBS: phosphate-buffered saline
PCR: polymerase chain reaction
PDEy: Y subunit of the type 6 retinal cGMP phosphodiesterase
PDZ: PSD-95, Dig, ZO-1 homology
pERM: threonine-phosphorylated ERM proteins
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PH: pleckstrin homology
PIP: phosphatidylinositol phosphate
PIP2: phosphatidylinositol 4,5 -bisphosphate
PKA: cAMP-dependent protein kinase
PKC: protein kinase C
PMSF: phenylmethanesulfonyl fluoride
PTB: phosphotyrosine-binding domain
RGS: regulators of G protein signalling
RNA: ribonucleic acid
RNAi: RNA interference
ROS: rod outer segments
RT: room temperature
SDS: sodium dodecyl sulphate
SDS-PAGE: SDS polyacrylamide gel electrophoresis
SH3: Src homology 3
TEMED: N, N, N', N'-tetramethyl-ethylenediamine
TPP: thromboxane A2 receptor
VIPiR: vasoactive intestinal peptide 1 receptor
VSVG: vesicular stomatitis virus glycoprotein
WASP: Wiscott-Aldrich syndrome protein
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1 Introduction
G protein-coupled receptor kinase 2 (GRK2) is the most extensively characterised 
member of the G protein-coupled receptor kinases (GRKs), a family of 
serine/threonine kinases that specifically phosphorylate agonist-occupied G protein- 
coupled receptors (GPCRs) (Penela, et al., 2003). Typically, such a phosphorylation 
event leads to the binding of cytosolic parrestin proteins to the receptor, which cause 
the receptor to become uncoupled from its associated effector G protein and initiate 
the internalisation of the receptor via clathrin-mediated endocytosis (Shenoy and 
Lefkowitz, 2003). In this way, GRK-mediated phosphorylation of GPCRs is 
important in controlling their signalling activity as well as the number at the cell 
surface.
Agonist-occupied GPCRs allosterically activate GRKs and can enhance their 
phosphorylation of non-receptor substrates (Freeman et al., 2002; Haga et al., 1998; 
Pitcher et al., 1998a; Penn et al., 2000). In the case of GRK2, non-receptor 
substrates identified to date include tubulin, phosducin, ribosomal protein P2, 
synucleins, the inhibitory gamma subunit of the type 6 retinal cyclic guanosine 
monophosphate (cGMP) phosphodiesterase and the p-subunit of the epithelial Na+ 
channel (Carman et al., 1998; Dinudom et al., 2004; Freeman et al., 2002; Haga et 
al., 1998; Pitcher et al., 1998a; Pronin et al., 2000; Ruiz-Gomez et al., 2000; Wan et 
al., 2001). Parrestins have also been shown to act as molecular scaffolds for kinase 
relays downstream of GPCRs (Shenoy and Lefkowitz, 2003, see below). These 
findings have led to the hypothesis that ligand binding not only instigates receptor 
desensitisation by GRK2, but may also promote other, novel GPCR-mediated 
signalling pathways downstream of the activated GRK.
The actin cytoskeleton has previously been shown to play an important role in 
receptor endocytosis and vesicle trafficking (da Costa et al., 2003). In this thesis, I 
identify the cortical actin/plasma membrane cross-linker ezrin as a novel substrate of 
GRK2 and examine its role in GPCR-mediated actin cytoskeleton rearrangements 
and receptor endocytosis. The introduction will give a general overview on GPCRs 
and the structure and functions of GRKs (Sections 1.1 and 1.2). It will also describe 
the role of the actin cytoskeleton in receptor-mediated endocytosis and the structure
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and functions of the ezrin-radixin-moesin family of actin cross-linker proteins 
(Sections 1.3 -  1.6).
1.1 GPCRs
G protein-coupled receptors are a family of receptor proteins encoded by over 800 
genes in the human genome, whose members share similar amino acid sequences and 
a characteristic tertiary architecture of seven transmembrane-spanning-domains 
(Pierce et al., 2002). The determination of the three-dimensional crystal structure of 
the light-activated visual GPCR, rhodopsin, revealed a highly organised bundle of 
seven integral membrane a-helices linked by extracellular and cytoplasmic loops and 
it is thought that other GPCRs will display a comparable configuration (Figure 1.1 A) 
(Palczewski et al., 2000). Many types of ligands, such as hormones, chemokines, 
neurotransmitters, ions, odorants and photons of light, have been shown to bind to 
and activate various GPCRs, implicating these receptors in diverse physiological 
functions including endocrine regulation, behaviour and sensory recognition 
(Gainetdinov et al., 2004). Furthermore, the majority of pharmaceutical drugs 
manufactured today target GPCRs either directly or indirectly.
GPCRs can be grouped into three families, A, B and C, based on sequence similarity. 
The families share the overall structure of seven transmembrane helices, with over 
25% sequence homology in this core region, as well as shared motifs and conserved 
amino acids. The largest group is family A, to which most GPCR types belong, 
including rhodopsin and the olfactory receptors. Family B receptors include those 
for hormones such as calcitonin, parathyroid hormone and the gastrointestinal 
peptide hormone family. Members of family C have large extracellular amino 
termini that are required for agonist binding and receptor activation. They include 
some taste receptors, the GABAb receptor and the metabotropic glutamate receptor 
family (Pierce et al., 2002).
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Figure 1.1. Classical structure and signalling of GPCRs. A. Crystal structure o f rhodopsin determined 
to 2.8A. The dotted lines indicate the approximate position o f the plasma membrane. Adapted from 
Palczewski et al., 2000. B . Classical |32AR signalling. In the absence o f agonist, |32AR is in a low- 
affmity conformation. Agonist binding leads to a transient high-affmity receptor/agonist/G protein 
complex. The activated receptor stimulates the dissociation o f GDP from the G as-subunit and its 
replacement with GTP. This activates the Gas-subunit and causes it to detach from the fty dimer. 
Both GTP-Gas and (3y regulate separate downstream intracellular effectors. One such effector is 
adenylyl cyclase, which on activation by G TP-G as increases cytoplasmic cAMP levels, thus 
activating PKA. |32AR: p2-adrenergic receptor. C: carboxyl terminus. N: amino terminus. PKA: 
cAMP-dependent protein kinase.
16
Most GPCRs primarily signal via activation of associated heterotrimeric GTP- 
binding proteins (G proteins) comprising of a ,  (3 and y subunits (Figure 1.1B). 
Fifteen a-subunits have been identified and have been grouped into four gene 
families, G as, G ai, G aq and G a l2, all of which contain a guanine nucleotide- 
binding site and can hydrolyse GTP. The p- and y-subunits form a tightly linked 
dimer consisting of any combination of four P-subunits and fourteen y-subunits 
cloned to date (Gainetdinov et al., 2004). A fifth P-subunit, Gp5, does not associate 
with y-subunits, but instead binds to RGS proteins (Witherow and Slepak, 2003). In 
general, heterotrimeric G protein complexes are categorised by the class of a-subunit 
bound, i.e. Gs refers to a G protein heterotrimer that contains Gas.
In the absence of agonist, a GPCR and its associated G protein are considered to be 
in a low affinity state whereby the a-, p- and y-subunits of the G protein interact to 
form a heterotrimeric complex and GDP is bound to the a-subunit. Agonist- 
occupancy of the GPCR activates the receptor and leads to a transient high affinity 
agonist/receptor/G protein complex. The activated receptor stimulates the 
dissociation of GDP from the a-subunit and its replacement with GTP. This binding 
of GTP activates the a-subunit and may cause it to detach from the Py dimer: 
subsequently both GTP-a and Py regulate separate downstream intracellular effectors 
involved in various second messenger signalling pathways and ion channel 
modulation (Figure 1 .IB) (Pierce et al., 2002).
The four families of a-subunits couple to the regulation of different effectors. Gs 
subunits stimulate cAMP production by adenylyl cyclase, whereas Gi proteins inhibit 
adenylyl cyclases; Gq a-subunits activate phospholipase C-p (PLCp), which
hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate
2+and diacylglycerol and leads to an increase in intracellular Ca ; and G12 proteins 
stimulate guanine nucleotide exchange factors for the Rho family of small GTPases 
(Cabrera-Vera et al., 2003). The py subunits have been demonstrated to regulate 
adenylyl cyclases, PLCp, potassium channels, phosphatidylinositol 3-kinases, G 
protein-coupled receptor kinases and secretory granule exocytosis via binding to the 
SNARE complex (Blackmer et al., 2005; Cabrera-Vera et al., 2003). Following 
receptor and G protein activation, regulators of G protein signalling (RGS proteins)
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act to promote the hydrolysis of GTP by the a-subunits (Sierra et al., 2000). GDP-a 
reassociates with the py dimer and signalling to downstream effectors ceases.
A recent study has demonstrated that, following agonist stimulation of the p2- 
adrenergic receptor (p2AR), Gs appears to be trafficked into the cell via lipid rafts. 
The internalised G a subunit did not colocalise with the internalised p2AR, or 
endosomes and lysosomes (Allen et al., 2005). These data indicate that activated Gs, 
and possibly other Ga subunits, can enter the cell, where they may mediate 
signalling at sites distinct from the plasma membrane.
1.1.1 Mechanisms of desensitisation
Continuous activation of a GPCR leads to a reduction in its ability to signal to 
downstream pathways, a process known as desensitisation, often followed by 
internalisation of cell surface receptors. The most common immediate mechanism of 
regulating GPCR signalling is that of receptor phosphorylation. GPCRs such as the 
p2AR, the opioid receptors and the leutinising hormone receptor have additionally 
been demonstrated to undergo transcriptional and translational regulation to control 
their expression over a longer time-frame. Expression of receptors can be regulated 
by diverse mechanisms, including the action of signalling molecules such as 
chemokines and steroid hormones, as well as chromatin remodelling and histone 
acetylation. Post-transcriptional modifications involve mRNA splicing and down- 
regulation of mRNA (Collins et al., 1991; Wei and Loh, 2002; Zhang and DuFau, 
2003).
1.1.1.1 Heterologous desensitisation
Second messenger kinases such as cAMP-dependent protein kinase (PKA) and 
protein kinase C (PKC) are activated downstream of Gs and Gq respectively (Hansen 
and Cassanova, 1994; Lustig at el., 1993). These kinases participate in a negative- 
feedback loop by directly phosphorylating GPCRs and uncoupling them from their 
associated G proteins. Following activation both PKA and PKC can also 
phosphorylate other GPCRs, even those not stimulated by the particular agonist 
acting on the cell, and thus regulate the response of those receptors to an activating
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ligand (Gainetdinov et al., 2004). This process is known as heterologous 
desensitisation.
Activation of PKA via the Gs-coupled p-adrenergic receptors (PAR) leads to 
phosphorylation of the receptor by PKA and uncoupling from Gs. This 
simultaneously enhances the coupling of the pAR to Gi, which further inhibits Gs- 
mediated signalling and initiates activation of the extracellular signal-regulated 
kinase/mitogen-activated protein kinase (ERK/MAPK) pathways (Daaka et al., 
1997a; Zamah et al., 2002). This mechanism is known as signal switching and 
serves to regulate the Ga-coupling specificity of the receptor.
1.1.1.2 Homologous desensitisation
1.1.1.2.1 Uncoupling
Homologous desensitisation is mediated by G protein-coupled receptor kinases and 
arrestin proteins. GRKs are activated by and phosphorylate agonist-occupied 
GPCRs, and are discussed in detail in Section 1.2. Phosphorylation of an activated 
GPCR by a GRK promotes the binding of an arrestin adaptor protein, which 
sterically hinders (uncouples) the interaction of the receptor with its associated G 
protein (Luttrell and Lefkowitz, 2002). This serves to attenuate G protein-mediated 
second messenger signalling (Figure 1.2).
Arrestins are a family of cytosolic proteins that recognise GRK-phosphorylated, 
agonist-occupied GPCRs (Lohse et al., 1992). Visual arrestins (arrestin-1, or rod 
arrestin, and arrestin-4, or cone arrestin) are expressed in retinal cells and regulate 
phototransduction by rhodopsin and cone opsin. The non-visual arrestins (arrestin-2, 
or Parrestinl, and arrestin-3, or Parrestin2) are ubiquitously expressed in all other 
tissues and modulate the homologous desensitisation of almost all the non-visual 
GPCRs (Gainetdinov et al., 2004; Luttrell and Lefkowitz, 2002).
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Figure 1.2. Homologous desensitisation and trafficking o f GPCRs by GRK2. Agonist binding 
activates the GPCR and leads to the dissociation o f G a  and Py subunits. GRK2 is recruited to the 
agonist-occupied receptor and free Py at the plasma membrane, where it is activated. Active GRK2 
phosphorylates the GPCR carboxyl-terminus, promoting the binding of a parrestin adaptor protein. 
The recruitment o f Parrestin sterically hinders the interaction o f the receptor with the associated G 
protein. The GPCR- parrestin complex is targeted to clathrin-coated pits and internalised into acidic 
endosomal compartments. Here the GPCR is either dephosphorylated and recycled back to the 
plasma membrane or degraded. GRK2* indicates activated GRK2. P denotes a phosphate group. 
PP2A: protein phosphatase 2A.
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1.1.2 Clathrin-mediated receptor endocytosis
In addition to mediating GPCR/G protein uncoupling, arrestins promote 
internalisation of phosphorylated, activated receptors via clathrin-mediated 
endocytosis (Goodman et al., 1996). Following agonist treatment, Parrestins can be 
shown to translocate from the cytosol to phosphorylated GPCRs at the plasma 
membrane. Here they also directly bind to phosphoinositides, the heavy chain of the 
coat protein clathrin and the (3-subunit of the adaptor protein AP-2, which acts to 
enhance clathrin coat assembly and receptor recruitment to clathrin-coated pits 
(CCPs) (Gaidarov et al., 1999; Goodman et al., 1996; Laporte et al., 1999; Laporte et 
al., 2000). These interactions serve to target GPCRs to CCPs, which then undergo 
fission from the cell surface via the action of the GTPase dynamin (Scott et al., 2002; 
Zhang et al., 1996) (Figure 1.3). Internalised phosphorylated receptors are 
dephosphorylated and recycled back to the plasma membrane (resensitisation) or 
degraded (downmodulation) (Figure 1.2).
1.2 GRKs
1.2.1 Structure and function
G protein-coupled receptor kinases (GRKs) are a family of serine/threonine kinases 
originally identified by their ability to phosphorylate specifically agonist-occupied 
GPCRs. Seven mammalian GRKs have been identified to date and have been 
grouped into sub-families based on similarities in structure and function (Figure 
1.4A). These groups are:
oo GRK1, or visual GRK, subfamily
Comprises GRK1 (rhodopsin kinase) and GRK7 (cone opsin kinase) 
oo GRK2, or (3-adrenergic receptor kinase (pARK), subfamily 
Comprises GRK2 (pARKl) and GRK3 (pARK2) 
oo GRK4 subfamily 
Comprises GRK4, GRK5 and GRK6
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Parrestin
Figure 1.3. Clathrin mediated endocytosis of GPCRs. Parrestin is recruited to phosphorylated GPCRs 
at the plasma membrane, where it also binds to phosphoinositides, the heavy chain o f the coat protein 
clathrin and the p-subunit o f the adaptor protein AP-2. The interaction of parrestin with AP-2 serves 
to promote the recruitment o f phosphorylated GPCRs to clathrin coated pits (CCPs) where AP-2 
enhances clathrin coat assembly. The CCPs then undergo fission from the cell surface via the action 
of the GTPase dynamin, forming clathrin coated vesicles. The vesicles are subsequently uncoated in 
the cytosol where they fuse with the early endosome. Dyn: dynamin. P denotes a phosphate group.
Among all of the mammalian GRKs sequence homology is 53-93%, with 87% 
similarity between GRK1 members, 84% similarity between GRK2 members and 
70% similarity between GRK4 members (Hisatomi et al., 1998; Pitcher at al., 
1998b). GRKs -2, -3, -5 and -6 are ubiquitously expressed, whereas GRK-1 and -7 
are restricted to retinal cells and GRK4 is mainly found in the testes, although it has 
also been shown to function in neurons (Penela et al., 2003; Perroy et al., 2003). 
Furthermore, GRKs -4 and -6 undergo alternative splicing. GRK4 has four splice 
variants with differentially spliced exons in the amino- and carboxyl-termini and 
GRK6 has three carboxyl-terminal splice variants (Willets et al., 2003). Homologues 
exist in both Drosophila melanogaster and Caenorhabditis elegans. The Drosophila 
GPRK1 has 65% homology to bovine GRK2, D rosophila  GPRK2 has 50% 
homology to bovine GRK5, and the equivalent C. elegans proteins show 51% and 
53% homology to bovine GRK2 and GRK5 respectively (Cassill et al., 1991; Pitcher 
et al., 1998b).
GRKs share a highly conserved, centrally located catalytic domain of approximately 
263-266 amino acids that is related to PKC and PKA families (Pitcher et al., 1998b). 
The 185 amino acid amino-terminal domains of the GRKs are structurally similar 
and contain a region of homology to regulators of G protein signalling proteins (RGS 
domain) as well as sites required for regulation of kinase activity and localisation. It 
had been speculated that the amino-terminus may be important for receptor 
recognition, mainly due to the similarity in its size and structure amongst the GRKs, 
however the recently determined crystal structure of GRK2 indicates that a receptor 
may dock onto the kinase domain (Figure 1.4B) (Lodowski et al., 2003).
Conversely, the carboxyl-terminal regions of the GRKs show variety in structure and 
length (Figure 1.4A). Through either post-translational modifications or regions that 
bind lipids or membrane proteins, they function in the targeting and translocation of 
the kinases to the plasma membrane. The carboxyl-termini of the GRK1 subfamily 
are 100 amino acids in length and are isoprenylated, while those of the GRK2 
subfamily are 230 amino acids long and contain a pleckstrin homology (PH) domain 
that mediates binding to phospholipids and Gfty. Members of the GRK4 subfamily 
have a carboxyl-terminus of approximately 130 amino acids: GRKs -4 and -6 are
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palmitoylated and GRK5 has a polybasic region of positively charged amino acids 
that bind phospholipids (Penela et al., 2003; Willets et al., 2003).
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Figure 1.4. GRK structure. A. Cartoon depicting the structural organisation and key regulatory sites 
of the GRKs. Sites of protein and lipid binding are indicated above and below each kinase. The lipid 
modifications depicted are: famesylation (GRK1), geranylgeranylation (GRK7) and palmitoylation 
(GRK4 and-6). CaM: calmodulin. Clathrin: clathrin box. PH: pleckstrin homology domain. PIP2: 
phosphatidylinositol 4,5-bisphosphate. PL: phospholipid binding. RGS: regulator o f G-protein 
signalling homology domain. + indicates positively charged amino acids. B. Crystal structure of 
GRK2, adapted from Lodowski et al., 2003. N: amino terminus.
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In general, the catalytic activity of GRKs towards both receptor and non-receptor 
substrates is enhanced by agonist-occupied GPCRs (Freeman et al., 2002; Haga et 
al., 1998; Pitcher et al., 1998a; Penn et al., 2000). Although there is no known 
consensus sequence for substrates, GRKs have been demonstrated to preferentially 
phosphorylate activated GPCRs on either the third intracellular loop or the 
cytoplasmic carboxyl-terminal tail; often a pair of acidic amino acids are located at 
the amino-terminal side of the phosphorylation site (Pitcher et al., 1998b). Recently, 
the sites of GRK2 interaction on the a 2A-adrenergic receptor were located to the 
second and third intracellular loops, specifically a number of basic residues within 
three discrete regions on the third loop. Mutation of these residues inhibited both 
GRK2-mediated phosphorylation of the receptor and receptor-mediated activation of 
GRK2 (Pao and Benovic, 2005).
In order to phosphorylate a receptor the GRK must first be targeted to the plasma 
membrane, where it is allosterically activated by the agonist-occupied receptor. 
With over 800 GPCRs encoded in the genome and only seven GRKs, most of which 
have an overlapping expression profile, the activity of the GRKs must be strictly 
regulated within the cell. Consequently, a number of different mechanisms to 
control the activity, sub-cellular localisation and expression levels of the GRKs have 
arisen (Kohout and Lefkowitz, 2003).
1.2.2 Regulation of activity and localisation
1.2.2.1 GRK1 subfamily
Due to the covalent carboxyl-terminal famesylation of GRK1 and the predicted 
geranylgeranyl modification of GRK7, these kinases can associate with the plasma 
membrane on light activation of the visual GPCRs, rhodopsin or cone opsin (Kohout 
and Lefkowitz, 2003; Pitcher et al., 1998b). The activity of GRK1 is modulated by 
recoverin, a calcium-binding protein (CBP) with a similar tissue distribution (Pitcher 
et al., 1998b). Myristoylated recoverin associates with membranes, where it binds to 
the amino-terminus of GRK1 in a Ca2+-dependent manner ( I C 5 0  = 0.8pM) and 
inhibits its activity, presumably by hindering the interaction of the kinase with 
rhodopsin (Sallese et al., 2000a). Since levels of Ca2+ in the photoreceptor cell are 
high in the dark, it is predicted that recoverin would inhibit GRK1 activity until the
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cell is illuminated, leading to a reduction in the concentration of free Ca2+, 
disassociation of recoverin from GRK1 and phosphorylation of rhodopsin (Kohout 
and Lefkowitz, 2003). GRK1 also undergoes autophosphorylation at serine and 
threonine residues within the amino- and carboxyl-termini, which impairs the ability 
of the kinase to bind to phosphorylated, light-activated rhodopsin (Pitcher et al., 
1998b). This has been suggested to serve as a mechanism to release GRK1 from 
rhodopsin following desensitisation.
1.2.2.2 GRK2 subfamily
GRK2 and GRK3 are primarily cytoplasmic and briefly translocate to the plasma 
membrane on agonist-occupancy of a GPCR. This is thought to be predominantly 
due to the release of the Gpy dimer from G a following heterotrimeric G protein 
activation. GRKs -2  and -3 bind to Gpy at a site overlapping the PH domain in the 
carboxyl-terminus and possibly also via the amino-terminus (Carman et al., 2000; 
Eichmann et al., 2003). This interaction is required for localisation of GRK2 at lipid 
vesicles and phosphorylation of agonist-occupied GPCRs in vitro (Pitcher et al., 
1995; Pitcher et al., 1998b). Additionally, GRK2 was shown to require PIP2 and 
other acidic phospholipids for activity: GRK2 was unable to phosphorylate receptors 
reconstituted in 1 0 0 % phosphatidylcholine vesicles, but the presence of acidic 
phospholipids stimulated its activity (DebBurman et al., 1995; DebBurman et al., 
1996; Pitcher et al., 1995). PIP2 and Gpy were demonstrated to act synergistically to 
activate GRK2 by simultaneously binding to the PH domain (DebBurman et al., 
1996; Pitcher et al., 1995). The association was also shown to occur in intact cells 
following GPCR stimulation, which induced translocation of GRK2 to the plasma 
membrane where it co-immunoprecipitated with GPy (Daaka et al., 1997b). This 
study also demonstrated the specificity of GRK2 and GRK3 for different Gp 
subunits: G pi and Gp2 were able to bind to both GRK2 and -3, whereas Gp3 
preferentially bound GRK3 (Daaka et al., 1997b). These results agree with an earlier 
in vitro study, which further indicated that GRK2 might preferentially interact with 
Gy2 over Gy3 (Muller et al., 1993).
GRK2 and GRK3 can also be recruited to the plasma membrane via association with 
GTP-bound, active Gq/11 at their amino-terminal RGS domain. RGS domain-
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containing proteins modulate heterotrimeric G protein signal pathways by acting as 
GTPase activating proteins (GAPs) for G a subunits to promote GTP hydrolysis and 
terminate signalling (Sierra et al., 2000). GRKs -2  and -3 specifically bind Gq/11 
(Carman et al., 1999a) and the residues within the GRK2 RGS domain that are 
important for this interaction were recently identified as arginine-106, phenylalanine- 
109, aspartate-110, methionine-114, lysine-115, glutamate-116, leucine-117 and 
valine-137 (Steme-Marr et al., 2003). Mutation of these amino acids inhibited 
translocation of GRK2 to the plasma membrane but did not affect kinase activity 
(Steme-Marr et al., 2003). The GRK2 binding site of Gq has also recently been 
characterised and is localised to a helical region that contains overlapping sites for 
binding to both GRK2 and other RGS proteins (Day et al., 2004).
Although GRK2 has only weak GAP activity, it has been demonstrated to selectively 
inhibit Gq-mediated stimulation of inositol triphosphate production by PLCp 
(Carman et al., 1999a; Sallese et al., 2000b). This was not as a result of GPCR 
desensitisation since the RGS domain alone or a catalytically inactive mutant 
(G R K 2 K22or) were also able to terminate Gq signalling (Carman et al., 1999a; Sallese 
et al., 2000b). That the RGS domain of GRK2 can sequester Gq and inhibit inositol 
triphosphate production by a number of Gq-coupled receptors has led to the 
speculation that GRK2 may also mediate phosphorylation-independent 
desensitisation of GPCRs (Pao and Benovic, 2002).
The cellular localisation of GRK2 is also regulated by endocytic coat proteins. 
GRK2 associates with caveolin-rich membrane fractions and contains a 
caveolin-binding motif within its carboxyl-terminal PH domain as well as at the 
amino-terminus (Carman et al., 1999b). Caveolin-1 and -3 were demonstrated to 
significantly inhibit the catalytic activity of GRK2 (Carman et al., 1999b), suggesting 
that caveolin may function to restrict inactive GRK2 to specific membrane domains 
in order to either suppress its activity or to localise it to a particular target prior to 
activation.
Additionally, a clathrin box has been identified in the carboxyl-tail of GRK2 that 
allows the interaction of GRK2 with clathrin heavy chain (Shiina et al., 2001) and 
GRK2 has been shown to be associated with internalised GPCRs (Ruiz-Gomez and
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Mayor Jr., 1997; Schulz et al., 2002). Although the functional significance of this 
association is unknown, it is possible that GRK2 could directly mediate the 
internalisation of a subset of GPCRs (Claing et al., 2000; Shiina et al., 2001). The 
endothelin B (ETBR), vasoactive intestinal peptide 1 (VIPiR), and angiotensin 1A 
(ATjaR) GPCRs have all been shown to recruit GRK2  and to internalise via a 
Parrestin-independent mechanism, suggesting that GRK2 may act as a clathrin 
adapter in this process (Claing et al., 2000; Freedman et al., 1997; Oppermann et al., 
1996; Shetzline et al., 2002). GRK2 also brings GRK-interactor (GIT) proteins to 
parrestin-dependent GPCRs at the plasma membrane (Claing et al., 2000; Premont et 
al., 1998). GIT proteins act as GAPs towards ADP-ribosylation factors (Arfs), small 
GTPases believed to function in the recruitment of coat proteins onto membranes 
(Donaldson, 2003), suggesting a second mechanism for GRK2 to modulate GPCR 
internalisation via the clathrin pathway (Premont et al., 1998; Premont et al., 2000).
Both PKC and PKA phosphorylate GRK2 and regulate its kinase activity. PKC 
phosphorylation enhances GRK2 activity towards GPCRs and the phosphorylation 
site has been identified as serine-29, although a carboxyl-terminal site may also exist 
(Chuang et al., 1995; Krasel et al., 2000; Winstel et al., 1996). A recent study has 
suggested that this phosphorylation relieves the tonic inhibition of GRK2 by 
calmodulin and allows GRK2 to translocate to the plasma membrane (Krasel et al.,
2000). PKA in complex with the A kinase-anchoring protein AKAP79, which 
targets PKA to both the plasma membrane and the P2AR, promotes increased 
receptor phosphorylation by GRK2. Phosphorylation of serine-685 by PKA was 
shown to enhance the binding of GRK2 to G(3y at the plasma membrane (Cong et al., 
2 0 0 1 a).
GPCR stimulation can lead to activation of signalling pathways such as the 
ERK/MAPK cascades (Pierce et al., 2002). Following agonist occupancy of P2AR, 
activation of this cascade is facilitated by the interaction of the non-receptor tyrosine 
kinase c-Src with parrestin, which recruits c-Src to the plasma membrane (Luttrell et 
al., 1999; Miller et al., 2000). c-Src can phosphorylate GRK2 to increase its catalytic 
activity (Fan et al., 2001; Samago et al., 1999). The serine/threonine kinase ERK1 
has also been demonstrated to phosphorylate GRK2 in vitro, reducing its catalytic 
activity for both receptor and soluble substrates (Elorza et al., 2000; Pitcher at al.,
28
1999). Phosphorylation occurs at serine-670, which lies within the Gpy-binding 
domain (Pitcher et al., 1999), and could cause GRK2 to be released from Gpy and 
dissociate from the GPCR at the plasma membrane. Since GRK2 and ERK1 have 
been shown to associate following P2AR stimulation (Elorza et al., 2000), it has been 
suggested that ERK1 may regulate receptor desensitisation by rapidly “switching 
o ff’ GRK2 phosphorylation of P2AR after agonist binding (Kohout and Lefkowitz, 
2003).
In addition to regulation of subcellular localisation, direct association with a number 
of proteins can modulate the kinase activity of GRK2 subfamily members. Binding 
of the CBP calmodulin to sites at both the amino- and carboxyl-termini of GRK2 
inhibited the ability of GRK2 to phosphorylate rhodopsin, albeit at high 
concentrations of calmodulin (IC50 ~ 2pM) (Pronin et al., 1997). A second CBP, 
neuronal calcium sensor-1, has also been shown to interact with GRK2 and impair 
the desensitisation of the D2 dopamine receptor (Kabbani et al., 2002). The actin 
binding protein a-actinin is able to inhibit GRK2 activity (Freeman et al., 2000) and 
even intramolecular interactions have been implicated in modulation of this kinase 
(Samago et al., 2003). It is predicted that the amino- and carboxyl-termini of GRK2 
associate, leading to an inactive conformation that is also unable to translocate to the 
plasma membrane. Binding to phospholipids and proteins such as Gpy or Gq could 
cause release of the amino- and carboxyl-termini and membrane localisation 
(Samago et al., 2003).
1.2.2.3 GRK4 subfamily
Members of the GRK4 subfamily are predominantly associated with the plasma 
membrane, either via palmitoylation of the carboxyl tail (GRKs -4  and - 6 ) or, in the 
case of GRK5, through association of positively charged amino acids at the 
carboxyl-terminal with phospholipids (Kohout and Lefkowitz, 2003). GRK5 has 
also been shown to bind PIP2 at a site in the amino-terminus that is conserved in all 
GRK4 subfamily members (Pitcher at al., 1996). Phosphorylation of P2AR by 
GRK5 was increased specifically in the presence of PIP2 due to enhanced membrane 
localisation of the kinase (Pitcher et al., 1996). Although GRK4 subfamily members 
have RGS domains, their binding partners have not been identified.
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Like GRK2, GRK5 activity is downregulated by calmodulin, although GRK5 is 
more sensitive to calmodulin and associates with it at much lower concentrations 
(IC50 ~ 50nM) (Pronin et al., 1997). Calmodulin binding to sites at the amino- and 
carboxyl-termini leads to autophosphorylation of the kinase and inhibition of the 
interaction with both receptor and phospholipid (Pronin et al., 1997; Pronin et al., 
1998). The increased sensitivity of GRK5 to calmodulin implies that it would be less 
likely to desensitise Gq-coupled receptors than GRK2.
The activity of GRK5 is also modulated by phosphorylation. Following non-specific 
phospholipid stimulation, GRK5 undergoes autophosphorylation at sites distinct to 
those phosphorylated on calmodulin binding (Kunapuli et al., 1994). 
Autophosphorylation is thought to promote the association of GRK5 with agonist- 
occupied GPCRs. GRK5 is also a substrate of PKC although, in contrast to GRK2, 
its catalytic activity in vitro is inhibited following PKC-mediated phosphorylation 
(Pronin and Benovic, 1997).
The activity of GRK4 subfamily members can additionally be regulated by protein- 
protein interactions. Actin and the actin binding proteins a-actinin and spectrin 
inhibit the kinase activity of GRK5 against both GPCR and soluble substrates. 
Interestingly, calmodulin binding relieves the actin- and a-actin in -m ediated  
inhibition of soluble substrate phosphorylation, whereas PIP2 binding reduces the a - 
actinin-mediated inhibition towards receptor substrates (Freeman et al., 1998; 
Freeman et al., 2000). The co-ordinated regulation of GRK5 by these proteins and 
lipids could determine its substrate specificity under different cellular conditions.
1.2.3 Regulation of expression
GRKs are also tightly regulated at the level of their transcription and their stability 
within the cell. In vascular cells and lymphocytes, the expression of GRK2 mRNA 
is controlled by a variety of signal transduction pathways, although the precise 
mechanisms involved are unknown (Penela et al., 2003). Post-transcriptionally, 
GRK2 is polyubiquitinated and degraded by the proteasome an hour or so after
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expression in a pathway that requires parrestin and c-Src as well as GRK2 kinase 
activity (Penela et al., 2001a; Penela et al., 2003).
1.2.4 Receptor specificity and physiological roles
Identification of the particular GPCR targets phosphorylated by specific GRKs was 
originally achieved through the use of in vitro or tissue culture studies. Such work 
assessed GRK substrate specificity by utilising techniques including: purified GRKs 
acting on either rod outer segment preparations or purified receptors reconstituted 
into phospholipid vesicles; over-expression of GRKs and GPCRs in cultured cells; 
and inhibition of GRKs in vitro using antibodies or dominant negative GRK mutants 
(Pitcher et al., 1998b). Although these results gave some idea of the GRK(s) 
responsible for the desensitisation of an individual receptor, the development of 
mutant mice that lack different GRK isoforms has increased our knowledge of the 
physiological targets of a particular GRK and the role it plays in a particular tissue.
Mice lacking GRK1 expression display a prolonged response of retinal rod and cone 
cells to light and a decreased recovery rate. The light-stimulated desensitisation of 
rhodopsin is reduced (Lyubarsky et al., 2000). The importance of GRK1 in vision 
has been further demonstrated by the discovery that a congenital night blindness can 
be caused by null mutations in the gene encoding GRK1 (Yamamoto et al., 1997).
Transgenic mice homozygous for the GRK2 deletion (/3ARK1'a) have been generated 
(Jaber et al., 1996). These mice died during gestation and did not survive beyond 
embryonic day E l5.5, displaying cardiac abnormalities (Jaber et al., 1996). GRK2 
was also shown to modulate myocardial contractile function in (3ARKl+/~ mice over­
expressing the carboxyl terminus of GRK2 (PARKct), which inhibits endogenous 
GRK2 activity by competing for Gpy binding (Rockman et al., 1998). fiA R K l+/ 
/pARKct mice develop normally but have only 25% of wildtype GRK2 activity and 
show enhanced myocardial contractility in response to p-adrenergic receptor 
stimulation (Rockman et al., 1998). These studies indicate that GRK2 predominantly 
acts in the heart and modulates its function.
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Despite its homology to GRK2, deletion of GRK3 in transgenic mice leads to viable 
animals. The mice have an increase in the muscarinic receptor-mediated airway 
response to muscarinic agonist stimulation and decreased desensitisation of odorant 
receptors (Peppel et al., 1997; Walker et al., 1999). GRK3'' mice also show a 
reduced tolerance to the opioid fentanyl, suggesting that GRK3 may regulate the 
opioid receptor response to high efficacy opioids (Terman et al., 2004). Thus, 
although GRK3 shares sequence similarities with GRK2, its physiological function 
and receptor targets appear to be very different.
Mice lacking GRK5 are viable and have no developmental abnormalities, although 
they exhibit an enhanced behavioural sensitivity to muscarinic receptor stimulation 
and show reduced muscarinic receptor desensitisation in the brain (Gainetdinov et 
al., 1999). These data indicate that the M2 and M3 muscarinic receptors are the 
principal targets of GRK5 in the brain. A second study of these knockout mice 
indicated that GRK5 regulates the M2 muscarinic receptor (M2MR) in the airway 
but not the heart (Walker et al., 2004).
GRK6~~ mice show increased sensitivity to psychostimulant drugs such as 
amphetamine and cocaine and augmented signalling of dopamine D2 and D3 
receptors (Gainetdinov et al., 2003). A second study demonstrated that GRK6"A mice 
have an amplified inflammatory response following BLT1 receptor stimulation 
(Kavelaars et al., 2003). GRK6  may also play a role in regulation of chemotaxis 
since, in vitro, lymphocytes from GRK6~~ mice exhibit decreased motility in 
response to activation of the chemokine receptor CXCR4 while neutrophils from the 
same mice have enhanced chemotaxis following BLT1 or CXCR4 stimulation (Fong 
et al., 2002; Kavelaars et al., 2003; Vroon et al., 2004).
Overall it appears that, although most GRKs are ubiquitously expressed and appear 
to phosphorylate a wide range of GPCRs in vitro, the subcellular localisation, kinase 
activity and physiological function of an individual GRK is tightly regulated and its 
in vivo receptor targets restricted. However, it is has also been shown that a 
particular receptor may not be regulated by the same GRK in all tissues, such as is 
the case with the M2MR. Further studies investigating tissue-specific GRK 
knockouts or stimulating alternative GPCRs in each GRK-deficient mouse model
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should show which GRKs are active in a particular tissue or in response to different 
physiological conditions.
Recent research using RNA interference (RNAi) has indicated that the ATiAR can be 
phosphorylated by GRK2, -3, -5 and - 6  (Kim et al., 2005). Phosphorylation by 
GRK2 or -3  leads to parrestin recruitment and receptor internalisation, whereas 
phosphorylation by GRK5 or - 6  is required for parrestin-mediated ERK activation 
(Kim et al., 2005), see also Section 1.2.6.1. It therefore appears that the 
phosphorylation of the carboxyl tail of ATiAR by different GRKs can lead to distinct 
cellular outcomes. Such a mechanism of differential signalling regulation via 
phosphorylation by different GRKs may apply to other GPCRs, although further 
research is needed to identify any such receptors.
1.2.5 GRKs and disease
GPCRs regulate a large variety of vital functions within the human body. Therefore 
it is likely that, due to the role GRKs play in regulating GPCR function, disorders in 
GRK-mediated activity will contribute to or cause disease. Many studies have 
investigated the function of GRKs in heart disease. Muscarinic and adrenergic 
GPCRs are responsible for regulating homeostasis in the cardiovascular system and 
it appears that increases in GRK expression and activity are associated with different 
cardiac disorders (Rockman et al., 2002).
The desensitisation of P-adrenergic receptors (PARs) in response to persistent 
agonist signalling leads to a loss of pAR number and activity and results in chronic 
heart failure (Petrofski and Koch, 2003). Studies in animal models indicate that this 
is due to increased GRK2 (and possibly GRK5) expression and activity (Petrofski 
and Koch, 2003). Although the exact mechanisms involved are currently unknown, 
treatment with PAR blockers has been shown to reduce GRK2 expression and 
function (Koch and Rockman, 1999). Expression of the GRK2 inhibitor pARKct in 
mouse and rabbit models of human heart failure prevented progressive deterioration 
of the heart and was shown to improve survival synergistically with p-blocker 
treatment (Rockman et al., 2002). Increased GRK2 levels are also associated with 
myocardial ischaemia, hypertension, and pressure overload ventricular hypertrophy
33
(Koch and Rockman, 1999). It is possible that inhibition of GRK2 with pARKct 
could be a powerful new therapy for all of these heart disorders, although effective 
methods of gene therapy to transfer the inhibitor to affected cells have yet to be 
developed.
Changes in GRK expression levels are also associated with a number of other 
diseases. Increased GRK2 activity is concomitant with chronic morphine treatment 
and may contribute to opiate addiction and tolerance (Ozaita et al., 1998; Terwilliger 
at al., 1994), whereas decreases in GRK2, as well as GRK6 , function are seen in 
rheumatoid arthritis (Lombardi et al., 1999). GRK2 expression is significantly 
reduced in leukocytes from patients with multiple sclerosis (Vroon et al., 2005). 
Alterations in GRK2 and GRK5 expression have also been demonstrated in 
differentiated thyroid carcinoma and hypothyroidism (Metaye ct al., 2002; Penela et 
al., 2 0 0 1 b).
1.2.6 Signalling roles of the receptor desensitisation machinery
Although GRKs and parrestins were originally identified and characterised as 
essential mediators of GPCR desensitisation, it now appears that they, along with 
proteins such as GIT, also function as effectors in signalling pathways downstream 
of GPCRs.
1.2.6.1 Parrestin and ERK
As well as acting in GPCR desensitisation and internalisation, parrestins have been 
shown to play a role in initiating signals following GPCR stimulation. They can 
function as adapters for the non-receptor tyrosine kinase c-Src and scaffolds for 
MAPKs, thus initiating ERK/MAPK cascades that regulate processes including gene 
expression, cell growth and apoptosis (Figure 1.5) (Shenoy and Lefkowitz, 2003). 
Upon agonist occupancy of P2AR, parrestin binds c-Src and recruits it to the plasma 
membrane, where it phosphorylates dynamin and promotes clathrin-mediated 
receptor endocytosis (Ahn et al., 1999). parrestin-mediated recruitment of c-Src 
following stimulation of a GPCR also leads to ERK 1/2 activation via the small G 
protein Ras, the MAPK kinase kinase Raf-1 and MEK1 (MAPK/ERK kinase 1) 
(DeFea et al., 2000; Luttrell et al., 1999; Luttrell et al., 2001). parrestin acts as a
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scaffold, forming a complex with Raf-1, MEK1 and ERK (DeFea et al;., 2000; 
Luttrell et al., 2001). Stimulation of GPCRs that transiently associate with parrestins 
(class A receptors) cause nuclear translocation of ERK and activation of mitogenic 
pathways; class B receptors, which remain associated with parrestins in endosomal 
compartments, lead to retention of ERK activity in the cytosol and a decrease in the 
mitogenic response, possibly inducing alternative ERK signalling pathways such as 
cell migration (Ge et al., 2003; Shenoy and Lefkowitz, 2003).
MEK1 MKK4
response
Figure 1.5. parrestin scaffolding of MAPK cascades. Following agonist binding to the GPCR and its 
GRK-dependent phosphorylation, parrestin is recruited to the receptor, bringing it with components of 
a MAPK cascade. Association with parrestin facilitates the activation o f the kinases in the cascade, 
ultimately leading to activation of either ERK or JNK3. P: parrestin. P denotes a phosphate group.
Parrestins can also scaffold components of the MAPK-related JNK3 (c-Jun amino- 
terminal kinase 3). On ATiAR stimulation, parrestin2  forms a complex with the 
MAPK kinase kinase ASK1 (apoptosis signal-regulating kinase 1), the MAPK kinase 
MKK4 and JNK3, resulting in JNK3 activation (McDonald et al., 2000). The active 
JNK3 is retained in the cytosol, although the purpose for this is currently unknown.
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Recent research has shown that Parrestins are also important in processes such as 
chemotaxis, apoptosis and even regulation of transcription (Gao et al., 2004; Shenoy 
and Lefkowitz, 2003).
1.2.6.2 GIT
As discussed above, GIT1 was originally identified as a GAP for Arfs 1 and 6 , with a 
role in mediating GPCR endocytosis (Claing et al., 2000). As well as being recruited 
to the plasma membrane via its interaction with GRK2 (Premont et al., 1998), GIT1 
has been shown to bind to the focal adhesion adapter paxillin, and a complex of the 
Rac/Cdc42 GEF PIX and the p21 GTPase-activated protein kinase, PAK (Premont et 
al., 2000). A recent study has indicated that c-Src-phosphorylated GIT1 is associated 
with MEK 1 and is required for both ATiAR- and epidermal growth factor (EGF) 
tyrosine kinase receptor-stimulated ERK activation, possibly at focal adhesions (Yin 
et al., 2004). Combined with reports that GIT1 family members are important for 
focal adhesion turnover and cell motility (Turner et al., 1999; West et al., 2001; Zhao 
et al., 2000), these interactions suggest that, following GPCR activation, GIT1 may 
regulate the cytoskeleton as well as receptor internalisation.
1.2.7 Non-receptor substrates of GRKs
A number of non-receptor substrates have been identified for GRKs, indicating that 
they too may have additional roles within the cell. Tubulin was the first to be 
characterised. It has been shown to associate with the carboxyl-terminus of GRK2, 
which can phosphorylate tubulin with a Km of l-3pM  (Carman et al., 1998, Haga et 
al., 1998; Pitcher et al., 1998a). Furthermore, stimulation of GPCRs in vivo and in 
vitro promotes both the GRK2/tubulin interaction and the phosphorylation reaction 
(Haga et al., 1998; Pitcher et al., 1998a). GRKs -2 , -3 and -5  have also been 
demonstrated to phosphorylate phosducin and phosducin-like protein, cytosolic 
proteins that regulate heterotrimeric G protein signalling by binding Gpy (Ruiz- 
Gomez et al., 2000). Phosphorylation by GRK2 reduces the binding of phosducin to 
G(3y, suggesting that GRKs may regulate G|3y signalling following GPCR activation 
(Ruiz-Gomez et al., 2000).
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Synucleins, small lipid-binding proteins predominantly expressed in the brain, are 
phosphorylated by all GRKs (Pronin et al., 2000). Phosphorylation is enhanced in 
the presence of phospholipids and G|3y (GRK2) or phospholipids alone (GRK5), 
implying that GRKs may phosphorylate synucleins following GPCR activation. 
GRK phosphorylation hinders synuclein-mediated inhibition of phospholipase D2, 
an enzyme that stimulates endocytic vesicle formation via production of phosphatidic 
acid. Since synucleins associate with synaptic vesicles, it is possible that GRKs 
could modulate receptor endocytosis through interactions with these proteins (Pronin 
et al., 2 0 0 0 ).
GRK2 was also shown to phosphorylate the inhibitory y subunit of the type 6  retinal 
cGMP phosphodiesterase (PDEy) (Wan et al., 2001). Phosphorylation is induced 
following both thrombin G protein-coupled receptor and EGF receptor stimulation 
and leads to augmented activation of p42/p44 MAPK and association of PDEy with 
dynamin II (Wan et al., 2001). This study also indicated that GRK2 is essential for 
EGF-mediated p42/p44 MAPK stimulation. Further evidence suggests that GRK2 
may act downstream of the EGF receptor, since treatment of cells with EGF leads to 
association of GRK2 with a complex of PDEy and the MAPK activator c-Src (Wan 
et al., 2003).
The ribosomal protein P2 has been identified as a GRK2 substrate (Freeman et al., 
2002). Phosphorylation by GRK2 promotes translational activity in purified 60S 
ribosomal subunits and is enhanced following fcAR stimulation (Freeman et al., 
2002). A more recent study has shown that GRK2 can also phosphorylate the p- 
subunit of epithelial Na+ channels, causing them to become insensitive to regulation 
by ubiquitin protein ligases (Dinudom et al., 2004). These studies establish GRKs as 
potential mediators of an array of signalling pathways additional to those leading to 
GPCR desensitisation. Activation of GRKs through agonist occupation of GPCRs 
could lead to cytoskeletal rearrangement, modulation of protein translation and 
activity, facilitation of endocytosis, and participation in signalling pathways such as 
those downstream of G|3y and c-Src.
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1.3 A role for the actin cytoskeleton in GPCR 
desensitisation
1.3.1 Actin structure
The actin cytoskeleton of eukaryotic cells consists of a network of microfilaments 
that extend throughout the cytoplasm, just beneath the plasma membrane, forming 
the cell cortex. Rather than acting as a static scaffold, this microfilament network 
provides a highly adaptable and dynamic structure that undergoes constant assembly 
and disassembly. Filamentous actin (F-actin) is a two-stranded helical polymer 
created following nuclear hydrolysis of globular actin monomers (G-actin). A 
dynamic equilibrium exists between F- and G-actin, with soluble G-actin monomers 
being added to the fast growing barbed ends of microfilaments and disassembly 
occurring at the slow growing pointed ends (Figure 1.6A) (reviewed in Pollard and 
Borisy, 2003).
Arp2/3 is a 200kDa complex made up of the actin related proteins Arp-2 and -3 and 
five novel subunits designated ARPC1-5 (May, 2001). It acts as the central control 
of actin filament nucleation and branching by overcoming the energetic barrier 
involved in the formation of new actin filaments from G-actin (Figure 1.6A) (May,
2001). Arp2/3 is activated by members of the WASP (Wiscott-Aldrich syndrome 
protein) family of scaffolding proteins (Mullins, 2000). WASP family proteins are 
modular molecules able to bind to PIP2 , the small GTPase Cdc42, actin and Arp2/3 
(Figure 1.6B). In the presence of Cdc42 and PIP2 , WASP is activated and can 
stimulate the Arp2/3 complex to initiate actin polymerisation (Rohatgi et al., 1999). 
WASP proteins contain a proline-rich region and are regulated by an array of SH3 
(Src homology 3) domain-containing proteins, including intersectin and syndapins 
(da Costa et al., 2003, see below). The actin binding proteins Abpl (actin binding 
protein 1) and cortactin have been identified as alternative activators of Arp2/3 in 
yeast and mammalian cells respectively (Goode et al., 2001; Weaver et al., 2001).
The actin network is involved in many essential cell functions such as maintenance 
of cell shape, motility, attachment to the extracellular matrix and cytokinesis. 
Microfilaments form cellular structures, such as lamellipodia (thin cytoplasmic 
sheets containing arrays of microfilaments), filopodia (narrow membrane protrusions
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rich in F-actin bundles) and stress fibres (contractile actin filaments), and can 
undergo remodelling in response to both extracellular and intracellular signals. This 
reorganisation of actin filaments is highly regulated by the Rho family of small 
GTPases (Burridge and Wennerberg, 2004). By utilising the ability of the actin 
cytoskeleton to undergo dynamic changes via F-actin assembly and disassembly, a 
cell can react quickly to any change in conditions.
o G-actin
o Arp2/3
Active
WASP
pAPz0  <Cdc42 
/ \
G -actin
Figure 1.6. Actin filament nucleation by Arp2/3 and WASP. A. Active WASP binds Arp2/3 (1), and 
a G-actin monomer (2). This facilitates actin nucleation at the barbed end, elongating and branching 
F-actin (3). At the pointed end of F-actin, actin monomers dissociate and are returned to a pool 
available for F-actin nucleation (4). B . Proposed WASP activation mechanism. WASP is auto­
inhibited through binding of its GTPase binding domain (GBD) to its carboxyl terminus. Binding of 
Cdc42 and PIP2 to the GBD and basic domains leads to unmasking o f the verproline-cofilin-acidic 
(VCA) domain. The free VCA domain binds to Arp2/3 and G-actin, facilitating Arp2/3-mediated 
actin nucleation. PH: pleckstrin homology. PRD: proline-rich domain.
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1.3.2 Actin and clathrin-mediated endocytosis
The main steps of clathrin-mediated endocytosis, following cargo selection, are those 
of plasma membrane invagination and coat formation, vesicle fission, transport of 
the vesicle from the membrane, uncoating and fusion to endosomes (Figure 1.3). All 
of these stages require remodelling of actin and the cell cortex. Data from yeast 
indicate that, rather than playing a passive role, the actin cytoskeleton is directly 
involved in endocytosis. Approximately one third of the proteins implicated in 
internalisation in Sacchoromyces cerevisiae participate in actin assembly and many 
of these have mammalian homologues (Engqvist-Goldstein and Drubin, 2003).
Several mammalian proteins have been identified that associate with components of 
both the actin cytoskeleton and the endocytic machinery (Figure 1.7). Some of these 
proteins have been shown to interact directly with the clathrin coat. A splice variant 
of the actin-based motor protein myosin VI associates with the adaptor protein AP-2 
and is enriched in clathrin-coated vesicle (CCV) preparations. The localisation of 
this variant with CCVs was dependent on a large insert in the tail domain, over­
expression of which inhibited transferrin endocytosis (Buss et al., 2001). Recent 
research has also demonstrated that, in hippocampal neurons, myosin VI exists in a 
complex with AP-2 and AMPA-type glutamate receptors and that internalisation of 
AMPA-type receptors is inhibited in myosin Vi-deficient neurons (Osterweil et al., 
2005). Since myosin VI is known to move towards the pointed ends of 
microfilaments, which are oriented away from the plasma membrane, it is 
hypothesised that myosin VI could provide the force for membrane invagination or 
transporting CCVs towards the cell body (Buss et al., 2001).
Huntingtin interacting protein 1R (HiplR) is an F-actin-binding protein that co- 
localises and co-purifies with CCVs (Engqvist-Goldstein et al., 1999). The yeast 
homologue, Sla2p, is essential for both actin assembly and endocytosis (Engqvist- 
Goldstein and Drubin, 2003). In mammalian cells, H iplR  is believed to associate 
with the clathrin light chain as over-expression of the clathrin hub domain, which 
competes for binding to the light chain, caused H iplR  to dissociate from CCVs 
(Bennett et al., 2001). Furthermore, RNAi silencing studies have indicated that 
H iplR regulates the interaction between the endocytic machinery and the actin 
cytoskeleton (Engqvist-Goldstein et al., 2004).
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The adaptor protein intersectin is an SH3 domain-containing protein that can 
associate with both CCV coat components, such as AP-2 and clathrin, and other 
proteins associated with endocytosis, including dynamin and synaptojanin (da Costa 
et al., 2003). Although these interactions indicate a role for intersectin as a 
scaffolding molecule in endocytosis, a splice variant, intersectin-1, has also been 
shown to mediate actin nucleation via WASP and Cdc42 (Hussain et al., 2001, see 
below). Disruption of the association between intersectin and Cdc42 inhibited 
clathrin-mediated endocytosis of the T cell antigen receptor (McGavin et al., 2001).
Dynamin can also bind many other SH3 domain-containing proteins that are 
involved in actin remodelling (da Costa et al., 2003; Schafer, 2002). Dynamin is 
believed to primarily function as a mechano-enzyme mediating fission of a CCV 
from the plasma membrane, however it has also been associated with actin comet 
tails generated by the Listeria monocytogenes pathogen in host cells and regulation 
of the actin cytoskeleton in lamellipodia (Lee and De Camilli, 2002; McNiven et al., 
2000). It is thought that it mediates actin assembly via its interactions with proteins 
such as Abpl and cortactin, which activate Arp2/3, and syndapin, a WASP-binding 
adaptor protein that regulates actin cytoskeleton remodelling during endocytosis (da 
Costa et al., 2003; Engqvist-Goldstein and Drubin, 2003, see below). A study using 
evanescent field microscopy to visualise late stages in CCV formation demonstrated 
that the recruitment of dynamin to vesicles just prior to their translocation was 
accompanied by a transient burst of actin assembly (Merrifield et al., 2002). More 
recently, research using RNAi to suppress cortactin expression has indicated that 
both binding to Arp2/3 and actin polymerisation are necessary for cortactin to 
associate with dynamin (Zhu et al., 2005). This suggests that, following the 
recruitment of dynamin to a ligand-bound receptor, actin polymerisation by Arp2/3 
promotes the association of cortactin with dynamin. The action of cortactin would 
further increase actin polymerisation via Arp2/3 and may serve to drive the fission of 
CCVs (Zhu et al., 2005).
An additional protein that has been implicated in both clathrin-mediated endocytosis 
and actin remodelling is Arf6 . Arfs are believed to function in the recruitment of 
coat proteins onto membranes, the activation of lipid-modifying enzymes and
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remodelling of the actin cytoskeleton (Donaldson, 2003). Although active Arf6  has 
not been shown to directly recruit coat proteins to membranes, it is localised at the 
plasma membrane and has been demonstrated to stimulate PIP2 production through 
activation of phosphatidylinositol phosphate (PIP) 5-kinase, both directly and via 
phospholipase D (Cavenagh et al., 1996; Honda et al., 1999; Melendez et al., 2001). 
A localised concentration of PIP2 at the plasma membrane would lead to clathrin 
recruitment and could facilitate dynamin-induced vesicle fission (Takei and Haucke,
2001).
Both Arf6  and its guanine nucleotide exchange factor, ARNO, bind to |3arrestin2 and 
the cycle of Arf6  GTP binding and hydrolysis is required for p2AR internalisation 
(Shenoy and Lefkowitz, 2003). Arf6  has been shown to be essential for the 
endocytosis of a number of GPCRs, regardless of whether they internalise via a 
clathrin-dependent or -independent process (Houndolo et al., 2004). It is now well 
established that Arf6  modulates actin microfilaments in processes such as formation 
of membrane protrusions, membrane ruffling and migration (Donaldson, 2003), and 
it may serve as a further link between GPCR endocytosis and the actin cytoskeleton.
Although it is still unclear as to the exact role(s) of actin in mammalian clathrin- 
mediated endocytosis, one study has advanced understanding of how actin is coupled 
to endocytosis in yeast (Kaksonen et al., 2003). The study used real-time 
fluorescence microscopy to localise and track GFP-tagged proteins during the early 
stages of CCV formation. The results showed that the WASP homologue Lasl7p is 
recruited at an early stage to actin “patches” at sites of endocytosis followed by the 
HiplR homologue Sla2p, the yeast homologue of the mammalian endocytic adaptor 
Epsl5 (Panlp) and a second adaptor protein (Slalp). Actin, Abpl and the Arp2/3 
complex are then brought to the patch and slow movement of the structure is seen. 
The early components dissociate and the patch is seen to move rapidly towards the 
interior of the cell. Additionally, actin nucleation was demonstrated at the endocytic 
site (Kaksonen et al., 2003).
In yeast Lasl7p, Panlp and Abpl can activate Arp2/3, implying that actin assembly 
may be stimulated sequentially during endocytosis as these proteins are recruited. 
Since homologues exist in mammalian cells, a similar process may occur. Recent
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research has demonstrated that phosphorylation of Panlp by the Prklp kinase serves 
to inhibit Arp2/3-mediated actin polymerisation on endocytic vesicles (Toshima et 
al., 2005). This is thought to promote vesicle fusing with early endosomes as it has 
been shown that actin polymerisation must cease following internalisation to allow 
vesicle fusion (Sekiya-Kawaski et al., 2003).
Cortactin
p2/3Coat proteins
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Figure 1.7. Summary o f the protein associations between components o f the endocytic machinery 
and the actin cytoskeleton. Blue lines between proteins indicate specific interactions. Dynamin is 
thought to regulate actin assembly via Abpl and cortactin, which activate Arp2/3, and syndapin, 
which binds and regulates WASP. Intersectin can associated with AP-2, clathrin and dynamin, and 
also mediates actin nucleation via WASP. H iplR is an F-actin binding protein that co-purifies with 
clathrin coated vesicles and has been shown to regulate the interaction between the endocytic 
machinery and the actin cytoskeleton. Myosin VI associates with AP-2 and may act to facilitate 
membrane invagination or transport o f vesicles towards the cell body. Figure adapted from Schafer, 
2002.
The effect of actin-perturbing drugs on the clathrin-mediated endocytosis of 
transferrin in mammalian cells has also been investigated. The uptake of transferrin 
in a number of different cell lines grown on a variety of substrates and treated with 
either latrunculin A, cytochalasin D or jasplakinolide was examined (Fujimoto et al.,
2000). The report concluded that the requirement for actin in internalisation 
depended on cell type and growth conditions. These conclusions, together with the 
inconsistent results yielded from other studies using these drugs, have led to the 
notion that while the actin cytoskeleton does not play an obligate role in the
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internalisation of the transferrin receptor via clathrin-mediated endocytosis in 
mammalian cells, it may facilitate and regulate the process (Fujimoto et al., 2000; 
Schafer, 2002). More recent research using fluorescence microscopy has 
demonstrated that disruption of the F-actin assembly/disassembly cycle by actin- 
perturbing drugs inhibits clathrin-mediated endocytic events in mammalian cells 
(Yarar et al., 2005). The assembly and disassembly of F-actin is required for CCP 
formation, the constriction of CCVs from the plasma membrane and CCV 
internalisation. However, actin disruption inhibited the internalisation of 
approximately 80% of the CCVs and 45% of total cell surface transferrin receptor, 
indicating that mammalian cells may have alternative actin- and clathrin-independent 
endocytosis pathways (Yarar et al., 2005).
1.3.3 Rho GTPase family
The Rho family consists of 23 ubiquitous small GTPases that act as molecular 
switches to control cellular functions through regulation of the actin cytoskeleton, 
downstream of extracellular cues (Wherlock and Mellor 2002). Within the cell, 
these GTPases cycle between inactive (GDP-bound) and active (GTP-bound) 
conformations that serve as “o ff’ and “on” states in intracellular signalling pathways 
(Figure 1.8). The GTP-bound proteins activate downstream effectors until 
hydrolysis of the GTP to GDP switches the signal “o ff’.
The GTP/GDP cycling of small GTPases is highly controlled (Figure 1.8). GEFs 
(guanine nucleotide exchange factors) promote GDP release and GTP binding, while 
GAPs (GTPase-activating proteins) stimulate the hydrolysis of GTP. Both Rho 
GAPs and Rho GEFs are subject to regulation and can act upstream and downstream 
of a number of signalling pathways (Moon and Zheng, 2002; Schmidt and Hall,
2002). Rho proteins require prenylation of a carboxyl-terminal CAAX motif for 
membrane targeting and function. Inactive Rho GTPases are thought to exist in a 
complex with Rho GDIs (guanine nucleotide dissociation inhibitors), which inhibit 
GDP dissociation. GDIs have also been shown to extract Rho proteins from 
membranes, masking the prenylated tail and leading to their sequestration in the 
cytosol (Olofsson, 1999). Proteins such as the plasma membrane/actin cross-linker 
radixin (see Section 1.6) have been demonstrated to bind to RhoGDI and cause the 
displacement of Rho (Takahashi et al., 1997), suggesting that GDIs could deliver
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inactive Rho proteins to particular sites for activation by GEFs, possibly as 
components of specific signalling complexes (Olofsson, 1999; Sasaki and Takai, 
1998).
Figure 1.8. The Rho GTPase activation cycle. Within the cell, Rho GTPases cycle between inactive 
GDP-bound and active GTP-bound conformations. This cycle is highly controlled by GEFs (guanine 
nucleotide exchange factors), which promote GDP release and GTP binding, and GAPs (GTPase- 
activating proteins), which stimulate the hydrolysis of GTP. Inactive Rho GTPases are thought to 
exist in a complex with Rho GDIs (guanine nucleotide dissociation inhibitors), which inhibit GDP 
dissociation. The GTP-bound proteins activate downstream effectors until hydrolysis o f the GTP to 
GDP switches the signal “o f f ’.
Pi GTP
GDP
Effectors
45
1.3.3.1 Rho and actin cytoskeleton regulation
The most extensively characterised members of the Rho GTPase family are Rho, Rac 
and Cdc42. Initial studies with constitutively active and dominant negative forms 
indicated that they functioned to regulate remodelling of the actin cytoskeleton. Rho 
was implicated in stress fibre formation, Rac induced lamellipodia, Cdc42 promoted 
filopodia, and all three were involved in adhesion complex formation (Nobes and 
Hall, 1995; Ridley and Hall, 1992; Ridley and Hall, 1992b). Over 40 Rho family 
effectors have been identified and Rho GTPases have been found to act in a variety 
of actin-dependent processes (including migration, morphogenesis, cytokinesis and 
endocytosis), transducing extracellular cues by linking membrane receptors to actin 
remodelling in a co-ordinated fashion (Burridge and Wennerberg, 2004; Qualmann 
and Mellor, 2003; Raftopoulou and Hall 2004). Rho proteins also regulate other 
pathways such as those leading to cell polarity, cell cycle progression and 
transcription factor regulation (Bishop and Hall, 2000; Etienne-Manneville and Hall,
2002).
1.3.4 Rho GTPases in clathrin-mediated endocytosis
In the same way that the actin cytoskeleton is not strictly essential for clathrin- 
dependent endocytosis, the involvement of the Rho family of GTPases is not 
absolutely required, although they appear to regulate internalisation. Early studies 
implicated RhoA and Rac in transferrin clathrin-mediated endocytosis as expression 
of constitutively active mutants inhibited receptor internalisation and CCV budding 
(Lamaze et al., 1996). GTP-bound Rac has been demonstrated to interact with 
synaptojanin 2 and recruit it to the plasma membrane (Malecz et al., 2000). 
Following vesicle internalisation synaptojanin 2  hydrolyses PIP2 , leading to vesicle 
uncoating and endosome formation (Cremona et al., 1999). Since Rac can also 
stimulate PIP2 production by PIP 5-kinases (Ren and Schwartz, 1998), it is possible 
that Rac controls the rate of both CCV coating, at localised sites of PIP2 at the 
plasma membrane (Takei and Haucke, 2001) and uncoating, via activation of 
synaptojanin 2 .
The Rac GEF Sosl has been shown to bind to syndapins, endocytic adapter proteins 
that associate with synaptojanin (da Costa et al., 2003; Wasiak et al., 2001). 
Syndapins are also WASP binding partners and may promote Rac translocation and
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activation at the plasma membrane via interactions with Sosl, leading to localised 
PIP2 synthesis and WASP activation (Wasiak et al., 2001). A further connection 
between Rac and endocytosis may be via the Arp2/3 activator Abpl, which can bind 
both dynamin and F-actin (Kessels et al., 2001) and which localises to sites of de 
novo F-actin assembly following Rac activation (Kessels et al., 2000).
Cdc42 may play a role in clathrin-mediated endocytosis by means of its interaction 
with the endocytic adaptor protein intersectin. A splice variant of intersectin, 
intersectin-1, contains a Dbl-homology domain that imparts a GEF activity towards 
Cdc42. Binding of WASP to intersectin-1 upregulates its GEF function, promoting 
GTP-bound Cdc42 and leading to actin remodelling via WASP activation (Hussain 
et al., 2001). Expression of a mutant intersectin-1 that lacked the Dbl-homology 
domain reduced Cdc42 activation following T cell antigen receptor stimulation and 
inhibited receptor internalisation (McGavin et al., 2001). Furthermore, studies have 
shown that the Cdc42 effector ACK (activated Cdc42-associated tyrosine kinase) 
may be involved in directing the trafficking of endocytosed receptors to the lysosome 
through its interaction with sorting nexin 9, which has been demonstrated to be 
regulate dynamin activity during clathrin mediated endocytosis (Qualmann and 
Mellor, 2003, Soulet et al., 2005).
Rho has also been implicated in the regulation of traffic through early and late 
endosomes. RhoD is involved in early endosome motility, which it impedes through 
recruitment of a Diaphanous-family protein, hDia2C, and subsequent tethering of 
endosomes along actin filaments (Gasman et al., 2003). A second Rho-type protein, 
RhoB, is localised to the cytosolic surface of endosomes where it controls the 
trafficking of the epidermal growth factor receptor to the lysosome via its effector 
PRK1 kinase (Gampel et al., 1999). Consequently, Rho family GTPases may be 
involved in the regulation of clathrin-mediated internalisation during both vesicle 
formation at the plasma membrane and sorting through endocytic compartments.
1.4 Additional pathways of receptor endocytosis
Internalisation of the ETBR and VIPiR receptors has been demonstrated to be 
independent of Parrestins and dependent on dynamin, suggesting that they internalise
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via caveolae pathway (Claing et al., 2000). A number of other GPCRs and 
constituent molecules of downstream signal cascades have been localised to 
caveolae, although it is unclear as to whether these findings implicate caveolae in 
GPCR internalisation or if  they act as lipid rafts to compartmentalise particular 
signalling pathways. Additionally, the M2MR and ATiAR appear to internalise in a 
parrestin- and dynamin-independent process that may not require clathrin or caveolin 
(Claing et al., 2000; Delaney et al., 2002; Roseberry and Hosey, 2001; Zhang et al., 
1996). Internalisation of the M2MR is regulated by Arf6  (See Section 1.3.2), which 
has also been shown to regulate the clathrin-mediated endocytosis of the P2 
adrenergic and luteinising hormone/chorionic gonadotropin receptors (Claing et al., 
2001; Delaney et al., 2002; Mukherjee et al., 2002). Interestingly, internalised 
M2MR colocalises with early endosomes derived from clathrin-dependent endocytic 
pathway, indicating that two distinct mechanisms of GPCR internalisation may 
converge (Delaney et al., 2002).
1.5 Trafficking
Following internalisation into endocytic vesicles, GPCRs can be divided into two 
groups: those that are promptly recycled back to the cell surface and those that are 
more readily degraded in the lysosome (von Zastrow, 2003). The sorting of 
receptors to either the recycling or lysosomal pathways occurs in an early endosomal 
compartment and it appears that the information required for this decision is located 
in the cytoplasmic carboxyl tails of the receptors. Studies utilising chimeric 
receptors have shown that these sorting signals are transplantable and can mediate 
the recycling of a normally degraded GPCR and vice versa (Gage et al., 2001; Trejo 
and Coughlin, 1999).
One protein that may be involved in recognising such a signal is the Na+/H+ 
exchanger regulatory factor (NHERF, or EBP50). This PDZ (PSD-95, Dig, ZO-1 
homology) domain-containing protein can bind to the very carboxyl terminus of the 
p2AR and is also indirectly associated with the actin cytoskeleton via its interactions 
with ezrin-radixin-moesin (ERM) proteins (Hall et al., 1998a; Hall et al., 1998b; 
Reczek et al., 1997, see Section 1.6). Disruption of the interaction of NHERF with 
either p2AR or ERM proteins caused mis-sorting of the usually recycled receptor to
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lysosomes (Cao et al., 1999). NHERF has also been shown to regulate the 
trafficking of the human k  opioid receptor (hKOR) as over-expression of NHERF 
inhibited agonist-induced hKOR downmodulation, presumably by increasing 
receptor recycling (Li et al., 2002).
Additionally, the A-ethylmaleimide-sensitive factor (NSF) has been demonstrated to 
recognise an overlapping region of the p2AR tail as NHERF and modulate (32AR 
recycling (Cong et al., 2001b). NSF can also bind to the carboxyl tail of the D1 
dopamine receptor, which undergoes agonist-induced endocytosis and recycling 
(Heydom et al., 2004). It is unclear, however, whether NSF is necessary for p2AR 
internalisation, as a recent study has demonstrated that PDZ ligands within the 
carboxyl-termini of GPCRs are sufficient to promote receptor recycling 
independently of NSF (Gage et al., 2005). O f the three GPCR PDZ ligands 
investigated in the study, one did not bind to NHERF but still promoted efficient 
receptor recycling (Gage et al., 2005). Since p-finger motifs believed to function as 
internal PDZ ligands have been identified within the carboxyl tails of a number of 
GPCRs that are recycled to the plasma membrane following endocytosis (Paasche et 
al., 2005), it is possible that PDZ ligands represent general recycling sorting signals 
within GPCR carboxyl tails.
GPCRs that are degraded after agonist-induced internalisation also interact with 
sorting proteins. Sorting nexin 1 has been shown to associate with the protease- 
activated receptor-1 GPCR in an interaction required for targeting the receptor to 
lysosomes (Wang et al., 2002). The D5 dopamine receptor can bind sorting nexin 1 
via its carboxyl tail and, although little is known about the trafficking of D5, this 
interaction may mediate its fate following endocytosis (Heydom et al., 2004).
Ubiquitination has also been shown to act as a signal for internalisation and GPCR 
trafficking. The p 2AR, along with Parrestin, was demonstrated to be rapidly 
ubiquitinated on agonist occupancy (Shenoy et al., 2001). Ubiquitination requires 
the interaction of parrestin with an E3 ubiquitin ligase, MDM2, which catalyses the 
covalent attachment of ubiquitin to lysine residues of the substrate. A p2AR receptor 
mutant that could not be ubiquitinated was internalised but not degraded efficiently
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and ubiquitination of Parrestin was shown to be necessary for receptor internalisation 
(Shenoy et al., 2001). Ubiquitination was also shown to be important for lysosomal 
degradation of the CXCR4 chemokine receptor (Marchese and Benovic, 2002). 
Transmembrane proteins that are ubiquitinated are sorted into multivesicular 
endosomes via a succession of proteins including the ubiquitin-binding protein 
Hrs/Vps27, from where they are trafficked to the lysosome (reviewed in Raiborg et 
al., 2003).
Parrestins may have a further role in modulating the recycling of internalised 
GPCRs. Some receptors, such as the P2AR, D1 dopamine receptor, endothelin A 
receptor and \i opioid receptor, recycle rapidly (class A receptors) while others, such 
as the ATiAR, vasopressin 2 receptor and substance-P receptor, recycle slowly (class 
B receptors). The association of Parrestins with class A receptors is transient and 
only occurs at the plasma membrane. In contrast, parrestins have a more prolonged 
interaction with class B receptors and are trafficked with them to endosomal vesicles 
(Pierce et al., 2002).
Hence, desensitisation and internalisation are important processes for regulating the 
signalling capabilities of GPCRs. Many different mechanisms exist to control 
endocytosis and subsequent sorting of receptors back to the plasma membrane or to a 
degradation pathway. The variety of proteins involved and the large number of 
GPCRs expressed suggests that particular subsets of receptors may employ different 
methods of regulation, many of which have yet to be identified.
1.6 ERM proteins
Within this thesis, I shall show that ezrin is a novel substrate of GRK2. Ezrin is a 
member of the ezrin-radixin-moesin (ERM) family of cross-linking proteins that 
regulate the structure and function of the actin cortex, principally at specific plasma 
membrane domains (reviewed in Bretscher et al., 2002). Their primary role is that of 
linking plasma membrane proteins or associated proteins to F-actin. Ezrin was 
originally purified from the cytoskeleton of intestinal epithelial cell microvilli and 
ERM members were subsequently found to be enriched in a number of other 
membrane structures, including membrane ruffles and adherens junctions (Bretscher,
50
1989; Tsukita et al., 1989). They are thought to function in cell motility, adhesion 
and morphogenesis; growth signal transduction; and regulation of membrane 
transport and membrane protein localisation.
The vertebrate ERM proteins have a molecular weight of approximately 80 kDa and 
show a high level (approximately 80%) of amino acid and structural conservation 
(Bretscher et al., 2002). Homologues exist in C. elegans, Drosophila, tapeworms 
and Lytechinus variegates (sea urchin), although none have yet been identified in 
Sacchoromyces cerevisiae, suggesting that they are unique to multicellular 
organisms. Studies of the single Drosophila ERM protein Dmoesin indicate that it 
has a critical role in organising cell polarity, cell adhesion and the actin cytoskeleton 
during development (reviewed in Polesello and Payre, 2004). Elucidation of the 
distinct roles of the three mammalian ERM members has proved more difficult since 
the structural similarity and overlapping tissue expression implies that they will show 
functional redundancy. This has been demonstrated in targeted gene inactivation 
studies in mice: moesin knockouts have no apparent defects, even in the absence of 
ezrin and radixin upregulation, and radixin knockouts show only liver malfunction 
due to the absence of apical microvilli in bile canaliculi (Doi et al., 1999; Kikuchi et 
al., 2002). Recently, however, the generation of ezrin-null mice has indicated that 
ezrin is essential for the organisation of the apical surface of the intestinal epithelium 
(Saotome et al., 2004; Tamura et al., 2005). Mice lacking ezrin were born at 
submendelian ratios, failed to thrive and died before weaning. It is not yet known 
whether other ezrin-rich tissues were affected.
1.6.1 Structure
ERM proteins consist of two structural domains, the amino- and carboxy-ERM 
association domains (N- and C-ERMADs), connected by a coiled-coil (a-helical) 
region (Figure 1.9A). The N-ERMAD comprises a FERM (4.1, ezrin, radixin, 
moesin) domain. Proteins that contain FERM domains are characterised as part of 
the Protein 4.1 superfamily, members of which generally associate with the plasma 
membrane and cytoskeleton (Chishti et al., 1998). The globular FERM domains of 
ezrin, radixin and moesin are highly conserved and are composed of three distinct 
subdomains, F I, F2 and F3 (Figure 1.9B). FI is structurally homologous to 
ubiquitin, F2 shares similarities with acyl-CoA binding proteins and F3 is related to
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PH, Enabled/VASP-1 (EVH1) and phosphotyrosine-binding (PTB) domains 
(Pearson et al., 2000). FERM domains serve as protein- and lipid-binding sites, 
which in the case o f ERM proteins enable them to interact with both plasma 
membrane-associated proteins (Finnerty et al., 2004; Hamada et al., 2003) and PIP2 
(Barret et al., 2000; Niggli et al., 1995).
The C-ERMAD consists of a p-sheet and six a-helices, four of which form an actin- 
binding domain within the last 34 residues of the carboxy-terminus (Pearson et al., 
2000). In the cytosol, ERM proteins adopt an inactive conformation wherein 
intramolecular or intermolecular interactions between the N- and C-ERMADs mask 
the membrane- and actin-binding sites (Gary and Bretscher, 1995; Magendantz et al., 
1995). Although ERM protein homo- and heterodimers have been identified (Gary 
and Bretscher, 1993), most cytosolic ezrin exists in a monomeric form in which its 
N- and C-ERMADs are associated (Berryman et al., 1995; Bretscher et al., 1995). 
This conformation is considered dormant since it masks the binding sites for 
molecules such as Rho GDI (Takahashi et al., 1997) or other ERM molecules (Gary 
and Bretscher, 1995) at the N-ERMAD and actin at the C-ERMAD (Figure 1.9C) 
(Algrain et al., 1993; Gary and Bretscher, 1995).
The crystal structure of inactive moesin reveals that the C-ERMAD forms an 
extended conformation that binds to the FERM domain, masking both a large 
proportion of the surface of the FERM domain and the carboxy-terminal actin- 
binding region (Pearson et al., 2000). Low-angle rotary-shadowing electron 
microscopy of inactive and active forms of radixin has shown that the inactive 
protein adopts a closed, globular structure and that the active protein assumes an 
extended form with two globular structures connected by a straight filamentous 
domain (Ishikawa et al., 2001). Further studies have demonstrated that the adhesion 
molecule I-CAM-2 binds to the radixin FERM domain in the same site as a P-strand 
of the C-ERMAD in dormant radixin (Hamada et al., 2003) and that the NHERF 
binding site is masked by the C-ERMAD in inactive ezrin and moesin (Finnerty et 
al., 2004; Reczek and Bretscher, 1998). These results endorse the hypothesis that the 
intramolecular association of the N- and C-ERMADs is responsible for the 
inactivation of ERM proteins.
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Figure 1.9. ERM protein structure and activation. A. Cartoon depicting the structural organisation 
and key regulatory sites of ERM proteins. Sites o f protein and lipid binding are indicated above and 
below. P indicates the phosphorylation site for activation, threonine-567, a-domain: a-helical region. 
FERM: 4.1, ezrin, radixin, moesin domain. T567: threonine-567. B. Cartoon depicting the structural 
organisation o f the globular subdomains (FI - F3) of the FERM domain. The regions with structural 
similarity to pleckstrin homology (PH) and phosphotyrosine-binding (PTB) domains are indicated. C. 
Cartoon depicting the dormant, inactive, structure o f ERM proteins. Cytosolic ezrin exists in a 
monomeric form in which its N- and C-ERMADs are associated, masking the binding sites for 
molecules at the N-ERMAD and the C-ERMAD. D. Cartoon depicting conformational activation o f 
ERM proteins. PIP2 binding to the FERM domain is thought to open the dormant structure. This 
allows kinases such as Rho kinase (Rho K) and protein kinase C (PKC-0) to phosphorylate the 
regulatory threonine, fully activating the ERM protein. C: carboxy 1-terminus. N: amino-terminus . 
PIP2: phosphatidylinositol 4,5-bisphosphate.
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1.6.2 Regulation of conformation and activity
It has been shown that various stimuli activate ERM members. Activation of Rho 
and resulting downstream pathways by growth factors such as lysophosphatidic acid 
(LPA) promotes ezrin-enriched microvillus formation (Matsui et al., 1999). 
Furthermore, EGF treatment of human carcinoma A-431 cells leads to ezrin 
oligomerisation and membrane ruffling, to which ezrin is localised (Berryman et al., 
1995; Bretscher, 1989). The formation of ezrin oligomers suggested that EGF 
stimulation was responsible for overcoming the closed, inactive conformation 
(Berryman et al., 1995).
The phosphorylation of a carboxy-terminal threonine (threonine-567 in ezrin; 
threonine-564 in radixin and threonine-558 in moesin) by Rho kinase was 
demonstrated following LPA stimulation of Swiss 3T3 cells (Matsui et al., 1998) and 
osteopontin treatment of osteoclasts (Chellaiah et al., 2003). This phosphorylation 
was shown to inhibit the binding of the carboxyl-terminus of radixin to its amino- 
terminus, but did not affect the carboxyl-terminus binding to actin (Matsui et al.,
1998). Further studies established that protein kinase C-0 (PKC-0) and myotonic 
dystrophy kinase-related Cdc42-binding kinase (MRCK) could phosphorylate 
moesin at threonine-558 (Nakamura et al., 2000; Pietromonaco et al., 1998). PKC-0 
phosphorylation unmasked the NHERF and F-actin binding sites of ezrin and moesin 
(Simons et al., 1998) and active MRCK was required for ERM protein activation and 
filopodia formation in NIH 3T3 cells (Nakamura et al., 2000). Additionally, PKC-a- 
induced cell migration was demonstrated to correlate with phosphorylation of ezrin 
at threonine-567 (Ng et al., 2001).
Analysis of the role of threonine-phosphorylated ERM proteins was performed using 
T567D ezrin to mimic the phosphorylated state and T567A ezrin, a non- 
phosphorylatable mutant (Gautreau et al., 2000). T567A ezrin was poorly associated 
with the actin cytoskeleton but could form oligomers at the plasma membrane. 
Conversely, T567D ezrin was shown to be linked to the cytoskeleton and to trigger 
the formation of structures such as microvilli, lamellipodia and membrane ruffles, to 
which it was localised. Moreover, T567D ezrin was a monomer at the plasma
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membrane, suggesting that phosphorylation at threonine-567 prevented N- and C- 
ERMAD association and was the active form of the protein (Gautreau et al., 2000). 
These results agreed with an earlier study in which threonine-phosphorylated ERM 
proteins were specifically localised to the plasma membrane in A-431 cells following 
EGF treatment (Yonemura et al., 1999).
Lipids have also been shown to play a role in ERM protein activation. Moesin 
phosphorylated at threonine-558 associates with F-actin only in the presence of poly- 
phosphatidylinositides (Nakamura et al., 1999). A PIP2-binding domain had 
previously been identified within the N-ERMAD of ezrin (Niggli et al., 1995) and 
was later more precisely localised to lysine residues at positions 63, 64, 253, 254, 
262 and 263 (Barret et al., 2000). A K253N, K254N, K262N, K263N ezrin mutant 
expressed in cells was cytosolic, although it still retained its ability to bind F-actin in 
vitro (Barret et al., 2000). Furthermore, injection of the PIP2 -binding drug neomycin 
into MDCK cells caused translocation of ezrin from the plasma membrane to the 
cytosol with associated loss of microvilli (Yonemura et al., 2002).
Examination of the crystal structure of inactive moesin indicates that threonine-558 
is both in contact with the FERM domain and exposed to solvent. Phosphorylation 
of this residue would weaken the electrostatic attraction between the positively 
charged region of the C-ERMAD helix and the negatively charged face of the FERM 
domain. Sterically, the phosphate group cannot be accommodated by the closely 
packed side-chains of surrounding residues and would thus lead to conformational 
rearrangement (Pearson et al., 2000). The structural relevance of PIP2 binding in 
ERM protein activation is less clear. Lysine residues 253, 254, 262 and 263 are 
located on the surface of the FERM F3 lobe and it has been postulated that 
negatively-charged phospholipids may bind to this positively charged face and 
interfere with the binding of a carboxyl-terminal helix (Barret et al., 2000; Pearson et 
al., 2000). A more recent study has determined that the ability to bind PIP2 is 
required for the phosphorylation of threonine-567 and conformational activation of 
ezrin (Figure 1.9D). PIP2 , along with threonine-567 phosphorylation, was also 
shown to be required for the correct apical membrane distribution of ezrin and its 
morphogenic effects (Fievet et al., 2004).
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Within a cellular context, however, regulation of ERM protein activity appears to be 
complex and involves phosphorylation at additional sites. CDK5 phosphorylation of 
threonine-235 augments ezrin activation and membrane localisation in senescent 
osteosarcoma cells, although this event requires prior phosphorylation of threonine- 
567 (Yang and Hinds, 2003). Phosphorylation of tyrosines-145 and -353 of ezrin 
occurs following signalling via growth factor receptors in epidermoid carcinoma 
cells or Lck activation in T cells (Autero et al., 2003; Crepaldi et al., 1997; Krieg and 
Hunter, 1992). Mutation of these tyrosine residues to phenylalanines did not affect 
the localisation of ezrin at microvilli but did inhibit hepatocyte growth factor- 
mediated motility and morphogenesis in epithelial cells (Crepaldi et al., 1997). 
Recently, c-Src-mediated phosphorylation of open, active ezrin at tyrosine-145 was 
demonstrated to be necessary for growth factor-induced cell spreading and 
proliferation (Srivastava et al., 2005). Finally, phosphorylation of serine- 6 6  in ezrin 
by PKA has been shown to be essential for cytoskeletal remodelling during parietal 
cell activation. This phosphorylation was not required to target ezrin to the plasma 
membrane, but was important in regulating parietal cell membrane morphology in 
response to histamine (Zhou et al., 2003). It therefore seems that, following 
conformational activation, further phosphorylation events are likely to be important 
for regulating specific ERM-mediated cytoskeletal reorganisation in response to 
particular stimuli.
1.6.3 Cross-linking the plasma membrane to the actin cytoskeleton
The active, elongated conformation of an ERM protein has both its amino-terminal 
PIP2- and protein-binding domains and carboxyl-terminal F-actin-association domain 
exposed, satisfying the structural requirements of a membrane/actin cross-linker. 
The FERM domain of the ERM members has been shown to interact directly with 
the cytoplasmic tails of transmembrane adhesion molecules including I-CAM-1, -2 
and -3, CD43 and CD44 and the Na+/H+ exchanger NHE1 (reviewed in Bretscher et 
al., 2002). Expression of the transmembrane and cytoplasmic domains of ERM- 
binding membrane proteins such as CD43, CD44 and I-CAM-2 induced microvilli 
formation and ERM protein phosphorylation dependent on ERM binding (Yonemura
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et al., 1999). This data suggests that ezrin is directly responsible for the actin 
reorganisation that follows ligand binding to adhesion receptors.
The scaffolding protein NHERF also binds to the ERM FERM domain, providing an 
indirect link to transmembrane proteins such as P2AR and the platelet-derived 
growth factor receptor (Hall et al., 1998a; Hall et al., 1998b; Maudsley et al., 2000; 
Reczek et al., 1997). NHERF has been implicated in the regulation of GPCR 
trafficking, the control of the Na+/H+ exchanger NHE3, and the apical membrane 
targeting of specific proteins, all of which exploit the ability of NHERF to bind to F- 
actin via ERM proteins (reviewed in Voltz et al., 2001 and discussed in Section 1.5). 
The binding sites of both NHERF and I-CAM-2 have been identified within the 
FERM domains of moesin and radixin respectively (Finnerty et al., 2004; Hamada et 
al., 2003). These appear to be distinct, suggesting that adhesion receptors and 
scaffolding molecules may bind to ERM proteins simultaneously.
1.6.4 Role of ERM in downstream signalling pathways
Additionally to their direct involvement in cell surface morphogenesis following 
stimulation, ERM proteins are also implicated in signal-transduction pathways via 
interactions with cytosolic signalling molecules. The growth factor response 
pathways mediated by Rho require ERM protein activation to bring about 
cytoskeletal modifications such as stress fibre and focal adhesion formation (Hirao et 
al., 1996; Mackay et al., 1997). ERM proteins might also be downstream of Rac and 
Cdc42. Ezrin, radixin and moesin were identified as effectors of Rac required for 
actin polymerisation at the cell periphery (Mackay et al., 1997), and the Cdc42- 
effector MRCK has been shown to phosphorylate moesin at threonine-558 and may 
regulate ERM activation downstream of Cdc42 signalling (Nakamura et al., 2000).
The involvement of ERM proteins in growth factor signal transduction implies that 
they may also be important for cell survival. Following growth factor signalling, 
ezrin is phosphorylated at tyrosine-145 and tyrosine-353 (Autero et al., 2003; 
Crepaldi et al., 1997; Krieg and Hunter, 1992). Phosphorylation of tyrosine-353 was 
demonstrated to be essential for epithelial cell survival as it is required for ezrin to 
interact with PI 3-kinase and activate the Akt survival pathway (Gautreau et al., 
1999).
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ERM proteins have also been demonstrated to function downstream of PKC. 
Following EGF stimulation of A-431 cells, membrane ruffling and colocalisation of 
ezrin and CD44 to the plasma membrane appear to depend on PKC-a (Miyata et al., 
1989; Stapleton et al., 2002). Recent studies indicate that both PKC-a and PKC-0 
can phosphorylate ERM proteins at the regulatory threonine (Ng et al., 2001; 
Pietromonaco et al., 1998) and both kinases may regulate the interaction between 
CD44 and ezrin required for chemotaxis (Legg et al., 2002; Stapleton et al., 2002).
In summary, members of the ERM family serve to cross-link F-actin to the plasma 
membrane, functioning to implement cortical cytoskeleton alterations in response to 
a variety of signals. Their regulated conformational activation and array of binding 
partners enable them to act as effectors in numerous signalling pathways, co­
ordinating membrane morphogenesis, cell adhesion, motility, trafficking and cell 
survival.
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1.7 Aim of this thesis
GRK2 was originally characterised as a GPCR-specific serine/threonine kinase, 
phosphorylating agonist-occupied receptors to initiate their homologous 
desensitisation and internalisation. It has recently become clear that components of 
the GPCR desensitisation machinery, such as Parrestin and GIT1, have additional 
roles in promoting novel signalling pathways downstream of GPCRs. Since a 
number of non-receptor substrates have been identified for GRK2, it appears likely 
that this and other GRKs can act as GPCR signal effectors.
My aim in this thesis was to investigate whether the actin/plasma membrane cross­
linker ezrin was a novel substrate for GRK2. Furthermore, I wanted to establish 
what role ezrin played in GPCR-mediated cytoskeletal rearrangements and receptor 
endocytosis. The majority of these analyses used HEK293 and Hep2 cell systems, 
although some in vitro work was also performed. Chapter 2 outlines the methods 
used in this thesis.
Chapter 3 investigates whether ezrin is a substrate o f GRK2. Its findings 
demonstrate that GRK2 can phosphorylate ezrin in vitro. Phosphorylation occurs 
within a carboxyl-terminal 53 amino acid stretch that encompasses the 
phosphorylation site required for ezrin activation, threonine-567. It also describes 
my attempts to demonstrate either directly or indirectly that threonine-567 of ezrin is 
the site of GRK2 phosphorylation.
Chapter 4 demonstrates that agonist treatment of MIMR-expressing Hep2 cells 
induces cytoskeletal reorganisation in the form of membrane ruffles to which active, 
phosphorylated ERM proteins are localised. These ruffles require both functional 
ezrin and active GRK2 at the plasma membrane, and it is probable that GRK2 is the 
kinase directly responsible for phosphorylating and activating ERM proteins in this 
cell system. These results indirectly demonstrate that GRK2 is likely to 
phosphorylate ezrin at threonine-567.
Chapter 5 describes experiments that show that ezrin may play an important role in 
GPCR internalisation, although this function may be limited to a subset of these
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receptors. Phosphorylated ERM proteins (pERM) are observed co-localised with 
internalised GPCRs at endosomal compartments. Ezrin is demonstrated to be 
required for P2AR endocytosis, but not the internalisation of the transferrin receptor, 
suggesting that it is not required for clathrin-mediated endocytosis per se. The 
findings from Chapters 3 - 5  will be discussed in detail in Chapter 6 .
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2 Materials & Methods
Tissue culture dishes were obtained from Nunc, culture medium from Gibco BRL, 
plasticware from Falcon or Sterilin and other reagents from Sigma, unless otherwise 
specified. All kits were used according to the manufacturers’ instructions and 
solutions made up with MilliQ deionised water unless specified. Buffer ingredients, 
cDNAs and antibodies referred to in the body of this Chapter are listed in tables 2.1, 
2.2 and 2.3. Ezrin and GRK2 constructs used in this thesis are also illustrated in
Figure 2.1.
2.1 Cell Culture
2.1.1 Cell lines
HEK293 cells stably expressing His6 -tagged P2AR (HEKp2 cells, a generous gift of 
Dr Stefano Marullo, Institut Cochin, Paris) were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) containing 10% foetal calf serum (FCS), 100IU penicillin 
and lOOjxg/ml streptomycin and 2mg/ml geneticin (Gibco BRL). COS, Hep2 and 
HEK293 cells were maintained in DMEM containing 10% FCS, 100IU penicillin 
and 100p,g/ml streptomycin. Cells were maintained in a humidified incubator at 
37 C, 5% CO2 . Confluent monolayers were passaged every 3-4 days by trypsinising 
and replating at a ratio of 1:10 (or approximately lx l0 6 cells per 9cm dish).
2.1.2 Cell thawing
To recover cells stored in liquid nitrogen, aliquots were rapidly thawed at 37 C and 
the cells diluted in 10 ml culture medium. Cells were pelleted by centrifugation 
(1000 rpm for 3 minutes) and the pellet was resuspended in 10 ml pre-warmed 
culture medium. Cells were maintained in a humidified incubator at 37 C, 5% CO2 . 
If HEKp2 cells were thawed, geneticin was not added to the culture medium until the 
cells had first reached confluency.
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Figure 2.1. Ezrin and GRK2 cDNA constructs used in this thesis. A. Human ezrin-VSV-G constructs 
(Algrain et al., 1993; Gautreau et al., 2000). B. Human GST-ezrin constructs (Roy et al., 1997). C. 
Bovine GRK2 constructs (Freedman et al., 1995; Pierce et al., 2001; Steme-Marr et al., 2003). A l 10: 
alanine-110. A567: alanine-567. D567: aspartate-567. FERM: 4.1, ezrin, radixin, moesin. GST: 
glutathione-S-transferase. PH: pleckstrin homology domain. R220: arginine-220. RGS: regulators of 
G protein signalling proteins. VSV-G: vesicular stomatitis virus glycoprotein.
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2.1.3 Cell freezing
For freezing, 2x l0 6 pelleted cells (taken from plates of 50% confluency) were 
resuspended in 1ml cold freezing medium on ice. Cells were frozen at -70 C for 1 
week and subsequently transferred to liquid nitrogen.
2.1.4 Electroporation of DNA into Hep2 and HEK293
Hep2 or HEK293 cells at approximately 75% confluence that had been plated 24h 
previously were trypsinised, spun down and washed in 10ml HEBS buffer. Washed 
cells were recovered by centrifugation and resuspended in 250qd HEBS and 
transferred to 0.4cm3 electroporation cuvettes, lpg  DNA was added to the cuvettes 
and the cells mixed gently by hand. Using the Gene Electropulser II (BioRad), cells 
were electroporated with 2 pulses of 400V, 125^iF, oo ohms. Cells were 
subsequently incubated at room temperature (RT) for 5 minutes before being plated 
onto coverslips in a 5cm tissue culture dish and left to express the construct(s) for up 
to 48h.
2.1.5 Transfection of DNA into COS and HEKp2
3 |lx1 of GeneJuice Transfection Reagent (Novagen) for every lq g  of DNA to be 
transfected was added to 150|il serum-free DMEM. The media was vortexed and 
incubated at RT for 5 minutes. DNA was added to the media, mixed gently by hand 
and incubated at RT for 15 minutes. The media/DNA mixture was then dropped 
onto 70% confluent cells that had been plated 24h previously in 10% DMEM. The 
cell media was mixed by gentle agitation and the cells were left to express the 
transfected construct(s) for up to 48h.
2.2 DNA manipulation
2.2.1 cDNA Constructs
Table 2.2 lists cDNA constructs used in this thesis and their suppliers. Constructs 
were stored at -20 C.
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2.2.2 Generation of GST-T567A-ezrin construct
In order to generate a glutathione S transferase (GST)-tagged ezrin construct with 
threonine-567 mutated to alanine, the T567A-ezrin cDNA was amplified from 
pCB6-Ezrin-T567A-VSVG (Figure 2.1 A) using the technique of polymerase chain 
reaction (PCR). The PCR primers were designed so that the resulting T567A-ezrin 
cDNA had a 5' EcoRI site and a 3' Xhol site. The cDNA was then inserted into the 
pGEX-5X-l vector (Amersham Biosciences) downstream of and in frame with the 
GST moiety.
2.2.3 PCR
In order to amplify T567A-ezrin cDNA from pCB6-Ezrin-T567A-VSVG, reactions 
were set up as follows:
lOpl lOx PCR buffer
lOpl lOx HF2 dNTP Mix
2  pi 3pM 5' primer
2  pi 3pM 3' primer
2  pi enzyme
lOpl template
64 pi ddH2Q
using the Advantage-HF2 PCR kit (BD Biosciences). The primers used were:
5 'primer 5' -TT GTT GG A ATT CAT GCCG AAACC A AT C AAT GTCC-3'
EcoRI
3 'primer 5'-TTGTTGCTCGAGTTACAGGGCCTCGAACTCGTC-3'.
Xhol
The PCR was performed in a PTC-2000 Peltier Thermal Cycler (MJ Research) for 
30 cycles under the following conditions:
94 C 10 seconds;
59 C 30 seconds;
6 8  C 2 minutes.
5 pi of the PCR product was run in a 1% agarose gel containing ethidium bromide 
along with the lkb Plus DNA ladder (Invitrogen) and visualised using the Gene 
Genius UV lightbox (Syngene) to confirm that the PCR was successful and had
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generated DNA of the expected size. The amplified DNA was purified from the 
remainder of the reaction using the QIAquick PCR purification kit (QIAGEN).
2.2.4 Restriction digestion
All of the amplified T567A-ezrin and 2pg of the pGEX-5X-l vector were digested 
with EcoRI and Xhol (Promega) at 37 C for lh  in separate reactions containing:
7pi 1 Ox Buffer D 
1 pi EcoRI 
lp l Xhol 
xpl DNA
Made up to 70 pi with H2O.
Digested T567A-ezrin was purified from the reaction using the QIAquick PCR 
purification kit. The restriction digest reaction containing pGEX-5X-l was run on a 
1% agarose gel containing ethidium bromide with the lkb Plus DNA ladder. 
Digested pEX-5X-l was cut from the gel under UV illumination and purified from 
the agarose using the QIAquick gel extraction kit (QIAGEN).
2.2.5 Ligation
The digested T567A-ezrin cDNA was ligated into the digested pGEX-5X-l vector at 
16 C overnight under the following conditions:
1.5 pi 1 Ox ligation buffer (Promega)
1 pi ligase (Promega)
5pl T567A-ezrin DNA
lp l pGEX-5X-l DNA 
6.5pl ddH20 .
5 pi of the reaction was used to transform DH5a Escherichia coli.
2.2.6 Bacterial transformation and plasmid DNA extraction
XL 1-Blue (Stratagene) or DH5a ultracompetent Escherichia coli were thawed on ice 
and mixed by hand. lOOpl were aliquoted into a pre-chilled 1.5ml Eppendorf tube 
and 20ng of DNA added. The cells were swirled and incubated on ice for 30 minutes 
before being heat shocked at 42 C for 30 seconds. The bacteria were then incubated
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on ice for 2 minutes. 0.9ml pre-warmed SOC medium (Invitrogen) was added and 
the cells incubated at 37 C for lh with shaking at 250rpm. Bacteria were then plated 
onto Luria Broth (LB) agar plates containing 100p,g/ml ampicillin or 25^ig/ml 
kanamycin and incubated at 37 C overnight.
Single colonies were picked from the plate and grown in either 5ml or 500ml of LB 
medium containing 100^ig/ml ampicillin or 25jxg kanamycin overnight at 37 C with 
shaking at 250rpm. The next day, bacteria were pelleted and the plasmid DNA was 
extracted using either a QIAprep Spin Miniprep or Maxiprep kit (QIA G EN ) 
respectively. To test whether the plasmid contained an insert of the right size, a 
restriction digest was performed using 5 units of the relevant restriction enzyme 
(Promega) for lh  at 37 C. Digested products were analysed on a 1% agarose gel 
containing ethidium bromide and their size determined using the lkb Plus DNA 
ladder. The concentration of the plasmid DNA was determined using an Ultraspec 
2000 spectrophotometer (Pharmacia Biotech).
2.2.7 Sequencing
Sequencing was carried out by MWG Biotech UK (Milton Keynes). Primers used to 
sequence GST-T567A-ezrin in pGEX-5X-l in stages along the 5' to 3' direction 
were: pGex forward (MWG Biotech UK); 5'-GTACTGCCCCCCTGAGACTG-3'; 
5 '-GTG AAATCAGGAAC ATCTCT-3' and 5'-CAAAGAAGGC AGAGAGAGAG- 
3'. pGex reverse (MWG Biotech UK) was used to sequence in the 3' to 5' direction. 
pGEX-2T-ez3 10-586 was sequenced using identical primers. The sequences obtained 
were compared to the published sequence of ezrin using the Gene Jockey II 
Sequence Processor program (Biosoft).
Sequencing of the PCR product of 310-586 verified that the region surrounding 
threonine-567 was error free and that the majority of the sequence matched that 
deposited in GenBank (GenBank identification NM 003379, Figure 3.4). An 
adenosine to thymidine substitution had occurred at base 1275. This was a 
conservative substitution and did not lead to change in the peptide sequence at 
residue 425 (ACA to ACT, i.e. threonine to threonine). A base reversal was detected 
at bases 1593 and 1594 (CG to GC), causing a change in the peptide sequence at
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residue 532 (CTC GTG to CTG CTG, i.e. leucine valine to leucine leucine). This 
constitutes a conservative substitution of the amino acid sequence, as both valine and 
leucine are aliphatic amino acids. The valine to leucine substitution at residue 532 
present in the 310-586 construct also occurred in GST-T567A-ezrin. Comparison of 
sequences of human ezrin deposited in SwissProt demonstrated that two sequences 
(A34400 and P 15311) contained a valine at position 532, whereas one sequence 
(NP 003370) had a leucine at 532. This may therefore represent a natural single 
nucleotide polymorphism of human ezrin and is unlikely to affect its function.
2.3 Immunofluorescence techniques
2.3.1 Membrane ruffling assay and immunofluorescence
Hep2 cells were grown to 60-70% confluency on glass coverslips prior to 
transfection with 0.5pg HA-M1MR cDNA by electroporation. Cells were then 
treated with lOOpM acetylcholine for 5 minutes or 200ng/ml EGF for 3 minutes at 
37 C to induce membrane ruffling. Following treatment, cells were fixed in 10% 
trichloroacetic acid for 15 minutes at 4 C and washed twice for 10 minutes in quench 
buffer at RT. Permeabilisation buffer was subsequently used to block and 
permeabilise fixed cells.
Primary antibody was diluted in permeabilisation buffer and incubations were 
performed for lh  at RT. Cells were washed three times with permeabilisation buffer 
and incubated with secondary antibody diluted in permeabilisation buffer for lh  at 
RT. The antibody 297S was used to visualise pERM, except where Flep2 cells were 
treated with the PKA inhibitor Rp-8 -Br-CAMPS (see Section 2.3.1.1), when a 
commercial anti-pERM antibody was used (Cell Signalling Technology). Where 
used, 1U Alexa Fluor 594-conjugated phalloidin (594-phalloidin, Molecular Probes) 
was diluted in 2 0 0 pl permeabilisation buffer per coverslip and added to the 
coverslips for 20 minutes prior to washing. After 3 washes in permeabilisation 
buffer followed by one wash in PBS and one wash in distilled water, coverslips were 
mounted on slides in mountant.
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2.3.1.1 Treatment with kinase inhibitors
Where used, cells were treated with lOpM Y27632, 20pM GF109203X or ImM Rp- 
8 -Br-CAMPS (BIOLOG) for 1 hour at 37 C prior to membrane ruffling assays.
2.3.2 Endocytosis assay
HEK293 or Hep2 cells were grown to 60-70% confluency on glass coverslips prior 
to transfection with receptor cDNA by electroporation. Cells were incubated in 
primary antibody diluted in serum free DMEM for lh  on ice. After washing three 
times in cold serum free DMEM, the cells were re-heated to 37 C and drugs added to 
induce receptor internalisation. Acetylcholine was used at a concentration of lOOpM 
for 20 minutes and (-)-isoproterenol was used at a concentration of 50pM for 15 
minutes or 30 minutes.
Following treatment, cells were fixed in 10% trichloroacetic acid for 15 minutes at 
4 C (anti-ezrin or 297S antibodies) or 4% paraformaldehyde for 15 minutes at RT 
(all other antibodies) and washed twice for 10 minutes in quench buffer at RT. 
Permeabilisation buffer was subsequently used to block and permeabilise fixed cells. 
Secondary antibody incubations were performed for lh  at RT. Cells were 
subsequently washed with permeabilisation buffer and mounted on slides in 
mountant.
Where used, cells on coverslips were incubated in lOOpM of the metal chelator 
Desferal at 4 C for 30 minutes before incubation in 200nM Alexa Fluor 647- 
conjugated transferrin (647-transferrin, Molecular Probes) in binding media (BM) for 
30 minutes at 4 C. The cells were then immediately placed in 200nM transferrin- 
647 in BM at 37 C, with or without 50pM (-)-isoproterenol. Coverslips were 
removed after 0 and 30 minutes and washed three times in ice cold BM. Cells were 
fixed in 4% paraformaldehyde (in PBS) for 15 minutes at RT and then permeabilised 
and labelled with antibody as above.
2.3.3 Confocal microscopy
Confocal images were taken at RT within 24h of immunofluorescent labelling of the 
cells. Nikon Plan Apo 40x and 60x oil immersion lenses and a Bio-Rad 1024 MRC
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confocal were used with a Nikon microscope and Bio Rad Lasersharp 2000 software 
to acquire the images. Images were optimised for contrast in Adobe Photoshop but 
no further manipulations were made.
2.3.4 Flow Cytometry and FACS® Analysis
HEKj32 cells at approximately 50% confluency were transfected using Gene Juice 
Transfection Reagent with either 5pg dynamin K44A, N-ezrin or C-ezrin (Figure
2.1 A) at a ratio of 2:1 with pDsRed-Express (BD Biosciences Clontech). 24h post­
transfection cells were detached in PBS containing lOmM EDTA, washed in ice-cold 
BM and resuspended at 5x l0 6cells/ml in cold BM containing 40pM  (-)- 
isoproterenol. Immediately, six aliquots of lOOpl (5xl0 5 cells) were washed in cold 
BM and kept on ice. The remaining cells were incubated at 37°C for 30 minutes, 
after which time a further six aliquots were taken and treated as above. The rest of 
the cells were cooled on ice, centrifuged (1500rpm, 5 minutes, at 4 C), washed three 
times in cold BM, resuspended in prewarmed BM containing lOOpM (-)-alprenolol 
and incubated for 30 minutes at 37°C. Six aliquots of cells were pelleted by 
centrifugation and washed in cold BM, as before.
All cells were labelled with primary antibody in wash buffer for lh on ice. The cells 
were then washed twice in cold wash buffer and fixed in 1 % FCS/1% 
paraformaldehyde (TAAB)/PBS overnight at 4 C. The fixative was removed by 
washing once in cold wash buffer and the cells were incubated with an AlexaFluor- 
488-conjugated secondary antibody in wash buffer for lh  on ice. Finally, the cells 
were washed three times in wash buffer. Cells expressing pDsRed-Express were 
assumed to also express the dynamin or ezrin mutants. These cells were gated and 
10000 pDsRed-Express expressing cells analysed for His6 -tagged P2AR expression 
using a FACS®Calibur flow cytometer (Becton Dickinson) and Cell-Quest software 
(Becton Dickinson).
2.4 Other techniques
2.4.1 Purification of GST-ezrin fusion proteins
GST-ezrin fusion proteins (Figure 2 .IB) were expressed in BL21 E. coli 
(Invitrogen), as described above. Single colonies of bacteria were picked and grown
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in 100ml LB medium containing lOOpg/ml ampicillin (LB/ampicillin) at 37 C, 
250rpm overnight. The cultures were diluted 1:10 in LB/ampicillin and grown at 
37 C with shaking at 250rpm until A55o^0.5. IPTG was added subsequently to the 
cultures at a final concentration of ImM to induce fusion protein expression for an 
additional 4h. Cultures were centrifuged at 2500g for 10 minutes at 4 C, bacterial 
pellets resuspended in 35ml cold PBS containing the protease inhibitors 40pg/ml 
phenylmethanesulfonyl fluoride (PMSF) and ImM benzamidine and subject to 
sonication for 2 x 2 minutes. Triton X-100 was added to a final concentration of 1% 
and the lysates centrifuged at 40000g for 30 minutes at 4 C. 1ml glutathione agarose 
was added to the clarified supernatants, which were incubated on a rotor mixer at 
4 C for 2h. The agarose was washed three times with cold 50mM Tris pH 8.0 /1% 
Tween/1 % Triton X-100 and once with cold 50mM Tris pH8.0. Where required, 
GST-fusion proteins were eluted from the agarose with 10-50mM glutathione in 
50mM Tris pH8.0 containing protease inhibitors, dialysed against 50mM Tris pH8.0 
containing protease inhibitors and concentrated in Centriprep YM-30 centrifugal 
filter devices (Amicon).
2.4.2 In vitro phosphorylation assays
GRK2 purified from Sf9 cells expressing recombinant baculovirus encoding the 
GRK was a generous gift of Dr. Robert Lefkowitz. All phosphorylation reactions 
were carried out with purified GST-ezrin fusion proteins (lpM ) or GST (4pM,) and 
GRK2 (0.2pM) in phosphorylation reaction buffer in the presence of 60pM 
[y32P]ATP (15000cpm/pmole) (Amersham Pharmacia Biotech), for 1 h at 37 °C in a 
total reaction volume of 25pi. Where used, 0.5mg/ml purified and sonicated lipids 
(PIP2 and phosphatidylcholine in PBS) and purified Gj3y from bovine brain (Dr. 
Robert Lefkowitz) were also included. Either 10% PIP2 and 2.125pM G|3y or 20% 
PIP2 and 8.7pM Gpy were used, with essentially equivalent results. Reactions were
32incubated on ice for 15 minutes prior to addition of [y PJATP in the presence or 
absence of 0.6pg purified bovine rod outer segments (ROS). Where ROS were used, 
the reactions were incubated under bright electric light. If larger quantities of 
phosphorylated ezrin constructs were required, reactions were carried out as 
described and then pooled. The reactions were terminated by addition of SDS 
reducing buffer and samples were resolved by SDS-PAGE (see Section 2.4.7).
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To detect proteins, the gel was immersed in Coomassie stain, heated for 1 minute at 
750W in a microwave and then allowed to cool at RT on a shaker. The gel was 
subsequently destained using Coomassie de-stain until proteins were visible. The gel 
was then placed on 2 sheets of filter paper, covered with Saran wrap and dried using 
a Model 583 Gel Dryer (BioRad) at 80 C for 90 minutes before being exposed to 
film (Biomax ML, Kodak) at -70 C overnight. Film was developed using an Agfa 
automatic film processor.
In order to determine the stochiometry of the phosphorylation reaction, known 
amounts of the phosphorylation reaction buffer containing [y P]ATP were spotted 
onto a piece of filter paper and allowed to dry. These were exposed, along with the 
dried gel, to a phosphorimager screen for 30 minutes at RT. The amount of ATP 
incorporated into each ezrin construct was determined by comparison with the 
standard ATP concentrations using a Molecular Imager FX (BioRad) and the 
Quantity One version 4.2.1 program (BioRad).
2.4.3 Protein extraction and determination of concentration
A 9cm tissue culture dish of confluent cells was washed in ice cold PBS. 500pl ice 
cold lysis buffer was added to the cells and the cells scraped with a rubber cell 
scraper before being transferred to a pre-chilled 1.5ml Eppendorf tube and incubated 
on a rotor shaker for 30 minutes at 4 C. The cells were then centrifuged at 12000 
rpm for 15 minutes at 4 C and the supernatant transferred to a new 1.5ml tube.
Protein concentration was determined using the BioRad protein assay. BioRad 
Protein Assay Dye Reagent Concentrate (BioRad) was diluted 1:5 in water and 
filtered. 2pl of cell lysate was added to 1ml of reagent and vortexed to mix. The 
A595 of samples was measured using an Ultraspec 2000 spectrophotometer and 
protein concentration determined by comparison with a standard curve obtained by 
measuring the A 5 9 5  of known amounts of BSA.
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2.4.4 Immunoprecipitation
Clarified cell lysates containing lmg total protein were taken and 2qg primary 
antibody added. The lysates were incubated at 4 C for 45 minutes on a rotor shaker. 
50pi protein A/G sepharose was then added and the lysates incubated at 4 C on a 
rotor shaker for a further 45 minutes. The sepharose gel was washed three times 
with lysis buffer and 50pl SDS reducing buffer added. The immunoprecipitated 
proteins were then subject to SDS-PAGE and western blotting. An aliquot of each 
clarified lysate was also subject to a binding control in which the incubation with 
primary antibody was omitted prior to incubation with protein A/G sepharose.
2.4.5 Assay to determine if GRK2-mediated phosphorylation of 
ezrin regulates ezrin function
COS cells at approximately 50% confluency were transfected using Gene Juice. 48h 
post-transfection cells were washed in cold PBS, lysed on ice in cold lysis buffer and 
incubated for 30 minutes at 4 C on a rotor mixer. The lysates were centrifuged at 
13000rpm for 15 minutes at 4 C and the supernatants transferred to clean tubes. The 
samples were diluted 10-fold in lysis buffer and 20pg lysate added to 50pl of a 50% 
slurry of GST-1-310 ezrin bound to glutathione agarose (3.7pg protein) or 50pl of a 
50% slurry of glutathione agarose alone that had been pre-washed with total cell 
lysate. Reactions were incubated at 4 C for lh on a rotor mixer. The agarose beads 
were washed 3 times in cold lysis buffer then 50pl SDS sample buffer added and the 
beads boiled at 90 C for 10 minutes to dissociate any bound protein. Resin-bound 
proteins were subject to SDS-PAGE and western blotting.
2.4.6 Determination of relative amount of endogenous ezrin in 
different cell lines
For total protein extraction to determine the relative quantities of ezrin in different 
cell lines (Hep2, HEK293 and HEKp2), a 9cm tissue culture dish of each confluent 
line was taken, trypsinised and resuspended in 5ml ice cold PBS. The total number 
of cells was determined using a haemocytometer. The cells were pelleted and 
resuspended in 1 ml gel running buffer. lxlO 6 cells from each line were subject to 
SDS-PAGE and western blotting. In order to determine the relative amounts of
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protein precipitated, the developed film was scanned using a GS-710 Calibrated 
Imaging Densitometer (BioRad) and the optical density of each band calculated 
using Quantity One version 4.2.1 software, with background subtracted.
2.4.7 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was performed using the Laemmli method (Laemmli, 1970) with a 
discontinuous SDS-polyacrylamide gel and the Hoefer Scientific Instruments (HSI) 
vertical slab gel unit SE 600 gel system. A 10% SDS-polyacrylamide resolving gel 
was cast between two glass plates by polymerising 10% (v/v) acrylamide in 0.375M 
Tris-HCl pH 8 . 8  and 1% sodium dodecyl sulphate (SDS), using 0.3% (v/v) 
ammonium persulphate and 0.07% (v/v) N, N, N', N'-tetramethyl-ethylenediamine 
(TEMED). A 4% stacking gel was cast above the resolving gel by polymerising 4% 
(v/v) acrylamide in 0.12M Tris-HCl pH6 . 8  and 1% sodium dodecyl sulphate (SDS), 
using 0.1% (v/v) ammonium persulphate and 0.1% (v/v) TEMED.
The polymerised gel was placed in an HSI SE 600 cell and immersed in gel running 
buffer. The appropriate volume of 6 x SDS reducing buffer was added to known 
concentrations of samples prior to heating at 95 C for 10 minutes. Samples were 
immediately cooled on ice, briefly centrifuged to collect all droplets and then loaded 
onto the gel. Rainbow Coloured Protein molecular weight markers (14.3 - 220kD, 
Amersham Biosciences) were also loaded onto the gel. The gel was subject to a 
constant voltage of 200-300V for 90 minutes.
2.4.8 Western blotting and immunodetection
The proteins separated on the 10% SDS-polyacrylamide gel were transferred onto 
nitrocellulose membrane (Hybond-ECL, Amersham) using a semi-dry 
electrophoretic transfer method. The stacking gel was discarded and the resolving 
gel and nitrocellulose membrane were soaked in transfer buffer and placed between 6  
sheets of filter paper that had also been soaked in transfer buffer. Horizontal 
electrophoretic transfer was performed in the SCIE-PLAS semi-dry electroblotting 
unit V20-SDB with a constant current of 0.8A per cm2 of nitrocellulose membrane 
applied for 2h. Transfer was considered complete if  visual transfer of the molecular 
weight standards to the nitrocellulose membrane had occurred.
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The nitrocellulose membrane to which the proteins had been transferred was 
incubated in blocking buffer for either lh  at RT or overnight at 4 C with constant 
agitation. The immobilised proteins were subject to immunoblotting with a primary 
antibody diluted in blocking buffer for lh at RT or overnight at 4 C. Following 3x 5 
minute washes in blocking buffer, a horseradish peroxidase-conjugated secondary 
antibody diluted in blocking buffer was added to the immunoblots for lh at RT. The 
blots were washed in TTBS for 3x 5 minutes.
0.125ml total of ECL reagent per cm of nitrocellulose membrane was added to the 
protein side of the blot and incubated at RT for 1 minute (ECL Western Blotting 
Detection Reagents or ECL Advance Western Blotting Detection Kit, depending on 
antibody used. Amersham Biosciences). After developing the blot was wrapped in 
cling film. Bound antibody was detected by exposing the immunoblot to film 
(Biomax ML, Kodak) for the required time and the film was developed using an 
Agfa automatic film processor. The optical density of each band was calculated as 
detailed in section 2.4.6.
2.4.8.1 Stripping antibodies from nitrocellulose membranes
Nitrocellulose membranes were submerged in pre-warmed stripping buffer and 
incubated in a sealed container in a 50 C water bath for 30 minutes with occasional 
agitation. The membranes were then washed twice in an excess volume of PBS-T 
for 10 minutes at RT on a shaker. Incubation in blocking buffer for lh  at RT was 
performed before immunoblotting with an alternative antibody, as detailed in Section 
2.4.8.
2.5 Antibodies
Table 2.3 lists antibodies used in this thesis, their concentrations and suppliers. 
Commercial antibodies were stored at 4 C or -20 C, according to manufacturers’ 
instructions. Non-commercial antibodies were stored at 4 C.
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2.6 Statistical analysis
Results were analysed using the student’s two-sample T-test to test whether 
measurements made on two populations were different from each other (Ennos,
1999). The null hypothesis proposed that the two populations were the same in 
every case.
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Table 2.1. Buffers
Binding medium (BM)
Blocking buffer
Coomassie de-stain 
Coomassie stain
Freezing medium
Gel running buffer
HEBS buffer
lxRPM I 
lOmM Hepes 
0.2% BSA 
pH 7.0
2% skimmed milk powder 
0.1% Tween-20 
made up in PBS
40% MeOH 
10% acetic acid
40% MeOH 
10% acetic acid 
0.05% Brilliant Blue R
20% FCS 
10% DMSO 
made up in DMEM
2M glycine 
0.25M Tris 
0.03M SDS
137mM NaCl 
20mM Hepes 
6mM D-glucose 
5mM KC1 
0.7mM Na2H P04
pH adjusted to pH7.05 with NaOH
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Lysis buffer 250mM NaCl
50mM HEPES pH7.2 
50mM NaF 
lOmM NaPP04 
2mM EDTA 
ImM benzamidine 
50nM calyculin A 
10% glycerol 
0.5% NP-40 
40p,g/ml PMSF
3% N-propyl-galate
made up in PBS
Stored at 4 C, away from light
PBS-T 0.1% Tween-20 
made up in PBS
Mountant 90% glycerol
Permeabilisation buffer 1% BSA 
0.2% saponin 
made up in PBS
Phosphorylation reaction buffer 20mM Tris-HCl pH 7.5
5mM MgCl2 
2mM EDTA 
2mM DTT
Quench buffer 0.37% glycine 
0.27% NH4C1 
0.05% azide
made up in PBS
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6x SDS reducing buffer
Stripping buffer
Transfer buffer
TTBS
Wash buffer (for FACS)
25mM Tris pH6.5 
10% glycerol 
8% SDS
5% (3-mercaptoethanol 
a few grains of Brilliant Blue G
lOOmM p-mercaptoethanol 
62.5mM Tris HC1 pH6.7 
2% SDS
0.05M Tris 
0.04M glycine 
0.01M SDS 
20% MeOH
50mM NaCl 
20mM Tris 
0.2% Tween-20
1% FCS 
0.02% azide 
made up in PBS
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Table 2.2 cDNA constructs
cDNA Construct
name
Supplier Reference
or
catalogue
number
pGEX-2T-ezi_586
pGEX-2T-ezi_533
pGEX-2 T-ez3 10-586 
pGEX-2T-ezi.3io
1-586
1-533
310-586
1-310
Dr. Christian 
Roy, Universite 
Montpellier
Roy et al., 
1997
pCB6-Ezrin-VSVG 
pCB6-Ezrin-Nter-V SVG 
pCB6-Ezrin-Cter-VSVG
WT-ezrin
N-ezrin
C-ezrin
Dr. Monique 
Arpin, Institut 
Curie, Paris
Algrain et 
al., 1993
pCB6-Ezrin-T567A-VSVG 
pCB6-Ezrin-T567D-V S V G
T567A ezrin 
T567D ezrin
Dr. Monique 
Arpin, Institut 
Curie, Paris
Gautreau et 
al., 2000
pEGB-pARK-CT GRK2-CT Dr. Robert 
Lefkowitz, 
Howard Hughes 
Medical 
Institute, NC
Pierce et al., 
2001
PBC12BI-PARK1
pBC 12BI-p ARK 1-K220R
GRK2
GRK2k22or
Dr. Robert 
Lefkowitz
Freedman et 
al., 1995
pEGFP-GRK2-(45-178)-
GFP
pEGFP-Dl 10A-GRK2-(45- 
178)-GFP
GRK245-178
GRK245-i78-
D110A
Dr. Rachel 
Steme-Marr
Steme-Marr 
et al., 2003
pSV2-neo-FLAG-p2AR 
pS V 2-neo-FL AG- 
p2AR(L413A)
p2AR
P2ARL413A
Dr. Robert 
Lefkowitz
Hall et al., 
1998b
pRK5-HA-M 1 MR 
pRK5 -H A-M2MR
M1MR
M2MR
Dr. Robert 
Lefkowitz
Claing et 
al., 2000
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pUHD10-3-elel DynaminK44A Dr. Robert 
Lefkowitz
Claing et 
al., 2000
pGEX-5X-l pGEX-5X-l Amersham
Biosciences
27-4584-01
pDsRed-Express pDsRed-Express BD Biosciences 
Clontech
632412
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Table 2.3 Antibody reagents
Antigen Antibody
name
Species and 
isotype
Dilution Supplier
Immunoprecipitation
Primary
Ezrin Anti-ezrin Rabbit 2 jig/ml Upstate
Biotechnology
GRK2 Anti-GRK2/3 Mouse
IgG2aK
2pg/ml Upstate
Biotechnology
Immunofluorescence
Primary
EEA1 EEA1 antibody Rabbit 1:2000 Abeam
Ezrin Anti-ezrin Rabbit 1:250 Upstate
Biotechnology
FLAG M2 Mouse IgG 1 1:400 Sigma
GRK2 Anti-GRK2/3 Mouse
IgG2aK
1:300 Upstate
Biotechnology
HA Anti-HA Rat 1:100 Roche
His6 Anti-His6 Mouse
IgG2a
1:200 BD Biosciences
81
LAMP1 Anti-human
LAMP1
Rabbit 1:750 Dr. Sven Carlsson, 
Umea University, 
Sweden1
pERM 297S Rat Undiluted Dr. S h igenobu  
Yonemura, RIKEN 
C e n t e r  f o r  
Developmental 
Biology, Japan2
pERM Anti-pERM Rabbit 1:50 Cell S ignalling  
Technology
VSVG Anti-VSVG, 
clone P5D4
Mouse IgGl 1:2000 Sigma
Secondary
Mouse IgG A lexa F luor 
488 anti-mouse
Donkey 1:800 Molecular Probes
A lexa Fluor 
594 anti-mouse
Donkey 1:800 Molecular Probes
A lexa F luor 
647 anti-mouse
Donkey 1:800 Molecular Probes
Rabbit IgG A lexa Fluor 
488 anti-rabbit
Donkey 1:800 Molecular Probes
1 Carlsson et al., 1988
2 Hayashi et al., 1999; Matsui et al., 1998
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Rabbit IgG A lexa Fluor 
594 anti-rabbit
Donkey 1:800 Molecular Probes
Rat IgG A lexa Fluor 
488 anti-rat
Donkey 1:800 Molecular Probes
Rat IgG A lexa F luor 
594 anti-rat
Donkey 1:800 Molecular Probes
Directly conjugated molecules
Alexa Fluor 594-conjugated phalloidin lU/200pl Molecular Probes
Alexa Fluor 647-conjugated transferrin 200nM Molecular Probes
Flow cytometry
Primary
His6 Anti-His6 Mouse
IgG2a
1:100 BD Biosciences
Secondary
Mouse IgG A lexa Fluor 
4 8 8  a n t i ­
mouse
Donkey 1:800 Molecular Probes
Western blotting and immunodetection
Primary
Ezrin Anti-ezrin Rabbit 1:500 Upstate
Biotechnology
GRK2 Anti-GRK2/3 Mouse
IgG2ax
1:300 Upstate
Biotechnology
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P-tubulin Anti-p-tubulin
(H-235)
Rabbit 1 : 2 0 0 Santa Cruz 
Biotechnology, Inc.
Secondary (peroxidase linked)
Mouse IgG Anti-mouse
IgG
Sheep 1:2500 Amersham
Biosciences
Rabbit IgG Anti-rabbit IgG Donkey 1:2500 Amersham
Biosciences
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3 Ezrin is a novel substrate of GRK2
GRK2 phosphorylates a number of non-GPCR substrates, including tubulin, 
phosducin, synucleins, PDEy, ribosomal protein P2  and the p-subunit of the 
epithelial Na+ channel (Carman et al., 1998; Dinudom et al., 2004; Wan et al., 2001; 
Freeman et al., 2002; Haga et al., 1998; Pitcher et al., 1998a; Pronin et al., 2000; 
Ruiz-Gomez et al., 2000). This indicates that GRK2 may potentially act as a 
mediator of signalling pathways other than those leading to GPCR desensitisation. 
Phosphorylation of PDEy has been shown to be required for EGF-mediated MAPK 
activation (Wan et al., 2001), indicating that GRK2-mediated phosphorylation of at 
least one non-receptor substrate has been shown to regulate downstream signalling 
events in a cellular setting.
In an attempt to identify novel non-GPCR substrates for GRK2, Dr. Julie Pitcher 
transfected HEK293 cells with either the P2AR, or the P2AR and GRK2. The P2AR 
regulates a variety of biological functions, such as the control of heart rate, and 
vascular and respiratory smooth muscle relaxation (Benovic, 2002; Rockman et al., 
2002). It is coupled to both Gs and Gi, classically stimulating cAMP production via 
adenylyl cyclase, activating PKA and some cAMP-gated ion channels (Benovic, 
2002). GRK2 has been shown to phosphorylate P2AR following agonist stimulation 
both in vitro and in vivo (Choi et al., 1997; Fredericks et al., 1996).
The transfected HEK293 cells were labelled with [32P]orthophosphate and either left 
untreated or treated with the p-adrenergic receptor agonist isoproterenol. Cells were 
subsequently lysed and P-labelled proteins subjected to two-dimensional gel
32electrophoresis and autoradiography. Proteins whose P-content increased upon 
expression of GRK2 in an agonist-dependent fashion were excised and identified 
using MALDI-TOF mass spectrometry. One potential GRK2 substrate identified in 
this fashion was the actin-binding protein ezrin (data not shown).
In this Chapter, I describe experiments designed to test the hypothesis that ezrin was 
a substrate o f GRK2 in vitro and to identify the site of phosphorylation. 
Furthermore, I intended to design and execute an assay to determine whether GRK2 
phosphorylation led to ezrin activation.
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3.1 Ezrin is a substrate of GRK2 in vitro
To determine if ezrin serves as a GRK2 substrate, I expressed and purified human 
GST-ezrin constructs from E. coli (Figures 2 .IB, 3.1 A and 3.2A) and subjected them 
to in vitro phosphorylation by purified GRK2, as described in the methods. The full- 
length GST-ezrin construct (residues 1-586) failed to serve as a substrate for GRK2 
(Figure 3 .IB). However, addition of Gpy and lipid vesicles consisting of 
phosphatidylcholine and PIP2 to the reaction led to efficient phosphorylation of 1- 
586 by GRK2 (Figure 3 .IB). The stochiometry of the phosphorylation was 
calculated to be between 0.15 and 0.3 pmoles ATP incorporated per pmole of 1-586.
The carboxy-terminal PH domain of GRK2 binds PIP2 and Gpy in a coordinated 
fashion to promote membrane localisation of the kinase (Pitcher et al., 1995). PIP2 
also binds the amino-terminus of ezrin; this interaction has been shown to facilitate 
phosphorylation of ezrin at threonine-567, by kinases such as Rho kinase- and PKC, 
and leads to ezrin activation (Fievetet al., 2004; Niggli et al., 1995). The PIP2 and 
GPy-dependence of GRK2-mediated ezrin phosphorylation thus presumably reflects 
the co-localisation of both kinase and substrate to the surface of lipid vesicles and 
PIP2-dependent changes in ezrin conformation.
3.2 Ezrin interacts with GRK2 and modulates its 
interaction with rhodopsin
I sought to investigate whether ezrin, in addition to serving as a GRK2 substrate, 
could modulate GRK2 activity. Purified rod outer segment (ROS) membrane 
preparations, which consist of approximately 90% rhodopsin, represent a convenient 
in vitro substrate for monitoring GRK2 activity. GRK2 phosphorylates specifically 
agonist-occupied (illuminated) rhodopsin (Gan et al., 2000). When purified ROS are 
incubated with GRK2 and ATP under a bright light, they are phosphorylated (Figure 
3.1C). Interestingly, adding increasing concentrations of up to lpM  1-586 to the 
reaction augmented the phosphorylation of ROS by GRK2, such that addition of 
lp,M 1-586 increased ROS phosphorylation over six-fold (Figure 3.1C). These 
results suggest that ezrin not only acts as a substrate for GRK2 but, by interacting 
with GRK2, serves to enhance its action against rhodopsin, either by directly
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activating it or by promoting the membrane localisation of GRK2. The latter 
explanation is most probable since, in the absence of Gpy in the purified ROS, the 
binding of ezrin to PIP2 within the ROS membrane could enhance the targeting of 
GRK2 to the plasma membrane, where it would be activated by light-stimulated 
rhodopsin.
3.3 GRK2 phosphorylates ezrin between residues 533 and 
586
I utilised GST-ezrin constructs with different domain deletions in an attempt to 
identify the region of ezrin that contains the GRK2 phosphorylation site(s). A GST 
fusion protein encompassing residues 310-586 of ezrin was a substrate of GRK2, 
localising the GRK2 phosphorylation site to the carboxy-terminus of the protein 
(Figure 3.2B). The reaction stochiometry was between 0.11 and 0.4 pmoles ATP 
incorporated per pmole 310-586, similar to that observed with the full-length 
construct.
Notably, addition of Gpy and POVcontaining lipid vesicles inhibited GRK2- 
mediated phosphorylation of this protein (Figure 3.2B). These results are consistent 
with the PIP2 and Gpy-dependence observed for GRK2-mediated phosphorylation of 
full-length ezrin. GST-310-586 lacks the auto inhibitory amino-terminal PIP2 
binding domain of ezrin; phosphorylation sites encompassed within this carboxy- 
terminal domain would thus be predicted to be accessible in the absence of PIP2 . 
Since in the presence of GPy GRK2 binds PHVcontaining vesicles (Pitcher, et al., 
1996), their addition would be predicted to sequester GRK2 away from its non-PIP2 
binding GST-310-586 substrate, thereby inhibiting GRK2-mediated 310-586 
phosphorylation.
An ezrin construct lacking the carboxy-terminus (residues 1-533) was poorly 
phosphorylated by GRK2, both in the presence and absence of Gpy and lipid (Figure 
3.2B).
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Figure 3.1. Ezrin is a substrate o f GRK2 in vitro and prom otes GRK2-m ediated rhodopsin 
phosphorylation. A. A GST-fusion construct corresponding to full-length ezrin (1-586) was over­
expressed in E. coli and purified as detailed in Chapter 2. The construct was subject to SDS-PAGE 
and Coomassie staining. Red arrow head indicates the full length protein construct, other bands are 
degradation products. B. Purified full-length ezrin (lp-M) was phosphorylated in the presence of 
0.2[xM GRK2 and in the absence or presence o f G^y and PIP2. Proteins were separated on a 10% 
SDS-polyacrylamide gel and visualized by autoradiography. No phosphorylation o f the GST moiety 
alone (GST) was observed. C. Rod outer segments (ROS) containing rhodopsin also serve as GRK2 
substrates (lane 1). Adding increasing concentrations o f full-length ezrin (1-586) up to l|j.M 
augmented GRK2 phosphorylation o f ROS (lanes 2-4). The optical densities o f the phosphorylated 
ROS bands were quantified and the relative values, compared to 0 p.M 1-586, calculated. Positions of 
protein molecular mass standards are indicated at the left o f the images. Bands shown in boxes are 
from gels imaged at the same exposure, but with irrelevant lanes removed.
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Figure 3.2. GRK2 phosphorylates the carboxyl-terminus o f ezrin between residues 533 and 586. A. 
GST-fusion constructs corresponding to the catboxyl-terminus o f ezrin (310-586) and a carboxyl- 
terminus deletion (1-533) were over-expressed in E. coli and purified as detailed in Chapter 2. The 
constructs were subject to SDS-PAGE and Coomassie staining. B. Purified proteins (l[xM) were 
phosphorylated in the presence o f 0.2pM  GRK2 and in the absence or presence o f G^y and PIP2. 
Proteins were separated on a 10% SDS-polyacrylamide gel and visualized by autoradiography. No 
phosphorylation o f the GST moiety alone (GST) was observed. C. A full-length ezrin construct in 
which threonine-567 had been mutated to alanine was cloned into the pGEX-5X-l vector (GST- 
T567A). The resulting mutant GST-fusion protein was over-expressed in £.coli, purified and subject 
to SDS-PAGE and Coomassie staining, along with the full-length, wildtype GST-ezrin construct 1- 
586. Positions of protein molecular mass standards are indicated at the left of the images. Bands 
shown in boxes are from gels imaged at the same exposure, but with irrelevant lanes removed. Red 
arrow heads indicate the full length protein constructs, other bands in each lane are degradation 
products.
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These results indicate that GRK2 phosphorylates the carboxy-terminus of ezrin, 
between residues 533 and 586. This region includes threonine-567, phosphorylation 
of which regulates the cross-linking activity of ERM proteins (Matsui et al., 1998). 
From these observations I speculated that GRK2 may, like Rho kinase and PKC, 
directly modulate the ability of ezrin to cross-link plasma membrane proteins to 
actin. Also notable was the Gj3y-dependence of GRK2-mediated phosphorylation of 
full-length ezrin, which suggest that this phosphorylation event might be dependent 
upon GPCR activation in a cellular context.
3.4 Assay to determine if GRK2-mediated phosphorylation 
of ezrin regulates ezrin function
Phosphorylation of ERM proteins at threonine-567 (or equivalent) has been shown to 
inhibit the association of the carboxyl-terminus of the protein with its amino- 
terminus, leading to ERM activation (Matsui et al., 1998). I therefore sought to 
examine whether GRK2-mediated phosphorylation of the carboxyl-terminal domain 
of ezrin would similarly inhibit its association with an amino-terminal ezrin fusion 
protein construct.
COS cells were transfected with the VSVG-tagged carboxyl-terminal domain of 
human ezrin (C-ezrin; residues 280-585). After 48 hours, the cells were lysed and 
the lysate incubated with glutathione agarose beads to which a GST-tagged amino- 
terminal construct of ezrin (residues 1-310) had been pre-bound. Following 
washing, bound protein was dissociated from the agarose beads and subject to SDS- 
PAGE and western blotting. C-ezrin bound to the 1-310 construct was detected 
using an anti-ezrin primary antibody that recognises residues 479-498 within the 
carboxyl-terminus of human ezrin (Upstate Biotechnology). Lysates of COS cells 
over-expressing C-ezrin and wildtype GRK2 or C-ezrin and a catalytically inactive 
GRK2 mutant (GRK2k220r) were similarly processed.
In agreement with published observations (Matsui et al., 1998), the carboxyl- 
terminal ezrin construct associated with the amino-terminal construct and could be 
specifically purified from the COS cell lysate (Figure 3.3). It was postulated that the 
C-ezrin construct co-expressed with GRK2 would be phosphorylated. If GRK2
90
phosphorylation leads to ezrin activation, the association of C-ezrin with GST-1-310 
would be predicted to be impaired. Conversely, co-expression of C-ezrin with the 
catalytically inactive mutant of GRK2 (GRK2k22or) would not be predicted to affect 
the phosphorylation status of C-ezrin or the ability of the amino- and carboxyl- 
termini of ezrin to interact.
1 2 0  ~i------------------------ — ------------------ ---------------------------------------------------------------------------------------------------------------------
COS lysate COS lysate +  GRK2 COS lysate +
GRK2K220R
Figure 3.3. GRK2-mediated phosphorylation o f ezrin inhibits the association o f the amino- and 
carboxyl-termini of ezrin. COS cells were transfected with C-ezrin (residues 280-585). The lysate 
was incubated with glutathione agarose beads to which the 1-310 GST-ezrin construct had been pre­
bound. Following washing, bound protein was dissociated from the agarose beads and subject to 
SDS-PAGE and western blotting. Any C-ezrin that had bound to the 1-310 construct was detected 
using an anti-ezrin primary antibody (COS lysate). This was repeated with lysates o f COS cells over- 
expressing C-ezrin and wildtype GRK2 (COS lysate + GRK2) or C-ezrin and the catalytically inactive 
GRK2 mutant GRK2k22or (COS lysate + GRK2K220R). The mean amount o f C-ezrin bound to 1-310 
in the absence o f GRK2 over-expression was considered to be 100% and the mean amounts o f C-ezrin 
bound in pulldown assays in the presence o f GRK2 over-expression were standardised accordingly 
(n=2).
Co-expression of GRK2 with C-ezrin reduced the relative amount (when compared 
to the total expressed in the cell lysate) of C-ezrin binding to 1-310 by 62.6%, 
whereas expression of GRK2k22or inhibited the C-ezrin/1-310 association by only 
9.5% (Figure 3.3). This data suggests that GRK2 activity can inhibit the association
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of the amino- and carboxyl-termini of ezrin, indicating that GRK2 phosphorylation 
serves to activate ezrin. These results suggest that threonine-567 may represent the 
site of GRK2-mediated ezrin phosphorylation.
3.5 Identification of the GRK2 phosphorylation site of 
ezrin
In order to determine the exact site(s) of GRK2 phosphorylation of ezrin, I attempted 
to identify which residues of GST-310-586 ezrin were phosphorylated after 
incubation with GRK2. Following confirmation of sequence, a total of 20|ig 310- 
586 protein was subject to in vitro phosphorylation as described in Section 2.4.2 and 
the pooled reactions were subject to SDS-PAGE and Coomassie staining of the gel. 
The band corresponding to 310-586 was excised from the gel and sent to Dr. Richard 
Cook at the DeBakey Centre for Research, Texas, USA. Following in-gel trypsin 
digestion, peptides derived from the digest were eluted from the gel slice and 
enriched for phosphopeptides using an iron chelate matrix. Electrospray MALDI- 
TOF mass spectrometry was subsequently used in an attempt to separate and identify 
the phosphopeptides.
Although some phosphopeptides were recovered using this procedure, they were 
present in such small quantities as to make their identification by MALDI-TOF 
untenable. Examination of the peptide sequence of 310-586 (Figure 3.4) reveals that 
the carboxyl terminus of ezrin is arginine- and lysine-rich, especially in the region 
surrounding the candidate phosphorylation site, threonine-567. Trypsin digestion of 
such a phosphorylated peptide would be predicted to lead to the generation of very 
small phosphopeptides (Figure 3.4) that would not be likely to be detected in the 
mass spectrometry procedure.
Although it could have been possible to repeat this procedure with alternative 
proteolytic strategies, in order to attempt to generate larger phosphopeptides, I 
decided on an alternative strategy to determine if threonine-567 represents the site of 
GRK2-mediated ezrin phosphorylation. I therefore undertook a different approach. 
Using a PCR-based method, I cloned a human ezrin construct in which the threonine 
at position 567 had been mutated to alanine from pCB6-Ezrin-T567A-VSVG into the
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pGEX-5X-l vector (GST-T567A-ezrin, Figures 2. IB and 3.2C). Sequencing 
confirmed that the GST-T567A construct was downstream of and in frame with the 
GST moiety of the pGEX vector and that there was no longer a VSVG tag at the 3' 
end. It also verified that threonine-567 had been mutated to alanine-567.
1 MPKPINVRVT TMDAELEFAI QPNTTGKQLF DQWKTIGLR
41 EVWYFGLHYV DNKGFPTWLK LDKKVSAQEV RKENPLQFKF
81 RAKFYPEDVA EELIQDITQK LFFLQVKEGI LSDEIYCPPE
121 TAVLLGSYAV QAKFGDYNKE VHKSGYLSSE RLIPQRVMDQ
161 HKLTRDQWED RIQVWHAEHR GMLKDNAMLE YLKIAQDLEM
201 YGINYFEIKN KKGTDLWLGV DALGLNIYEK DDKLTPKIGF
241 PWSEIRNISF NDKKFVIKPI DKKAPDFVFY APRLRINKRI
281 LQLCMGNHEL YMRRRKPDTI EVQQMKAQAR_ EEKHQKQLER
321 QQLETEKKRR ETVEREKEQM MREKEELMLR LQDYEEKTKK
361 AERELSEQIQ RALQLEEERK RAQEEAERLE ADRMAALRAK
401 EELERQAVDQ IKSQEQLAAE LAEYTAKIAL LEEARRRKED
441 EVEEWQHRAK EAQDDLVKTK EELHLVMTAP PPPPPPVYEP
481 VSYHVQESLQ DEGAEPTGYS AELSSEGIRD DRNEEKRITE
521 AEKNERVQRQ LLTLSSELSQ ARDENHTHN d iih n e n m I q
561 DEFEALGBD1YBTLBQ IBQGNTjQlI
Figure 3.4. Amino acid sequence of ezrin (accession number: NP_003370). Residues included in 
construct 310-586 are underlined. Those residues that encompass the GRK2 phosphorylation site, i.e. 
those that are found in construct 310-586 but not construct 1-533, are in blue. Threonine-567 is in 
red. Arginine and lysine residues in the vicinity of threonine-567 are highlighted in cyan.
I intended to use this mutant protein in in vitro phosphorylation assays to determine 
whether GRK2 phosphorylation of full-length ezrin would be inhibited in the 
absence of threonine-567. Unfortunately, due to time constraints, it was not possible
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to complete these experiments. However, I have verified that this construct contains 
the threonine to alanine substitution at residue 567 and it should serve as a useful 
tool for future investigations. Indeed, it has subsequently been used by Dr. Julie 
Pitcher in in vitro phosphorylation assays to demonstrate that it is not phosphorylated 
by GRK2 (Cant and Pitcher, 2005).
3.6 Summary
In summary, this Chapter provides evidence that ezrin is a substrate of GRK2 in 
vitro, supporting an earlier finding by Dr. Julie Pitcher that GRK2 phosphorylation 
of ezrin occurs in cultured mammalian cells. GRK2 phosphorylates full-length ezrin 
only when PIP2-containing lipid vesicles and Gpy are present, suggesting that this 
event would be dependent on GPCR activation in a cellular setting. This finding 
agrees with the result of Dr. Pitcher’s initial investigation where GRK2-mediated 
phosphorylation of ezrin was enhanced following agonist occupancy of the P2AR.
Phosphorylation of ezrin by GRK2 occurs within a carboxyl-terminal 53 amino acid 
stretch that encompasses the phosphorylation site required for ezrin activation, 
threonine-567. Attempts to demonstrate either directly or indirectly that threonine- 
567 was the site of GRK2 phosphorylation in vitro were unsuccessful within the time 
constraints of this thesis. However, Dr. Julie Pitcher has subsequently demonstrated 
that the GST-T567A-ezrin construct is not phosphorylated by GRK2, suggesting that 
threonine-567 does indeed represent the site of GRK2-mediated phosphorylation 
(Cant and Pitcher, 2005).
Interestingly, ezrin appears to increase the activity of GRK2 on ROS in vitro, 
indicating that GRK2 and ezrin may interact. Ezrin might act to enhance the action 
of GRK2 against rhodopsin by either directly activating it or by promoting the 
membrane localisation of GRK2. Although the latter explanation is most probable, it 
would be interesting to investigate whether ezrin has any effect on the GRK2- 
mediated phosphorylation of ROS in the presence of G|3y.
The implications of the results presented in this and the following two Chapters will 
be discussed in detail in Chapter 6.
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4 Ezrin is required for MlMR-mediated
ruffling
As described in the introduction to this thesis, it has previously been shown that 
ERM proteins are involved in the biogenesis of lamellipodia and filopodia, structures 
generated during cell migration (Bretscher, 1989; Yonemura et al., 1999). Directed 
cell migration, or chemotaxis, is a process that occurs throughout an organism’s 
lifespan, from embryonic development to wound repair and the leukocytic immune 
response. The motile cell becomes highly polarised, extending lamellipodia and 
filopodia in the direction of migration (Small et al., 2002). These protuberances 
attach to the underlying strata via adhesion complexes that link to the actin 
cytoskeleton to stabilise the structures and provide the traction force needed to propel 
the cell forward. The complexes are rapidly detached at the back of the cell as the 
cell body contracts and advances and the rear retracts (Horwitz and Webb, 2003).
4.1 The role of the actin cytoskeleton in migration
Lamellipodia and filopodia are sites of actin polymerisation where regulators of 
microfilament remodelling, such as Arp2/3, WASP, Abpl and cortactin are localised. 
As the cell moves forward, its cell body is pulled in the direction of migration. This 
contractile force is generated through the cross-linking of actin filaments by myosin 
motor proteins. Disassembly of microfilaments at the rear of the cell is thought to be 
mediated by the actin depolymerising factor/cofilin protein family (Pollard and 
Borisy, 2003). The Arp2/3 activator Abpl colocalises with Arp2/3 and F-actin at 
lamellipodia in response to growth factor stimulation of mammalian cells (Goode et 
al., 2001; Kessels et al., 2001). Cortactin, which can also bind actin and activate 
Arp2/3, is believed to stabilise the actin network of the lamellipodium as it can 
inhibit actin debranching (Weaver et al., 2001).
4.1.1 Membrane ruffles are compartments of actin reorganisation
Membrane ruffles have been identified as lamellipodia that “ruffle” as they curl away 
from the substrate (Small et al., 2002). A recent study has demonstrated that 
membrane ruffles consist of densely packed actin filaments that differ from the actin 
cytoskeleton that makes up the underlying cell lamella (Borm et al., 2004). The
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researchers demonstrated that ruffles are distinct compartments of actin 
reorganisation that are enriched in ezrin and filamin. They hypothesised that 
membrane ruffles are formed when a migrating cell fails to establish firm adhesions 
to its substrate, causing lamellipodia to retract towards the cell body (Borm et al., 
2004).
4.1.2 GPCR-mediated cell migration and ruffling
GPCRS such as the sphingosine-1-phosphate receptors, proteinase-activated receptor 
2 (PAR2), the p-opioid receptor and the chemokine receptors CCR2, CXCR1, 
CXCR2 and CXCR4 induce membrane ruffling and cell migration on agonist 
activation (D’Apuzzo et al., 1997; Ge et al., 2004; Jones et al., 2003; Richardson et 
al., 2003; Takayama and Ueda, 2005; Wang et al., 1999). GRK2 has been shown to 
be important in regulating the CCR2-mediated response to chemoattractants in 
leukocytes (Aragay et al., 1998) and is highly expressed in undifferentiated, 
multipotent migratory cells during early embryonic mouse development (Sefton et 
al., 2000). Furthermore, neutrophils and splenocytes derived from GRK6-deficient 
mice have altered chemotactic responses (Fong et al., 2002; Kavelaars et al., 2003; 
Vroon et al., 2004). These results suggest that GRKs also play key roles in 
regulating migratory responses to GPCR activation.
Other components of the GPCR desensitisation machinery may also contribute to 
cell motility. parrestin2-deficient splenocytes have impaired chemotactic responses 
and |3arrestin scaffolded to ERK has been shown to be required for migration 
following PAR2 activation (Fong et al., 2002; Ge et al., 2004). parrestin2 has also 
been demonstrated to play an essential role in mediating the migration of both 
ATiAR-expressing cells in response to both angiotensin II and lysophosphatidic acid 
(Hunton et al., 2005) and CXCR4-expressing cells in response to stromal cell- 
derived factor la ,  via the p38/MAPK signalling pathway (Sun et al., 2002). Finally, 
as discussed in Chapter 1 (Section 1.2.6.2), GIT family proteins may be required for 
focal adhesion dynamics and cell motility (Turner et al., 1999; West et al., 2001; 
Zhao et al., 2000).
96
4.2 MIMR-expressing Hep2 cells are a model for 
membrane ruffling
Hep2 cells over-expressing the HA-tagged Ml muscarinic receptor (MlMR) ruffle in 
response to agonist (acetylcholine) treatment. The Ml MR is widely expressed in the 
forebrain and appears to regulate processes such as learning and memory (Wess, 
2004). It is coupled to Gq (Offermanns et al., 1996), increasing intracellular levels 
of the second messenger Ca2+ and therefore activating PKC and Ca2+-gated ion 
channels on agonist stimulation. GRK2 has been demonstrated to phosphorylate 
Ml MR in vitro (Haga et al., 1996).
48 hours following transient transfection with HA-tagged M 1 MR, Hep2 cells were 
treated with the Ml MR agonist acetylcholine for 5 minutes. Following fixation and 
receptor staining, the cells were observed to demonstrate rapid and transient 
membrane ruffling around their periphery (Figure 4.1), followed by M l MR 
internalisation (Figure 4.1). Approximately 81±6% of cells ruffle. I used this model 
system to investigate the potential functional significance of GPy-dependent GRK2- 
mediated ezrin phosphorylation in GPCR-mediated cytoskeletal reorganisation.
Untreated +Ach
5  mi n  1 5 m i n  4 5  mi n
Figure 4.1. MIMR-expressing Hep2 cells are a model for membrane ruffling. Hep2 cells transiently 
expressing M l MR were treated with the muscarinic receptor agonist acetylcholine (Ach) for 5, 15 and 
45 minutes. Cells were fixed and the M l MR visualised as described in Chapter 2. Scale bar 
represents 20|un.
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4.3 Ezrin is required for MIMR-mediated membrane 
ruffling
To investigate a potential role for ezrin in MIMR-mediated membrane ruffling, I 
examined the subcellular localisation of endogenous ezrin in MIMR-expressing 
Hep2 cells. Treatment of these cells with acetylcholine for 5 minutes induced 
membrane ruffles to which endogenous ezrin was localised (Figure 4.2A). Using an 
antibody (297S) that specifically recognises ERM proteins phosphorylated at the 
regulatory threonine residue (pERM) (Hayashi et al., 1999; Matsui et al., 1998) it 
was observed that the cellular levels of pERM increase following agonist stimulation 
and that activated ERM proteins localise to ruffles (Figure 4.2A). These results 
demonstrate that M l MR activation promotes ERM protein phosphorylation and 
suggest that activated ERM proteins may play a role in ruffle formation.
To determine if activated ezrin is required for ruffling formation I co-transfected 
Hep2 cells with the M l MR and a VSVG-tagged full-length human ezrin construct 
(WT-ezrin) or the VSVG-tagged amino-terminal FERM domain of human ezrin (N- 
ezrin; residues 1-309). Expression of the FERM domain of ezrin has been shown to 
inhibit ezrin function in a number of model systems. In LLC-PK1 epithelial cells, 
expression of the FERM domain of ezrin causes redistribution of endogenous ezrin 
and impairs human growth factor-mediated cell migration (Crepaldi et al., 1997). 
Similarly, when expressed in NIH3T3 fibroblasts, the FERM domains of all three 
ERM proteins interferes with the cellular architecture, inhibiting filopodial 
protrusion and retraction (Amieva et al., 1999). Finally, in mice, expression of the 
FERM domain of ezrin inhibits ezrin-mediated breast carcinoma metastasis (Elliott 
et al., 2005).
Expression of full-length ezrin has no effect on agonist-dependent MIMR-mediated 
ruffling and the expressed protein, like the endogenous, localises to ruffles (WT- 
ezrin, Figures 4.2B and C). However, Hep2 cells co-transfected with M l MR and the 
FERM domain of ezrin (N-ezrin) show an approximate 64±9% reduction in ruffle 
formation following agonist stimulation (N-ezrin, Figures 4.2B and C). These results 
are consistent with an obligate role for activated, phosphorylated, ERM proteins in 
MIMR-mediated membrane ruffle formation in this system.
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D: M1MR M1MR
T : M1MR/WT-ezrin M 1M R /N -ezrin
T :  M1MR M1 MR
B
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i
M1MR M1 MR + W T -erin  M1MR + N -ezrin
Figure 4.2. Ezrin is required for MIMR-mediated membrane ruffling. A. The cellular distribution 
o f endogenous ezrin and pERM in Hep2 cells over-expressing M l MR was visualised by 
immunofluorescence 48 hours post-transfection. Where indicated, cells were treated with lOOpM 
acetylcholine for five minutes prior to fixation (Ach). B. Hep2 cells were transfected with M l MR 
and a wildtype ezrin construct (WT-ezrin) or M l MR and the FERM domain o f ezrin (N-ezrin). 48 
hours post-transfection cells were treated with agonist, lOOpM acetylcholine, for 5 minutes (Ach) and 
the effect on membrane dynamics visualised by immunofluorescence. T denotes the cDNA constructs 
transfected. D denotes the proteins detected. Scale bars represent 20pm. C. The effect of different 
ezrin mutants on M IM R-mediated ruffling was assessed by exposing the cells to 5 minutes o f 
acetylcholine treatment and counting the number o f ruffling cells that expressed both M 1 MR and the 
mutant construct. Data indicate the mean number o f ruffling cells. Error bars represent S.D. o f mean 
data collected from multiple experiments (n>3). *** indicates p<0.001.
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4.4 MIMR-mediated ruffling requires GRK2 activity
Since ezrin is a substrate of GRK2, I investigated a potential role for GRK2- 
mediated phosphorylation events in this model of cytoskeletal reorganisation. Hep2 
cells were co-transfected with M l MR and either the carboxy-terminus of GRK2 
(GRK2-CT, or pARKct) or the catalytically inactive mutant kinase (G RK 2k220r)- 
Both GRK2-CT and GRK2k22or contain the G|3y/PIP2 binding PH domain of GRK2 
and their expression inhibits agonist-dependent translocation of endogenous GRK2 
to activated GPCRs (Daaka et al., 1997b). Either construct would thus be anticipated 
to inhibit receptor-activated GRK2-mediated phosphorylation events. Cells co­
expressing M l MR and GRK2-CT or M l MR and G R K 2k22or show diminished 
membrane ruffling by approximately 90±5% (n>3, p<0.001) and 81±14% (n>3, 
p<0.001) respectively compared to those expressing M l MR alone, following 
acetylcholine treatment (Figures 4.3A and B and 4.4).
I also co-transfected Hep2 cells with either Ml MR and a GFP-tagged RGS domain 
of GRK2 (GRK245-i78), or Ml MR and a GFP-tagged Gq binding-defective mutant 
RGS domain (GRK245_i78D1 10A). When expressed, GRK245_i78 associates with 
GTP-bound Gq at the plasma membrane, whereas GRK245_i78D1 10A is unable to 
bind Gq and so remains localised in the cytosol (Steme-Marr et al., 2003). GRK245. 
i78 would therefore be expected to inhibit the translocation of endogenous GRK2 to 
activated GPCRs on agonist treatment, while expression of GRK245.i78D1 10A would 
not be expected to have an effect. Following agonist treatment, cells co-expressing 
M l MR and GRK245_i78 show reduced ruffling by approximately 75±9% (m>3, 
p<0.001) compared to those expressing M1MR alone (Figures 4.3C and 4.4). The 
number of cells co-expressing Ml MR and GRK245_i78D1 10A that show ruffling after 
acetylcholine treatment does not significantly differ from those expressing M l MR 
alone (ns>3) (Figures 4.3D and 4.4). These results imply that, in addition to ezrin, 
active GRK2 is required at the plasma membrane for the formation of membrane 
ruffles in Hep2 cells expressing Ml MR.
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Figure 4.3. GRK2 is required for MIMR-mediated membrane ruffling. Hep2 cells were transfected 
with M l MR and (A) the carboxy-terminus o f GRK2 (M 1MR/GRK2-CT), (B) M l MR and 
catalytically inactive GRK2 (M1MR/GRK2k22or), (C) M l MR and the GFP-tagged RGS domain of 
GRK2 (M 1MR/GRK2 45_178), or (D) M l MR and the GFP-tagged Gq binding-defective mutant GRK2 
RGS domain (GRK245_178D110A). 48 hours after transfection, the cells were treated with 100p,M 
acetylcholine (Ach) for 5 minutes. The cells were visualised by immunofluorescence. Asterisks 
indicate treated cells expressing both M l MR and the GRK2 construct. T denotes cDNA constructs 
transfected. D denotes proteins detected. Scale bar represents 20|xm.
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Figure 4.4. GRK2 mutants inhibit MIMR-mediated ruffling. The effect o f different GRK2 mutants 
on M IM R-mediated ruffling was assessed by exposing the cells to 5 minutes o f acetylcholine 
treatment and counting the number of ruffling cells that expressed both M l MR and the mutant kinase. 
101 Data indicate the mean number o f ruffling cells. Error bars represent S.D. o f mean data collected 
from multiple experiments (n>3). *** indicates p<0.001.
However, GRKs are also likely to regulate GPCR signalling in a phosphorylation- 
independent fashion. Since GRKs bind to Gpy and, where expressed, Gq-GTP, they 
may also mediate GPCR desensitisation by inhibiting signalling pathways 
downstream of Gpy and Gq (Pao and Benovic, 2002). Although GRK2 mutants such 
as GRK2-CT, GRK2k220r and GRK 245.i78 would be expected to interfere with the 
translocation of wildtype GRK2 to the plasma membrane, they could also terminate 
signalling via Gpy (GRK2-CT and GRK2k220r) and/or Gq (GRK2k22or and GRK245. 
i7g) (Carmen et al., 1999a; Rockman et al., 1998; Sallese et al., 200b).
In order to determine the exact roles of GRK2, Gpy and Gq in MIMR-mediated 
membrane ruffling, further experimental approaches are required. Acetylcholine 
stimulation of M 1 MR-expressing Hep2 cells transfected with the functional GPy
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scavenger transducin (Federman et al., 1992) would establish whether G(3y subunits 
are required for ruffling. The expression of carboxyl-terminal Gq peptides, which 
have been shown to interfere with endogenous Gq binding to GPCRs and activating 
PLCp (Akhter et al., 1998), in cells co-transfected with M l MR would indicate 
whether Gq-mediated activation of PLCp is required for membrane ruffling. This 
could additionally be investigated with the use of xanthine nucleotide-binding G aq 
mutants that act in a dominant negative manner to inhibit coupling of GPCRs to Gq 
and prevent PIP2 hydrolysis by PLCp (Goel et al., 2004; Yu et al., 2000).
4.5 GRK2 activity is required for ERM activation in Hep2 
cells
To examine the relationship between GRK2 activity and ERM phosphorylation in 
MIMR-mediated membrane ruffling, I co-transfected Hep2 cells with M l MR and 
GRK2-CT, agonist treated, fixed and detected endogenous pERM using the 297S 
antibody. In cells expressing M l MR alone, pERM were observed after agonist 
treatment and was localised to the ensuing ruffles (Figures 4.2A and 4.5). In cells 
expressing both Ml MR and GRK2-CT no ruffling was observed and pERM could 
not be detected, even after receptor stimulation (Figure 4.5). The fact that 
endogenous GRK2 activity is required for the detection of active ERM species in the 
cell suggests that it is GRK2 that is responsible for the phosphorylation of ERM 
proteins. Furthermore, since the antibody utilised specifically recognises pERM, 
GRK2 is implicated as the kinase responsible for phosphorylating ERM proteins at 
this functionally relevant site. These results cannot discount an alternative 
hypothesis that GRK2 phosphorylates and activates an additional kinase that is itself 
responsible for the phosphorylation and activation of ERM proteins at membrane 
ruffles. However, when considered in conjunction with the in vitro results presented 
in Chapter 3, the data are highly suggestive that GRK2 directly phosphorylates and 
activates ERM proteins following Ml MR activation in Hep2 cells.
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Figure 4.5. GRK2 activity is required for ERM activation in Hep2 cells. Hep2 were transfected with 
M l MR and GRK2-CT and incubated for 48 hours. The cells were subsequently treated with 
acetylcholine for 5 minutes (Ach) and M l MR, GRK2-CT and endogenous pERM detected by 
immunofluorescence. Asterisks indicate cells co-expressing M l MR and GRK2-CT. T denotes the 
cDNA constructs transfected. D denotes the proteins detected. Scale bars represent 20pm.
4.6 MIMR-mediated membrane ruffling in Hep2 cells is 
not Rho kinase, PKC or PKA dependent
Earlier studies have shown that ezrin can be phosphorylated at threonine-567 by 
PKC, Rho kinase and PKA (Matsui, et al. 1998; Ng et al., 2001; Simons et al., 1998; 
Zhou et al., 2003). I examined whether these kinases were responsible for the 
phosphorylation of ERM proteins in our model system. Hep2 cells over-expressing 
Ml MR were pre-treated with the Rho kinase inhibitor Y27632 (Figure 4.6A), the 
PKC inhibitor GF109203X (Figure 4.6B) or the PKA inhibitor Rp-8-Br-CAMPS 
(Figure 4.6C) prior to agonist stimulation. pERM were subsequently detected in 
these treated cells using 297S (cells treated with Y27632 and GF109203X) or the 
Cell Signalling Technology anti-pERM antibody (cells treated with Rp-8-Br- 
CAMPS). None of the inhibitors prevent ruffle formation following agonist 
treatment, nor do they inhibit ERM phosphorylation or localisation of pERM to the 
ruffles (n>3). These results suggest that the MIMR-dependent phosphorylation of
104
D+10lxM Y27632
T:  M1MR
D: M1MR
Q  +1mM Rp-8-Br-CAMPS
T:  M1MR
D: M1MR 
- o
Iro
<4—•c  
3
B +20flM GF109203X
T :  M1MR
D: M1MR
M1MR +  M1MR + M IM R + Rp-
Y 2 7 6 3 2  G F 1 0 9 2 0 3 X  8-B r-CA M PS
Figure 4.6. MIMR-mediated ruffling in Hep2 is not Rho kinase, PKC or PKA dependent. 48 hours 
following transfection, Hep2 cells overexpressing M l MR were treated with either the Rho kinase 
inhibitor (A: Y27632, 10pM), the PKC inhibitor (B: GF109203X, 20pM), or the PKA inhibitor (C: 
Rp-8-Br-CAMPS, ImM) for 1 hour. Cells were then subject to lOOpM acetylcholine for 5 minutes 
prior to fixation (Ach). M l MR and endogenous pERM were visualised by immunofluorescence using 
either the 297S antibody (A and B) or a commercial anti-pERM antibody (C). T denotes the cDNA 
constructs transfected. D denotes the proteins detected. Scale bar represents 20pm. D. The effect of 
the different kinase inhibitors on MIMR-mediated ruffling was assessed by counting the number of 
ruffling cells following inhibitor treatment and addition of agonist for 5 minutes. Data indicate the 
mean number o f  ruffling cells. Error bars represent S.D. o f mean data collected from multiple 
experiments (n>3).
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ERM proteins observed in Hep2 cells is not mediated by Rho kinase, PKC or PKA. 
This further supports my contention that GRK2 is responsible for mediating this 
phosphorylation event.
4.7 EGF-mediated membrane ruffling in Hep2 cells is
dependent on PKC and Rho kinase and independent of 
PKA and GRK2
A short (2-5 minutes) treatment with EGF induces membrane ruffles in A-431 cells 
(Bretscher, 1989). Ezrin is recruited to these ruffles in a PKC-dependent manner 
(Stapleton et al., 2002). I therefore treated Hep2 cells with EGF for 3 minutes in 
order to activate endogenous EGF receptors and stimulate membrane ruffling. 
Ruffle formation occurred and was visualised by staining the cells with Alexa Fluor 
594-conjugated phalloidin (Figure 4.7A). To demonstrate the efficacy of the kinase 
inhibitors used above, I treated the cells with Y27632, GF109203X and Rp-8-Br- 
CAMPS prior to stimulation with EGF. The treatment protocol was identical to that 
used for MIMR-expressing Hep2 cells.
EGF-mediated ruffling is diminished by 50±6% in cells treated with Y27632 (n=3, 
0.01<p<0.05) and 66±6% in cells treated with GF109203X (n=3, 0.001<p<0.01). 
Treatment with Rp-8-Br-CAMPS does not significantly affect EGF-induced ruffling 
in these cells (Figure 4.7A and C). Although a recent study demonstrated that 
Y27632 did not suppress EGF-induced membrane ruffling in human lens epithelial 
cells (Maddala et al., 2003), it appears that Rho kinase is necessary for ruffling 
downstream of EGF in our model system. These results show that both Y27632 and 
GF109203X are effective inhibitors under the conditions used and confirm that 
neither PKC nor Rho kinase are required for MIMR-mediated ruffling. Due to the 
lack of a positive control for Rp-8-Br-CAMPS efficacy, a role for PKA in our 
M l MR model cannot be ruled out, although it is unlikely as no role for PKA in 
membrane ruffling has yet been determined.
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Figure 4.7. EGF-mediated membrane ruffling in Hep2 cells is dependent on PKC and Rho kinase 
and independent o f PKA and GRK2. A. Hep2 cells were treated with EGF for 3 minutes to stimulate 
ruffling. Ruffle formation was visualised by staining the cells with Alexa Fluor 594-conjugated 
phalloidin. EGF-mediated ruffling is diminished in cells treated with Y27632 and GF109203X. 
Treatment with Rp-8-Br-CAMPS does not significantly affect EGF-induced ruffling. B. Hep2 cells 
were transfected with the kinase-dead mutant GRK2k220r- 48 hours later, cells were treated with EGF 
for 3 minutes to induce ruffling and ruffles were visualised with Alexa Fluor 594-conjugated 
phalloidin (Actin). Cells expressing GRK2k22or were identified by staining with an anti-GRK2 
antibody (GRK2k22or)- Expression o f GRK2k22or does not affect EGF-mediated ruffling in Hep2 
cells. T denotes cDNA constructs transfected. D denotes proteins detected. Scale bars represent 
20pm. C. The effect o f the different kinase inhibitors or GRK2k22or expression on EGF-mediated 
ruffling was assessed by exposing the cells to 3 minutes of EGF treatment and counting the number of 
ruffling cells. Data indicate the mean number of ruffling cells. Error bars represent S.D. o f mean data 
collected from multiple experiments (n>3). * indicates 0.01 <p<0.05, ** indicates 0.001 < p <0.01.
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To determine whether GRK2 was involved in EGF-mediated membrane ruffling, I 
treated Hep2 cells transfected with G R K 2 k22or with EGF for 3 minutes and 
visualised the ruffles using phalloidin-594. The expression of the catalytically 
inactive GRK2 mutant has no effect on EGF-stimulated ruffling in Hep2 cells (n=3) 
(Figure 4.7B and C). These results indicate that expression of the GRK2k22or mutant 
specifically inhibits MIMR-mediated ERM-dependent membrane ruffling in this 
Hep2 cell model system.
4.8 Summary
In summary, the results in this Chapter demonstrate that agonist treatment of M1MR- 
expressing Hep2 cells induces cytoskeletal reorganisation in the form of membrane 
ruffles to which active, phosphorylated ERM proteins are localised. These ruffles 
require both functional ezrin and active GRK2 at the plasma membrane, but are not 
dependent on Rho kinase, PKC or PKA. It is probable that GRK2 is the kinase 
directly responsible for phosphorylating and activating ERM proteins in this cell 
system, although I have not formally ruled out the possibility that GRK2 indirectly 
activates ERM proteins via phosphorylation of an as yet identified kinase. These 
results indirectly demonstrate that GRK2 is likely to phosphorylate ezrin at 
threonine-567, as postulated in Chapter 3, since this would lead to the observed 
activation of ezrin and its detection by 297S.
The action of GRK2 in membrane ruffling appears to be specific to the Ml 
muscarinic receptor, since I have demonstrated that expression of a catalytically 
inactive GRK2 mutant does not affect EGF-mediated ruffling in Hep2 cells. These 
results suggest that GRK2 acts downstream of Ml MR to promote actin cytoskeletal 
rearrangements and might also act downstream of other GPCRs, such as CCR2, to 
mediate cytoskeletal reorganisation prior to chemotaxis. Therefore, in addition to 
modulating the number and activity of GPCRs at the cell surface, and thus a cell’s 
chemotactic response following receptor stimulation (Aragay et al., 1998), GRK2 
may actually play a direct role in this important process.
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5 Ezrin and receptor endocytosis
Although the actin cytoskeleton is presumed to regulate clathrin-mediated 
endocytosis, few studies have investigated whether it is involved in GPCR 
internalisation and trafficking. Disruption of the cortical actin cytoskeleton with 
latrunculin has been demonstrated to inhibit the internalisation of the thromboxane 
A2 (TPP), bombesin and endothelin A receptors (Laroche et al., 2005; Lunn et al., 
2000), and cytochalasin D treatment has been shown to disrupt the trafficking of the 
CXCR1 and CXCR2 receptors to the plasma membrane following endocytosis 
(Zaslaver et al., 2001). It is therefore possible that actin regulates both GPCR 
internalisation and recycling.
While there is no evidence that GPCRs can bind actin directly, it is possible that they 
indirectly associate with actin via binding to adapter proteins. NHERF can bind to 
the very carboxyl terminus of the p2AR and is indirectly associated with the actin 
cytoskeleton via its association with ERM proteins (Hall et al., 1998a; Hall et al., 
1998b; Reczek et al., 1997). Disruption of either of these interactions causes mis- 
sorting of the p2AR to lysosomes, rather than recycling to the plasma membrane 
(Cao et al., 1999). Over-expression of NHERF has also been shown to inhibit 
agonist-induced hKOR downmodulation, presumably by increasing its rate of 
recycling (Li et al., 2002). The carboxyl-tail of the \i opioid receptor was recently 
demonstrated to bind to the actin binding protein filamin (Onoprishvili et al., 2003). 
This interaction was shown to be required for opioid receptor trafficking, as 
agonist-induced down-regulation of the receptor is inhibited in cells that do not 
express filamin (Onoprishvili et al., 2003). This study, however, did not distinguish 
between a reduction in the rate of receptor internalisation and an increase in the rate 
of receptor recycling to the plasma membrane. Filamin has also been shown to 
interact with the carboxyl-terminal tail of the calcitonin receptor and its expression 
necessary for both the decreased degradation of the internalised calcitonin receptor 
and increased recycling of the receptor back to the plasma membrane (Seek et al.,
2003). The calcium sensing receptor and the dopamine D2 and D3 receptors have 
also been reported to interact with filamin, suggesting that it may play a role in the 
endocytic sorting and recycling of a number of GPCRs (Seek et al., 2003).
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ERM proteins serve as actin/plasma membrane cross-linkers and may play a role in 
GPCR trafficking via NHERF (Cao et al., 1999). As I have shown that pERM 
colocalise with Ml MR at the plasma membrane following agonist occupancy and are 
required for MIMR-dependent cytoskeletal reorganisation (see Chapter 4), I 
investigated whether ERM proteins are involved in GPCR internalisation.
5.1 HEK|$2 cells express high levels of endogenous ezrin
In order to determine the relative levels of endogenous ezrin in different cell lines, I 
extracted total cellular proteins from confluent plates of Hep2 cells, HEK293 cells 
and HEK293 cells stably expressing His6-tagged P2AR (HEKp2). lxlO6 cells from 
each line were subject to SDS-PAGE and western blotting and the relative amount of 
ezrin detected using an anti-ezrin antibody (Figure 5.1 A). The blots were then 
stripped and re-probed with an anti-p-tubulin antibody to determine the relative 
amounts of total protein loaded onto the gels (Figure 5.1 A).
The optical densities of the ezrin and tubulin bands on the developed films were 
determined using a densitometer. The relative levels of ezrin expression in each cell 
line were calculated by expressing the optical density of the ezrin band as a 
percentage of the optical density of the tubulin band and then standardising relative 
to that expressed in Hep2 cells. This indicated that HEKp2 cells express the most 
ezrin, relative to Hep2 cells (Figure 5 .IB). Interestingly, HEKp2 cells express 
approximately three-fold more ezrin than the parental HEK293 cell line, suggesting 
that the stable over-expression of P2AR may lead to increased ezrin expression.
5.2 pERM colocalise with internalised p2AR and M1MR
To investigate a potential role for ezrin in GPCR internalisation, I examined by 
confocal immunomicroscopy the subcellular localisation of endogenous pERM 
following receptor activation and endocytosis. HEKp2 cells were treated with (-)- 
isoproterenol for 15 min to induce receptor internalisation (Figure 5.2A). This 
treatment increased endogenous pERM levels (detected using 297S), which 
colocalised with P2AR at internalised vesicles. The colocalisation of pERM with 
internalised receptor was also observed in HEK293 cells transiently over-expressing 
FLAG-tagged P2 AR (Figure 5.2B).
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Figure 5.1. Ezrin expression in different cell lines used in this thesis. A. Total cellular proteins were 
extracted from confluent plates of Hep2, HEK293 and HEK293 cells stably expressing His6-tagged 
p2AR (HEK|32). lxlO6 cells from each line were subject to SDS-PAGE and western blotting and the 
relative amount of ezrin detected using an anti-ezrin antibody (ezrin). The blots were stripped and re­
probed with an anti-|3-tubulin antibody to determine the relative amounts o f total protein loaded onto 
the gels (P tubulin). Positions o f protein molecular mass standards are indicated at the left o f the 
images. B. The optical densities o f the ezrin and tubulin bands on the developed films were 
determined using a densitometer. The relative levels o f ezrin expression in each cell line were 
calculated by expressing the optical density of the ezrin band as a percentage o f the optical density of 
the tubulin band and standardising relative to the amount o f ezrin expressed in Hep2 cells (n=l).
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This phenomenon is not restricted to P2AR or HEK293 cells. In Hep2 cells 
expressing M l MR, prolonged acetylcholine treatment (20 min) results in receptor 
endocytosis, which occurred following transient membrane ruffling (Figure 5.2C). 
Agonist treatment of Ml MR transfected Hep2 cells was associated with increased 
endogenous pERM levels and, in these cells also, active ERM proteins colocalise 
with internalised receptor (Figure 5.2C). In marked contrast, in Hep2 cells 
transfected with the HA-tagged M2 muscarinic receptor (M2MR), internalisation but 
not ERM phosphorylation is detected following agonist-stimulation (Figure 5.2D). 
In HEK293 cells M2MR has been shown to internalise in a GRK2- and p-arrestin- 
independent fashion (Claing et al., 2000; Pals-Rylaarsdam et al., 1995; Vogler et al., 
1999). Since GRK activity is required for Parrestin recruitment, and both the P2AR 
and Ml MR are internalised via a Parrestin-dependent mechanism (Claing et al., 
2002), these data suggest that GRK activity may be required for pERM and GPCR 
co-localisation at internalised vesicles.
5.3 p2AR co-localises with the transferrin receptor in early 
endosomes
I then investigated the nature of the internalised vesicles to which P2AR was 
trafficked following agonist activation. HEKP2 cells were treated with (-)- 
isoproterenol for 15 minutes and cells were stained with antibodies against the 
endosomal marker early endosome antigen 1 (EEA1) (Mu et al., 1995) and the 
lysosomal marker lysosomal-associated membrane protein 1 (LAMP1) (Carlsson et 
al., 1988). After 15 minutes of agonist treatment P2AR could be observed within 
internalised vesicles, the majority of which were co-labelled with EEA1 (Figure 
5.3A). These vesicles do not contain the LAMP1 protein (Figure 5.3A).
HEKp2 cells were then incubated with Alexa Fluor 647-conjugated transferrin (647- 
transferrin) for 30 minutes on ice, followed by an immediate incubation at 37°C for 
30 minutes with both 647-transferrin and (-)-isoproterenol. The transferrin receptor 
is constitutively expressed in human cell lines and is trafficked to early endosomal 
compartments following transferrin binding (Dautry-Varsat, 1986). After 30 minutes 
of agonist treatment, the P2AR co-localises with the transferrin receptor in internal 
vesicles that do not label with LAMP1 (Figure 5.3B). It therefore appears that the
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Figure 5.2. pERM proteins co-localise with internalised (32AR and M l MR, but not M2MR. A & B. 
HEK293 cells stably expressing (32AR (A) or transiently expressing (32AR (B) were treated with 50pM 
isoproterenol (Iso) for 20 m inutes. |32AR and endogenous pERM  were detected using 
immunofluorescence. C & D. Hep2 cells were transfected with M1MR (B) and M2MR (C) and 
incubated for 48 hours. The cells were then subject to 100pM acetylcholine for 20 minutes (Ach) and 
receptor and endogenous pERM visualised by immunofluorescence. 297S, a rat anti-pERM antibody 
was used for visualisation of endogenous pERM. T denotes cDNA constructs transfected. D denotes 
proteins detected. Scale bars represent 20pm.
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Figure 5.3. fl2AR co-localises with the transferrin receptor in early endosomes. A. HEK|32 cells 
were treated with (-)-isoproterenol (ISO) for 15 minutes and then stained with antibodies against the 
endosomal marker EEA1 and the lysosomal marker LAMP1. (32AR (green) could be observed within 
internalised vesicles, the majority of which were co-labelled with EEA1 (red), (colocalisation appears 
yellow). These vesicles do not contain the LAMP1 protein (red). B. HEK|32 cells were incubated 
with Alexa Fluor 647-conjugated transferrin for 30 minutes on ice, followed by an immediate 
incubation at 37°C for 30 minutes with both 647-transferrin and ISO. The transferrin receptor is 
constitutively expressed in human cell lines and is trafficked to early endosomal compartments 
following transferrin binding (TfnR). After 30 minutes o f agonist treatment, the |32AR (green) co- 
localises with the transferrin receptor (blue) in internal vesicles (colocalisation appears cyan), but does 
not colocalise with LAMP1 (red). D denotes the proteins detected. Scale bars represent 20pm.
TfnR
LAMP1
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P2AR is trafficked to EEA1-positive recycling endosomal compartments following 
(-)-isoproterenol stimulation. The absence of co-localisation of P2AR and LAMP1 
suggests that the receptor is not directed to lysosomes after up to 30 minutes of 
agonist activation. The co-localisation of pERM and the agonist-occupied P2AR at 
internalised vesicles suggests that activated ezrin is trafficked to the early endosome 
along with the receptor.
5.4 Ezrin is required for p2AR endocytosis
Since pERM co-localise with internalised P2AR, I sought to examine whether 
activated ezrin plays a role in regulating the agonist-dependent trafficking of this 
receptor. Mock transfected HEKp2 cells were subject to 30 minutes of agonist 
treatment followed immediately by 30 minutes of antagonist (alprenolol) treatment. 
Samples were removed prior to treatment (untreated), after agonist treatment (ISO 
(30 min)) and after agonist removal and subsequent antagonist treatment (ALP (30 
min)). Plasma membrane-located P2AR was labelled with an anti-His6 monoclonal 
antibody and a fluorescently labelled secondary antibody and quantified by flow 
cytometry analysis. Results were compared to those of HEKP2 cells expressing a 
dominant negative dynamin construct (dynamin K44A), the dominant negative N- 
ezrin construct or the carboxyl-terminal C-ezrin construct.
Following agonist treatment of mock transfected cells, levels of P2AR at the plasma 
membrane decreased by approximately 32% (Figure 5.4, ISO (30min)). Removal of 
agonist and treatment with antagonist resulted in the delivery of both internalised and 
newly synthesised receptor to the plasma membrane. In cells transfected with 
dynamin K44A, which is known to inhibit endocytosis (van der Bliek et al., 1993), 
less than 5% of total P2 AR at the cell surface was internalised. Expression of N- 
ezrin inhibited P2AR internalisation such that only 11 % of cell surface receptor was 
endocytosed following isoproterenol treatment. Similarly, cells expressing C-ezrin 
internalised less than 20% of the surface P2AR. Neither the mutant dynamin 
construct nor the ezrin deletion constructs affected delivery of P2AR to the plasma 
membrane after removal of agonist.
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Figure 5.4. Ezrin is required for |32AR endocytosis. Fluorescence flow cytometry was used to 
estimate internalisation of |32AR in HEK293 cells stably expressing the His6-tagged receptor (HEK|32 
cells). Cells were incubated with 40pM isoproterenol for 30 min, washed, and then incubated with 
lOOpM alprenolol for 30 minutes to stop further endocytosis. Receptors present in the plasma 
membrane prior to treatment (untreated), after isoproterenol treatment (Iso (30min)) and after 
alprenolol treatment (Alp (30min)) were labelled with an anti-His6 monoclonal antibody. Following 
fixation, the primary antibody was detected with a fluorophore-conjugated secondary antibody and 
quantified by flow cytometry. This was repeated for HEK|32 cells overexpressing a dominant 
negative dynamin construct (dynamin K44A), the FERM domain o f ezrin (N-ezrin) or the carboxyl- 
terminus o f ezrin (C-ezrin). Data indicate the mean surface receptor fluorescence of cells. Error bars 
represent S.D. o f mean fluorescence data collected from multiple samples o f a representative 
experiment (n=4). *** indicates p<0.001. ** indicates 0.001<p< 0.01.
It appears that not only does phosphorylated, active ezrin colocalise with internalised 
feAR at early endosomes, it is also required for agonist-induced P2AR endocytosis. 
Expression of the FERM domain of ezrin has been shown to inhibit ERM function in 
a number of model systems and is thought to compete with endogenous ERM 
proteins for plasma membrane binding sites (Algrain et al., 1993; Amieva et al., 
1999; Crepaldi et al., 1997; Elliott et al., 2005). My results are consistent with this 
hypothesis, as expression of N-ezrin inhibits what I believe to be an ezrin-dependent
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process. Although over-expression of C-moesin has been observed to have no effect 
on ERM function (Amieva et al., 1999), transfected cells in this study were only 
observed 6 hours after electroporation and just the effect on cell morphology was 
examined. C-moesin and C-ezrin bind to actin filaments (Algrain et al., 1993; 
Amieva et al., 1999) and over-expression may inhibit the interaction of endogenous 
ERM proteins with actin, compete with endogenous ERM proteins for threonine-567 
phosphorylation or bind to the amino-termini of endogenous activated ERM proteins, 
preventing their association with the plasma membranes and binding partners. 
Furthermore, over-expression of the carboxyl-terminus o f radixin has been 
demonstrated to interfere with cytokinesis at the cleavage furrow, to which ERM are 
localised (Henry et al., 1995). More work is required to investigate how over­
expression of the ERM carboxyl-termini affects the function of endogenous ERM 
proteins, as it is apparent that C-ezrin has an inhibitory effect on ezrin-dependent 
GPCR endocytosis in my model system.
5.5 Ezrin is not required for endocytosis of the transferrin 
receptor
If ezrin is required for clathrin-mediated endocytosis per se, expression of ezrin 
deletion- and point-mutants would be anticipated to inhibit the internalisation of the 
transferrin receptor, which is known to internalise via CCPs (Dautry-Varsat, 1986). 
To investigate this hypothesis, I transfected HEK|32 cells with WT-ezrin, N-ezrin or 
C-ezrin. The cells were incubated with 647-transferrin for 30 minutes on ice and 
then immediately incubated at 37°C for 30 minutes in the presence of 647-transferrin. 
Following fixation and permeabilisation, the cells were labelled with an anti-VSVG 
antibody to detect expression of the ezrin constructs. Immunofluorescence data 
suggests that expression of dominant negative ezrin or the carboxyl-terminal domain 
of ezrin has no observable effects on transferrin receptor internalisation when 
compared to cells over-expressing wildtype ezrin (Figure 5.5).
These results indicate that ezrin is required for the endocytosis of a subset of GPCRs, 
rather than for clathrin-mediated internalisation in general. Quantifying the extent of 
the down-modulation of transferrin receptors in cells expressing the mutant ezrin 
constructs would have more robustly demonstrated the specificity of ezrin for GPCR
117
endocytosis. However, it was impractical to use flow cytometry to analyse 
transferrin receptor internalisation since it was not possible to label surface 
transferrin receptors using 647-transferrin, which causes immediate endocytosis of 
the receptors on binding, and anti-transferrin receptor antibodies did not label the 
receptor efficiently.
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Figure 5.5. Ezrin is not required for endocytosis o f the transferrin receptor. HEK293 cells were 
transfected with either wildtype ezrin (WT-ezrin), the FERM domain o f ezrin (N-ezrin) or the 
carboxy 1-terminus of ezrin (C-ezrin). The cells were incubated with 647-transferrin for 30 minutes on 
ice and then at 37°C for 30 minutes. Following fixation and permeabilisation, transferrin receptor 
(TfnR) and expressed ezrin constructs (Ezrin) were visualised by immunofluorescence. Expression of 
N-ezrin or C-ezrin have no observable effects on transferrin receptor internalisation when compared 
to cells over-expressing WT-ezrin. T denotes the cDNA constructs transfected. D denotes the 
proteins detected. Scale bar represents 20p.m.
5.6 Co-localisation of pERM with P2AR does not require 
NHERF
Previous studies have shown that the Na+/H+ exchanger regulatory factor (NHERF) 
can bind to the carboxyl-terminus of the P2AR via its PDZ domain (Hall et al., 
1998a), and to the FERM domain of ERM proteins (Reczek et al., 1997; Reczek and
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Bretscher, 1998). I investigated whether NHERF was responsible for the co­
localisation of pERM with internalised j32AR. HEK293 cells were transiently 
transfected with either FLAG-tagged wildtype |32AR or a mutant FLAG-tagged 
p2AR that cannot bind NHERF (P2ARL413a)- Cells were subject to 15 minutes of 
isoproterenol treatment, fixed, permeabilised and stained for receptor and 
endogenous pERM with 297S. As in Figure 5.2B, activation of transiently expressed 
p2AR led to receptor internalisation and colocalisation with activated ERM proteins 
(Figure 5.6). Similarly, pERM could be seen co-localised with p2ARL4 i3A at internal 
vesicles, indicating that NHERF is not required for this interaction.
D: R ec ep to r  p E R M
Figure 5.6. NHERF is not required to link pERM to p2AR. HEK293 cells were transfected with 
either the wildtype p2AR or a mutant (32AR that cannot bind NHERF (P2ARl413A). Cells were subject 
to 15 minutes of isoproterenol treatment, fixed and permeabilised. Receptor and endogenous pERM 
were visualised by immunofluorescence. T denotes the cDNA constructs transfected. D denotes the 
proteins detected. Scale bar represents 20pm.
5.7 Ezrin co-immunoprecipitates with GRK2
The results in this and the previous Chapter show that ezrin is in close proximity to 
agonist-occupied GPCRs at the plasma membrane immediately after receptor 
stimulation and then within endocytic vesicles. I have demonstrated that NHERF is
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not required for the co-localisation of ezrin with the P2AR, however ezrin may be 
conveyed to GPCRs via interactions with other proteins, such as components of the 
desensitisation machinery. Since the results in Chapter 3 suggest that ezrin may 
interact with GRK2,1 sought to investigate whether ezrin can associate with GRK2.
COS cells were transfected with either GRK2, GRK2 and a VSVG-tagged human 
ezrin mutant construct in which threonine-567 had been substituted with alanine 
(T567A-ezrin) or GRK2 and a VSVG-tagged human ezrin mutant construct in which 
threonine-567 had been substituted with aspartate (T567D-ezrin). T567D-ezrin has 
been shown to mimic ezrin phosphorylated at threonine-567, whereas T567A-ezrin is 
a non-phosphorylatable mutant (Gautreau et al., 2000). 48 hours after transfection, 
GRK2 was immunoprecipitated and subject to SDS-PAGE and Western blotting. 
Any ezrin bound to the GRK2 was detected using an anti-ezrin antibody. Faint 
bands were observed in the immunoprecipitated lanes that were not present in the 
control lanes, indicating that GRK2 can associate with both T567A- and T567D- 
ezrin (Figure 5.7A). Samples from the same lysates were subject to 
immunoprecipitation of ezrin and any bound GRK2 was detected. Again, a small 
amount of both over-expressed T567A- and T567D-ezrin could be detected bound to 
GRK2, but not to sepharose alone (Figure 5.7B).
The in vitro ROS phosphorylation assays described in Chapter 3 suggest that ezrin 
can interact with GRK2. The results communicated here are preliminary evidence 
that suggests that ezrin may associate with GRK2 in a manner that does not appear to 
depend on either the phosphorylation (i.e. activation) state of ezrin or agonist 
activation of a GPCR. Further investigation, such as in vitro binding assays, is 
required in order to characterise this putative interaction and to ensure that it is not 
an artefact of immunoprecipitation. GRK2 has been demonstrated to colocalise with 
internalised P2AR at endosomal vesicles (Ruiz-Gomez and Mayor Jr., 1997). If 
robustly proven to interact with ERM proteins, GRK2 could act to link ezrin to a 
GPCR following endocytosis, which would account for the colocalisation of ezrin 
and P2AR on internalised vesicles. Although this hypothesis is consistent with the 
data from the in vitro phosphorylation assays, where GRK2 was demonstrated to 
phosphorylate full-length ezrin at PIP2-containing vesicles, I have not proved that 
GRK2 colocalises with internalised P2AR and pERM in this experimental system.
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Figure 5.7. Ezrin interacts with GRK2. COS cells were transfected with either GRK2, GRK2 and 
T567A-ezrin (GRK2 + T567A), or GRK2 and T567D-ezrin (GRK2 + T567D). A. 48 hours post­
transfection, GRK2 was immunoprecipitated (IP) and subject to SDS-PAGE and Western blotting. 
Any ezrin bound to the GRK2 was detected using an anti-ezrin antibody (IB). GRK2 was found to be 
associated with both T567A- and T567D-ezrin (red arrow heads). B. Samples from the same lysates 
were subject to immunoprecipitation (IP) o f ezrin and any bound GRK2 was detected (IB). Again, 
both over-expressed T567A- and T567D-ezrin could be detected bound to GRK2 (red arrow heads). 
Positions o f protein molecular mass standards are indicated at the left o f the images. L: total cell 
lysate. A: immunoprecipitation with antibody and sepharose beads. S: immunoprecipitation with 
sepharose beads only.
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5.8 Summary
In summary, this Chapter demonstrates that ezrin may be required for GPCR 
internalisation, although this role may be limited to a subset of these receptors. 
Following agonist treatment, active, phosphorylated ERM proteins co-localise with 
both the P2AR and the M l MR at internalised vesicles that appear to be early 
endosomes. This co-localisation may depend on the nature of the endocytic 
mechanism employed by a given GPCR: pERM are not seen with the internalised 
M2MR, which has been shown to endocytose via a GRK- and parrestin-independent 
mechanism (Claing et al., 2002).
Ezrin is required for P2AR endocytosis, but expression of either the dominant 
negative FERM domain or the carboxyl-terminal domain of ezrin had no observable 
effect on the endocytosis of the transferrin receptor, suggesting that it is not required 
for clathrin-mediated endocytosis per se. Although NHERF has previously been 
shown to bind both P2AR and ERM proteins and to have a role in P2AR recycling, it 
does not appear to be necessary for the interaction of pERM with the P2AR following 
internalisation. Interestingly, my preliminary data in this Chapter suggests that ezrin 
may associate with GRK2. If these findings are verified through further 
investigation, they would support the data from Chapter 3 that indicate that ezrin and 
GRK2 may interact, since increasing concentrations of ezrin augments GRK2- 
mediated rhodopsin phosphorylation, possibly by enhancing the membrane 
localisation of GRK2 in the absence of Gpy.
It could therefore be speculated that GRK2 might associate with ERM proteins, 
which may promote the localisation of GRK2 to the plasma membrane. Once at the 
plasma membrane, agonist-occupation of GPCRs would activate GRK2 and lead to 
the phosphorylation of ERM proteins. Such a mechanism would explain the specific 
co-localisation of pERM with activated GPCRs that require GRK for endocytosis, 
such as P2AR and Ml MR, but not M2MR.
Although no studies have yet shown that GRK2 and M l MR colocalise following 
internalisation, GRK2 has been shown to colocalise with 6-opioid receptors 
following endocytosis (Schulz et al., 2002). Should future research indicate that
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ezrin can interact with GRK2, it would also be interesting to investigate whether 
pERM colocalise with internalised 6-opioid receptors, which have been 
demonstrated to internalise via a GRK-dependent mechanism (Schulz et al., 2002). 
However, further enquiry is also needed to determine whether pERM associate with 
other binding partners in order to co-localise with GPCRs at early endosomes, or if 
ezrin can directly associate with a subset of GPCRs. Overall, the results presented in 
this Chapter indicate that ERM proteins may act as important connectors between 
some GPCRs and the actin cytoskeleton during receptor-mediated endocytosis.
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6 Discussion
In this thesis, I have identified ezrin as a novel substrate of GRK2 and as a 
downstream effector of GPCR signalling. My data increase the list of known non­
receptor GRK2 substrates, which already includes tubulin, phosducin, ribosomal 
protein P2, synucleins, the inhibitory gamma subunit of the type 6 retinal cGMP 
phosphodiesterase and the p-subunit of the epithelial Na+ channel (Carman et al., 
1998; Dinudom et al., 2004; Wan et al., 2001; Freeman et al., 2002; Haga et al., 
1998; Pitcher et al., 1998a; Pronin et al., 2000; Ruiz-Gomez et al., 2000). These 
findings also corroborate the hypothesis that GRK2 may have additional functions 
within the cell, besides phosphorylation of agonist-occupied GPCRs.
6.1 Ezrin is a novel substrate of GRK2
The ability of GRK2 to phosphorylate ezrin was initially discovered by Dr. Julie 
Pitcher using a cellular assay. I subsequently confirmed this observation in vitro, as 
detailed in Chapter 3. Notably, GRK2-mediated phosphorylation of full-length ezrin 
is PIP2 and Gpy-dependent. This is consistent with previous findings that show PIP2 - 
mediated changes in ezrin conformation may facilitate phosphorylation at threonine- 
567 (Fievet et al., 2004; Nakamura et al., 1999). The PIP2- and Gpy-dependence of 
GRK2-mediated phosphorylation additionally suggests that this phosphorylation 
event might occur in an agonist- and GPCR-dependent fashion.
Using GST-ezrin fusion proteins, the GRK2 phosphorylation site within ezrin was 
localised to a carboxyl-terminal region of 53 amino acids (residues 533 to 586) that 
encompassed threonine-567. The phosphorylation of threonine-567 has been shown 
to be important for ezrin activation and is thought to disrupt its inactive conformation 
such that the plasma membrane and actin binding domains are exposed (Pearson et 
al., 2000). However, a number of other serine and threonine residues are also 
contained within this region (Figure 3.1) and further analysis was necessary to 
identify the exact phosphorylation site.
In order to determine if indeed threonine-567 represented the site of GRK2-mediated 
ezrin phosphorylation, I created a GST-ezrin fusion protein in which threonine-567
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was mutated to alanine (GST-T567A ezrin). Although I did not have the opportunity 
to utilise this fusion protein in in vitro phosphorylation assays during the course of 
my thesis, Dr. Julie Pitcher has recently demonstrated that this construct cannot be 
phosphorylated by GRK2 in either the presence or absence of PIP2 and Gpy* This 
finding directly confirms what the membrane ruffling data in Chapter 4 of this thesis 
implies: that threonine-567 represents the principle site of GRK2-mediated ezrin 
phosphorylation. This result, along with much of the work contained in this thesis, 
has recently been published (Cant and Pitcher, 2005).
6.2 GRK2 mediates cytoskeletal reorganisation
downstream of GPCRs via phosphorylation of ERM 
proteins
6.2.1.1 ERM proteins are required for MIMR-mediated ruffling in Hep2 cells
The data presented in Chapters 4 and 5 suggest that GRK2 activity in a cellular 
context leads to ERM protein activation. Stimulation of Hep2 cells overexpressing 
Ml MR and of HEK293 cells stably and transiently expressing P2AR leads to an 
increase in endogenous ERM proteins specifically phosphorylated at threonine-567 
(ezrin), -564 (radixin) or -558 (moesin). In the Hep2 cell system, brief exposure to 
agonist causes rapid and transient membrane ruffling that requires both active ezrin 
and GRK2. These observations are similar to those seen following stimulation of the 
adenosine 2b receptor, which colocalises with ezrin on agonist occupancy (Sitaraman 
et al., 2002).
Cytoskeletal reorganization and the association of ezrin with plasma membrane and 
actin filaments have previously been found to be regulated by the Rho family of 
small GTPases (Aspenstrom et al., 2004; Nakamura et al., 2000; Okamoto et al., 
1999) and to involve phosphorylation of ezrin by either Rho kinase or PKC, 
depending on the cellular context (Matsui et al., 1998; Simons et al., 1998). PKA- 
mediated ezrin phosphorylation has also been shown to be important for the 
cytoskeletal remodelling associated with acid secretion in gastric parietal cells (Zhou 
et al., 2003). In this thesis I have shown that in Hep2 cells expressing Ml MR, 
acetylcholine treatment leads to membrane ruffling and ERM protein activation even
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in the presence of the Rho kinase inhibitor Y27632, the PKC inhibitor GF109203X 
or the PKA inhibitor Rp-8-Br-CAMPS. That GRK2, but not Rho kinase, PKC or 
PKA, inhibition ablates MIMR-mediated ERM protein phosphorylation and ruffling 
suggests that GRK2 is responsible for the activation of ERM proteins and consequent 
actin filament/cell surface remodelling observed in this system.
6.2.1.2 Factors influencing GPCR-mediated membrane ruffling
6.2.1.2.1 Ga subunits
Stimulation of M l MR expressed in Hep2 cells leads to GRK2-mediated 
phosphorylation of ERM proteins and membrane ruffling. Interestingly, although 
agonist stimulation of P2AR expressed in HEK293 cells also leads to ERM protein 
activation, it does not cause membrane ruffling. It would therefore appear that the 
GRK2-mediated activation of ERM proteins via M l MR and P2AR results in 
different functional outcomes.
The differing cellular responses brought about by ERM activation following agonist 
occupancy of Ml MR in Hep2 cells and P2AR in HEK293 cells could reflect the 
different complement of proteins expressed by each cell line. However, stimulation 
of P2AR expressed in Hep2 cells does not lead to membrane ruffling, even though an 
increase in ERM protein phosphorylation is observed (Dr. Julie Pitcher, unpublished 
observations). This implies that ERM proteins are involved in different signalling 
pathways downstream of Ml MR and P2AR and that GRK2-mediated ERM 
phosphorylation, although required, is not sufficient for membrane ruffling.
That GRK2-mediated membrane ruffling in Hep2 cells is MIMR-dependent but not 
P2AR-dependent could be a reflection of the G a subtype associated with the 
receptors. Ml MR is coupled to Gq, whereas P2AR is coupled to Gs and Gi (Daaka 
et al., 1997a; Offermanns et al., 1994; Zamah et al., 2002). GRK2 binds Gq via its 
RGS domain and inhibits the Gq-mediated stimulation of PIP2 hydrolysis by PLCp 
(Carman et al., 1999a; Sallese et al., 2000b). A localised increase in PIP2 
concentration would not only augment ERM protein activation by GRK2 (Fievet et 
al., 2004), but could also increase actin polymerisation at the plasma membrane (Ren 
and Schwartz, 1998). Gq-coupled receptors such as Ml MR, AT2aR and the TP|3
126
receptor have been shown to induce actin reorganisation (Barnes et al., 2005; Dutt et 
al., 2002; Laroche et al., 2005), and bombesin signalling via Gq leads to Arf6 and 
Rac-dependent membrane ruffling in CHO cells (Boshans et al., 2000).
The activation of Gq-coupled receptors would therefore be expected to bring about 
membrane ruffling, regardless of the cell line the receptors are expressed in. 
However, stimulation of HEK293 cells expressing Ml MR does not lead to ruffling, 
although ERM protein phosphorylation occurs (Dr. Julie Pitcher, unpublished 
observations). These observations indicate that the functional outcome of GRK2- 
mediated ERM protein phosphorylation downstream of GPCRs may not only depend 
on the G a subunit coupled to the receptor, but is likely to be cell line-specific as 
well.
6.2.1.2.2 GRKs
GPCRs including CCR2 (Jones et al., 2003) and CXCR4 (D’Apuzzo et al., 1997) 
induce cytoskeletal reorganisation in the form of membrane ruffling and cell 
migration on agonist activation. Both CCR2 and CXCR4 have been shown to 
undergo GRK2-dependent endocytosis following ligand binding (Aragay et al., 
1998; Orsini et al., 1999). In addition, studies have demonstrated that neutrophils 
and splenocytes derived from GRK6-deficient mice have altered chemotactic 
responses (Fong et al., 2002; Kavelaars et al., 2003; Vroon et al., 2004), indicating 
that GRK6 may be involved in regulating the cytoskeletal remodelling required for 
their migration. In conjunction with the results in this thesis, these data suggest that 
GRKs may have a general role in regulation of the actin cytoskeleton in processes 
such as cell motility. It would be therefore be interesting to investigate whether ezrin 
or other ERM proteins serve as substrates for other GRK family members. The 
identification of ERM proteins as general GRK substrates could indicate a common 
pathway for actin filament modulation downstream of activated GPCRs.
6.2.2 The actin cytoskeleton and GPCR endocytosis
Many studies have demonstrated that the actin cytoskeleton has a role in clathrin- 
mediated endocytosis, as discussed in Chapter 1. Studies with actin perturbing drugs 
suggest that, while actin may not be absolutely essential for the clathrin-mediated 
internalisation of receptors, it probably facilitates and regulates the process
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(Fujimoto et al., 2000). More recent research has indicated that mammalian cells 
may have alternative actin- and clathrin-independent endocytosis pathways through 
which receptors can internalise following actin disruption (Yarar et al., 2005).
Drug-induced disruption of the actin cytoskeleton has demonstrated that actin 
polymerisation is involved in the internalisation of the bombesin, endothelin A and 
TPp receptors (Laroche et al., 2005; Lunn et al., 2000). However, the inhibition of 
clathrin-mediated TPp receptor endocytosis can be overcome by over-expression of 
parrestin2. Over-expression of parrestinl does not support TPp internalisation 
following actin disruption, even though both parrestinl and -2  mediate endocytosis 
of the receptor in the presence of an intact actin cytoskeleton (Laroche et al., 2005). 
This suggests that both actin-dependent and -independent mechanisms of clathrin- 
mediated GPCR sequestration exist.
6.2.3 Ezrin is required for clathrin-mediated endocytosis of a subset 
of GPCRs
In this thesis I demonstrate that in HEK293 cells stably expressing P2AR and Hep2 
cells expressing Ml MR, prolonged agonist stimulation causes receptor endocytosis 
paralleled by the colocalisation of pERM with receptor at endosomal vesicles. Flow 
cytometry analysis to quantify surface P2AR following isoproterenol treatment 
demonstrates that expression of either the dominant negative N-ezrin or the 
carboxyl-terminal C-ezrin fusion proteins inhibit receptor downmodulation to a 
similar extent as expression of the dominant negative dynamin K44A protein. Ezrin 
does not appear to be necessary for clathrin-mediated endocytosis per se since 
neither N-ezrin nor C-ezrin inhibited transferrin receptor internalisation in 
immunofluorescence assays.
Recently, the association of the low-density lipoprotein (LDL) receptor with ezrin 
has been shown to be necessary for its clathrin-mediated endocytosis (Smith et al.,
2004). pERM colocalise with LDL particles at the plasma membrane and, although 
active ERM proteins do not associate with internalised LDL, expression of N-ezrin 
significantly inhibits LDL uptake (Smith et al., 2004). This suggests that other, non-
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G protein-coupled, receptors may also utilise a similar ezrin- and clathrin-dependent 
endocytosis pathway.
Although my data suggest that ezrin may also have an important function in GPCR 
internalisation, this role may be limited to receptors that internalise in a GRK2- and 
Parrestin-dependent manner. M2MR endocytosis is not correlated with ERM protein 
activation and pERM are not associated with internalised M2 receptor. In HEK293 
cells M2MR has been shown to undergo endocytosis in a parrestin-independent 
fashion and does not appear to internalise via typical clathrin- or caveolin-dependent 
pathways in HeLa or HEK293 (Claing et al., 2000; Delaney et al., 2002; Pals- 
Rylaarsdam et al., 1995; Roseberry and Hosey, 2001; Vogler et al., 1999). In 
contrast, both P2AR and Ml MR are sequestered via a parrestin- and therefore GRK- 
dependent pathway in these cells (Claing et al., 2000). The routes of M l MR and 
M2MR internalisation in this Hep2 cell system have yet to be confirmed as being 
dependent and independent of parrestin/GRK respectively, however my results 
indicate that activated ezrin probably plays an obligate role in the internalisation of a 
subset of GPCRs.
Much is known about GPCR internalisation and the different mechanisms involved. 
Rapid sequestration of receptors such as P 2AR is characterised by GRK 
phosphorylation leading to Parrestin binding and endocytosis via clathrin-coated pits; 
other GPCRs may internalise via caveolae or even in a GRK-independent manner 
(Chini and Parenti, 2004; von Zastrow, 2003). My results suggest that a requirement 
for activated ERM proteins may be an additional distinguishing feature of these 
endocytic pathways and may correlate with GRK dependence. In order to further 
identify and characterise the GPCRs that internalise via an ERM protein-dependent 
route, endocytosis assays would need to be performed in cells that do not express 
ERM proteins. Ablation of ERM protein expression could be achieved either via an 
RNAi-based approach, or by using cells derived from ezrin, radixin or moesin 
knockout mice (Doi et al., 1999; Kikuchi et al., 2002; Saotome et al., 2004; Tamura 
et al., 2005). Since ERM proteins appear to be functionally redundant in most cell 
types (Doi et al., 1999; Kikuchi et al., 2002; Saotome et al., 2004; Tamura et al.,
2005), it is likely that the contribution of ERM proteins to GPCR endocytosis can 
only be examined in cells that do not express any of the three ERM family members.
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6.2.4 Ezrin colocalises with agonist-occupied GPCRs
6.2.4.1 Potential ezrin binding partners
Further investigation is required to establish how ezrin associates with GPCRs 
following agonist occupation. The ERM-binding protein NHERF is known to bind 
to the carboxy-termini of certain receptors, including the p2AR, and has been shown 
to be involved in sorting p2AR between the recycling endosome and lysosome 
following endocytosis (Cao et al., 1999). NHERF has also been shown to regulate 
the trafficking of the human k  opioid receptor and the parathyroid hormone receptor 
(Li et al., 2002; Sneddon et al., 2003). Additionally, the NHERF homologue 
E3KARP forms a complex with ezrin and the adenosine 2b receptor following 
stimulation of T84 cells with adenosine (Sitaraman et al., 2002).
My data indicate that NHERF is not required to link ERM proteins to a receptor 
following stimulation since pERM colocalise with both a mutant |32AR that is unable 
to bind NHERF, and to Ml MR, which does not contain the carboxyl-terminal motif 
recognised by NHERF (Hall et al., 1998b). However, it is possible that, like the 
integral membrane glycoprotein podocalyxin, |32AR may be able to bind ERM 
proteins both directly and via NHERF (Schmieder et al., 2004). Alternatively other, 
as yet unidentified, PDZ domain-containing proteins could link ERM proteins to 
GPCRs. PDZ ligands essential for internalisation have been identified within the 
carboxyl tails of a number of GPCRs, although the PDZ domain proteins that bind 
them have not been characterised (Gage et al., 2005; Paasche et al., 2005). Further 
studies will be necessary to identify such proteins and investigate whether they act as 
ERM protein binding partners.
pERM localisation could be dependent on other vesicle-associated proteins. For 
example, a recent study demonstrated that Arf6 colocalises with ezrin at the plasma 
membrane (Macia et al., 2004). Arf6 is thought to regulate vesicle formation in 
endocytosis and interacts with parrestin, suggesting that parrestin may be responsible 
for the recruitment of Arf6 (Claing et al., 2001), and hence possibly ERM proteins, 
to agonist-occupied GPCRs.
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6.2.4.2 Ezrin may interact with GRK2
Although I have not investigated whether parrestin or Arf6 associate with ERM 
proteins, my data suggests that ezrin may interact with GRK2. As demonstrated in 
Chapter 3, increasing the concentration of full-length ezrin fusion protein in a GRK2 
phosphorylation assay augments GRK2-mediated phosphorylation of rhodopsin in 
ROS. This result suggests that ezrin, in addition to serving as a GRK2 substrate, can 
interact with GRK2. The immunoprecipitation data from Chapter 5 appear to show 
that GRK2 can associate with ezrin, although these results are preliminary and 
further investigation is required to confirm this.
It could thus be speculated that ERM proteins might promote the translocation of 
GRK2 to the plasma membrane via their interaction with PIP2 . At the plasma 
membrane, GRK2 would be targeted to agonist-occupied GPCRs via binding with 
Gpy and/or Gq, leading to GRK2 activation and ERM phosphorylation. As GRK2 
has been demonstrated to remain associated with internalised P2AR and 6-opioid 
receptors (Ruiz-Gomez and Mayor Jr., 1997; Schulz et al., 2002), GRK2 could be 
suggested to act as the link between pERM and an internalised GPCR at the early 
endosome.
Should further studies, involving for example in vitro binding assays, indicate that 
GRK2 and ezrin can associate, it would also be interesting to map the sites of 
interaction for both proteins. Although the binding sites of kinases such as PKC and 
Rho kinase have not yet been determined, ezrin has been shown to interact with a 
number of membrane-associated and cytosolic proteins via its FERM domain 
(Finnerty et al., 2004; Hamada et al., 2003; Hirao et al., 1996; Manchanda et al., 
2005; Takahashi et al., 1997). Should this domain prove important for this putative 
association, it would be interesting to determine if GRK2, and even other GRKs, can 
interact with other ERM family members or FERM-domain containing proteins and 
whether these would also serve as GRK substrates. FERM domains are found in 
many membrane-associated cytoskeletal and signalling proteins (Bretscher et al., 
2002) and could function as general linkers between GRKs and the cytoskeleton or 
other signalling pathways.
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Thus, in much the same manner as GRK2 is responsible for recruiting GIT to GPCRs 
at the plasma membrane (Claing et al., 2000; Premont et al., 1998), GRK2 may also 
bring ERM proteins to activated GPCRs. However, unlike its interaction with GIT, 
GRK2 would not just passively target ERM proteins to GPCRs, but also serve to 
activate them. If this hypothesis proves correct, it should be noted that for receptors, 
such as the LDL receptor, that internalise in an ezrin- and clathrin-dependent but 
GRK-independent pathway, other factors such as Arf6 might be responsible for 
recruiting ezrin, and other non-GRK kinases may bring about ezrin activation. It is 
also possible that ERM proteins can directly bind to a number of receptors, such as 
the LDL receptor and a subset of GPCRs, and that it may form part of a complex 
with receptors as well as proteins involved in both endocytosis and actin cytoskeletal 
rearrangements. Both of these prospects require further investigation.
6.2.5 ERM proteins may play a role in numerous GPCR trafficking 
pathways
This thesis has shown that ERM proteins are involved in the endocytosis of a number 
of GPCRs. ERM proteins may also play a role in other GPCR trafficking pathways. 
The requirement of NHERF for p2 AR recycling has been demonstrated to depend on 
the interaction of NHERF with ERM proteins: disruption of its ERM binding domain 
caused mis-sorting of receptors to the lysosome (Cao et al., 1999). Furthermore, 
ERM proteins were shown to play a role in the tethering and fusion of vesicles 
delivering rhodopsin to the ROS (Deretic et al., 2003). These results indicate that, as 
well as regulating the internalisation of a subset of GPCRs, ERM proteins may have 
a more general role mediating GPCR trafficking. Although my data suggest that 
ezrin is not involved in the delivery of fcAR to the plasma membrane, it would be 
interesting to examine the role of ERM proteins in P2AR recycling in more detail. 
This would be possible by using antibody feeding assays prior to flow cytometry to 
analyse the recycling of internalised P2AR back to the plasma membrane in HEK 
cells over-expressing either N- or C-ezrin.
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6.3 GRKs as co-coordinators of cytoskeletal reorganisation 
downstream of GPCRs
In this thesis I demonstrate that the GRK2-mediated phosphorylation of ERM 
proteins is required for the cytoskeletal reorganisation associated with P2AR 
internalisation and MIMR-dependent membrane ruffling in Hep2 cells. Previous 
studies have shown that GRK2 activity can indirectly influence this actin 
remodelling via the recruitment of parrestin to phosphorylated, agonist-occupied 
GPCRs. parrestin recruits both c-Src to the plasma membrane, where it activates 
dynamin, and Arf6 (Ahn et al., 1999; Shenoy and Lefkowitz, 2003).
The large GTPase dynamin was originally characterised as a mechano-enzyme 
catalysing the fission of CCVs following endocytosis. It has also been shown to 
regulate actin filament dynamics at the plasma membrane via its interactions with 
actin-regulatory proteins, as reviewed in Chapter 1. In this way, dynamin acts to 
integrate both endocytosis and cytoskeletal reorganisation at the plasma membrane 
and probably functions to regulate actin polymerisation so that vesicle internalisation 
can proceed. Interestingly, following stimulation of migration in fibroblasts, 
dynamin is recruited to membrane ruffles at the leading edge and may regulate the 
cytoskeletal rearrangements required to alter cell morphology at the lamellipodia of 
motile cells (McNiven et al., 2000).
Likewise, Arf6 has been shown to have a dual role in both endocytosis and cell 
morphology remodelling. The cycle of Arf6 GTP binding and hydrolysis is required 
for P 2AR internalisation (Shenoy and Lefkowitz, 2003), possibly because it 
stimulates PIP2 production, which would recruit clathrin and dynamin to CCVs 
(Cavenagh et al., 1996; Honda et al., 1999; Melendez et al., 2001; Takei and Haucke, 
2001). Arf6 is also localised to and required for the formation of membrane ruffles 
(Honda et al., 1999; Song et al., 1998), where it is recruited following both EGF 
stimulation and signalling via the Gq-coupled bombesin receptor (Boshans et al., 
2000; Honda et al., 1999).
My data suggest that GRK2 can also directly influence actin remodelling, via the 
phosphorylation and activation of ERM proteins. GRK2-mediated ERM activation
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at agonist-occupied GPCRs directly regulates cytoskeletal reorganisation and 
receptor internalisation. In this way, GRK2 acts as a general coordinator of 
cytoskeletal remodelling downstream of GPCRs, which it regulates both directly (via 
ERM proteins) and indirectly (via parrestin, dynamin and Arf6).
Although more investigation is required to ascertain the exact pathways downstream 
of GRK2-mediated ERM protein activation that lead to cytoskeletal reorganisation, 
an initial general model can be suggested (Figure 6.1). Agonist binding to a GPCR, 
such as Ml MR or P2AR, leads to colocalisation of GRK2 and an ERM protein with 
the receptor at the plasma membrane. GRK2 is activated and phosphorylates the 
GPCR carboxyl-terminus, promoting the binding of parrestin. parrestin binds to 
Arf6 (Shenoy and Lefkowitz, 2003), bringing it to the plasma membrane. Rac is 
trafficked to the plasma membrane along with Arf6 (Boshans et al., 2000; 
Radhakrishna et al., 1999), where both stimulate the increased production of PIP2 
(Honda et al., 1999; Ren and Schwartz, 1998; Takei and Haucke, 2001). The action 
of Rac would lead to morphological changes such as the formation of ruffles and 
lamellipodia (Nobes and Hall, 1995; Ridley and Hall, 1992a; Ridley and Hall, 
1992b) and the increase in PIP2 could regulate a number of actin binding proteins, 
leading to actin polymerisation (Ren and Schwartz, 1998).
The presence of a localised concentration of PIP2 would also facilitate ERM protein 
phosphorylation by GRK2 and augment ERM protein activation (Fievet et al., 2004). 
Activated ERM proteins would act to cross-link the GPCR complex to the actin 
cytoskeleton. ERM proteins may also directly regulate actin organisation. 
Expression of the radixin FERM domain has been shown to displace Rho from 
RhoGDI, enabling Rho activation through the exchange of GDP for GTP (Takahashi 
et al., 1997). In addition to this, moesin has been demonstrated to inhibit WASP- 
mediated actin polymerisation both in vitro and in vivo via binding WASP at its 
FERM domain (Manchanda et al., 2005). Therefore, ERM proteins may exert a 
more direct effect on actin reorganisation by regulating the activity of both Rho and 
WASP.
The recruitment of parrestin to a GPCR not only brings Arf6 to the plasma 
membrane, but also targets the receptor to preformed CCPs. This is followed by
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dynamin recruitment and the fission of the CCV from the plasma membrane (Figure 
1.3). Whilst dynamin could serve to mediate vesicle fission through its regulation of 
the actin cytoskeleton, the actin cross-linking action of ERM proteins at the CCV 
may aid vesicle trafficking through remodelling of the underlying cortical actin. For 
a subset of GPCRs, ERM proteins may be added to the known sequence of protein 
interactions required for CCV formation and internalisation, in much the same way 
as an interaction with GIT is essential for those GPCRs that internalise via a 
parrestin- and clathrin-dependent pathway (Claing et al., 2000).
How ERM proteins co-ordinate actin reorganisation downstream of the Ml MR in 
Hep2 cells to bring about first membrane ruffling and then endocytosis, compared to 
their role in mediating the cytoskeletal remodelling required only for P 2AR 
internalisation in HEK293 cells needs further investigation. Components of the 
GPCR desensitisation machinery such as GRKs, parrestins and GIT have been 
shown to have roles in GPCR-mediated chemotaxis (as discussed in Chapter 4), 
suggesting that ruffling and cell migration may be closely linked to receptor 
endocytosis. Since chemotaxis depends on a cell distinguishing and responding to a 
ligand gradient, this must involve different degrees of receptor activation at different 
locations on the cell surface as it moves through the gradient. The dynamic control 
of GPCR signalling would be achieved by rapid turning on and off of receptor 
signalling, presumably via the desensitisation machinery. The involvement of ERM 
proteins in both processes would link them to the reorganisation of the cytoskeleton 
obligatory for chemotaxis and beneficial for receptor-mediated endocytosis.
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Figure 6.1. Proposed model o f the role o f GRK 2-m ediated ERM protein phosphorylation in 
cytoskeletal reorganisation. 1. Agonist binding to a GPCR leads to colocalisation o f GRK2 and an 
ERM protein with the receptor at the plasma membrane. GRK2 is activated and phosphorylates the 
GPCR carboxyl-terminus, promoting the binding o f parrestin. This brings Arf6 and Rac to the plasma 
membrane, where both stimulate the increased production o f  PIP2. 2. The localised concentration of 
PIP2 facilitates ERM protein phosphorylation by GRK2 and leads to ERM protein activation. 3. 
Activated ERM proteins act to cross-link the GRK2/GPCR complex to the actin cytoskeleton and may 
also influence actin organisation via WASP or RhoGDI. The action o f Rac leads to actin-mediated 
morphological changes such as the formation o f ruffles and lamellipodia, and an increase in PIP2 at 
the m em brane regulates a num ber o f actin binding proteins and thereby influences actin 
polymerisation. The resulting cytoskeletal remodelling could lead to membrane ruffling and/or GPCR 
internalisation.
It is not currently known at what stage an ERM protein would translocate to a GPCR at the plasma 
membrane, or with which protein(s) it would associate. Therefore, for simplicity, neither details o f 
the translocation o f ERM proteins to the plasma membrane nor any ERM interactions have been 
included in this diagram.
* indicates activated proteins. P denotes a phosphate group.
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6.4 GRK2 may regulate other ERM protein-dependent 
functions
As well as regulating ERM protein activation at the plasma membrane following 
GPCR stimulation, GRK2 could have a wider role in mediating ERM protein 
functions in other cellular processes. pERM have been localised to the cleavage 
furrow during cytokinesis (Tsukita and Yonemura, 1999) and, although their role 
during cytokinesis is not well understood, expression of the carboxyl-terminus of 
radixin has been shown to interfere with this process (Henry et al., 1995). Depletion 
of known cleavage furrow kinases Aurora B and Rho kinase does not inhibit ERM 
protein phosphorylation at the cleavage furrow, indicating the presence of another 
kinase (Yokoyama et al., 2005). Since GRK2 activity appears to be necessary for the 
regulation of mitosis and cytokinesis (Dr. Julie Pitcher, unpublished observations), it 
is tempting to speculate that GRK2 could be the kinase responsible for 
phosphorylating ERM proteins at the cleavage furrow.
6.5 Cellular screening techniques to identify novel 
substrates of GRK2
The data included in this thesis validates the use of a cellular screening technique to 
identify novel substrates for GRK2. Agonist treatment of HEK293 cells over­
expressing P2AR and GRK2 in the presence of [32P]orthophosphate led to the 
identification of a number of potential GRK2 substrates that were subsequently 
identified using MALDI-TOF mass spectrometry. During the course of my studies, I 
corroborated one of these findings by demonstrating that ezrin was both a substrate 
and an effector of GRK2. Such a screen is therefore a useful method to initially 
identify novel GRK2 substrates. With advances in both mass spectrometry and the 
purification of phosphorylated proteins using chelate matrices, the sensitivity of this 
screen could be improved.
6.6 Experimental weaknesses of this thesis
Throughout this thesis I have described experiments conducted in immortalised cell 
lines over-expressing particular proteins of interest. Transfection and over-
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expression of proteins might induce signalling pathways that do not normally occur 
in a physiological environment. With this in mind, it might be more physiologically 
relevant to work with primary cells or cells that have not been transformed to 
determine the signalling pathways activated in the absence of overexpression. 
Unfortunately this is not always experimentally feasible since the propagation of 
primary cells is more challenging, they are often difficult to transfect and it may be 
impossible to observe endogenous, untagged proteins for which no suitable antibody 
exists.
A further complexity involved with using immortalised cell lines such as HEK293 
and Hep2 is that they express endogenous kinases able to phosphorylate GPCRs. 
This can be helpful as it allows transfected receptors to be phosphorylated by the 
endogenous machinery on agonist-occupancy. However, it can make investigations 
to decipher the exact contributions of individual components, such as kinases, 
difficult. Inhibiting the action of one kinase, for example a particular GRK, may not 
completely abolish GPCR phosphorylation and desensitisation since other 
endogenous GRK subtypes, or kinases such as casein kinase 1 a , may still contribute 
in these cell lines (Tobin, 2002).
Moreover, kinases may have more than one action within the cell, which can 
complicate the interpretation of results. The recruitment of GRK2 to agonist- 
occupied GPCRs is concurrent with GRK2 binding to Gpy and, where associated, Gq 
(Carman et al., 1999a; Carman et al., 2000; Eichmann et al., 2003). It is therefore 
likely that GRK2 can also mediate phosphorylation-independent desensitisation of 
GPCRs by inhibiting signalling pathways downstream of Gpy and Gq (Pao and 
Benovic, 2002). Expression of either the GRK2 RGS domain alone or a catalytically 
inactive GRK2 mutant (G R K 2 k22or) can terminate Gq signalling and both the 
carboxyl-terminal domain of GRK2 and G R K 2 k22or can interfere with Gpy-mediated 
processes, even though none of these constructs can phosphorylate GPCRs or other 
GRK2 substrates (Carman et al., 1999a; Rockman et al., 1998; Sallese et al., 2000b). 
Whilst the singular use of any one of these mutants may not completely inhibit all 
GRK2-dependent effects, the sequential expression of all three within a model 
system should facilitate the determination of the respective contributions of GRK2-
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mediated phosphorylation and Gq- and Gpy-sequestration within a particular 
pathway.
The effect of Gq- and Gpy-sequestration can also be further investigated with the use 
of heterotrimeric G protein-derived constructs. Transducin is a GPy scavenger that 
can be transiently expressed in mammalian cells (Federman et al., 1992). Gq- 
derived constructs, such as carboxyl-terminal Gq peptides or xanthine nucleotide- 
binding Gq mutants, can also be transfected into cells to interfere with endogenous 
Gq signalling (Akhter et al., 1998; Yu et al., 2000). The sequential expression of 
each of these constructs in acetylcholine-stimulated MIMR-expressing Hep2 cells 
should inhibit the activities of Gpy and Gq respectively and thus further clarify the 
functions of GRK2 in MIMR-mediated ruffling.
However, it should be noted that both Gpy and Gq are required for localisation of 
GRK2 with agonist-occupied GPCRs at the plasma membrane. Therefore, the above 
approaches would also inhibit GRK2 activity at the plasma membrane and so would 
not determine whether signalling via GPy/Gq, or signalling via GRK2 is required. 
An alternative approach to determining the function of a protein, such as GRK2, is to 
use cells and transgenic animals in which the protein has been knocked out. 
However, the deletion of certain proteins can prove lethal in animal models and 
might restrict the viability of cell lines. This is the case with GRK2: fiARKl ^ mice 
are not viable (Jaber et al., 1996) and no cell lines currently exist in which GRK2 has 
been deleted. In addition, knocking out key proteins in regulatory and signalling 
pathways may affect the expression of other proteins within the cell, possibly 
hindering the characterisation of the role of an individual protein. With these 
limitations in mind it may be necessary to follow a number of approaches, based 
both in vitro and in vivo and using different systems and cell lines, in order to 
validate any protein function or signalling pathway under investigation. The 
utilisation of RNAi to ablate expression of GRK2, or any other particular protein, 
may be one such approach and may prove to be the most effective method to further 
characterise the role of GRK2 in a number of ERM protein-dependent processes.
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6.7 Further experimental approaches
It would be interesting to undertake further experiments in order to determine in 
more detail the role of ERM proteins in GPCR-mediated membrane ruffling and 
receptor-mediated endocytosis. For example, investigations could be carried out to 
identify the GPCRs that internalise in an ERM-dependent manner by repeating the 
flow cytometry-based endocytosis assay from Chapter 5 with a number of different 
receptors. A range of GPCRs could also be individually transfected into Hep2 cells 
to establish which promote agonist-dependent membrane ruffling. Such experiments 
could also be performed in cells derived from ERM knock out mice (Doi et al., 1999; 
Saotome et al., 2004; Tamura et al., 2005) to determine the extent of the contribution 
made by ERM proteins in both processes.
The results of these assays may also indicate the signalling pathway components that 
are important for ERM-dependent membrane ruffling and endocytosis, such as 
whether Gq is required for GPCR-mediated ruffling. Since M l MR but not P2AR 
mediates ruffling in Hep2 cells (Dr. Julie Pitcher, unpublished observations), it 
would be interesting to determine whether other Gq-coupled receptors can promote 
ruffling. Gq activates PLCp following agonist binding to its associated GPCR 
(Cabrera-Vera et al., 2003); GRK2 can sequester and inhibit Gq-mediated 
stimulation of PIP2 hydrolysis by PLCp (Carman et al., 1999a; Sallese et al., 2000b). 
It would therefore also be interesting to investigate the requirement for PIP2 in this 
model of membrane ruffling. This could be achieved by transfecting Hep2 cells 
simultaneously with PLCP2A, a carboxyl-terminal deletion mutant that cannot be 
activated by Gq, and constitutively active Rac2(12V), which stimulates the activity 
of PLCP2A (Illenberger et al., 2003), and ascertaining whether MIMR-mediated 
ruffling occurs in the presence and absence of active GRK2. Considering the results 
described in Chapter 4.4, it is likely that both GRK2 activity and the inhibition of 
PLCp will be necessary for MIMR-mediated membrane ruffling.
Similarly, identifying which GPCRs require ERM proteins for internalisation may 
aid further characterisation of the pathways and proteins involved in ERM-dependent 
GPCR endocytosis. The data presented in this thesis suggest that the role of ezrin in 
GPCR internalisation may be limited to a subset of receptors that includes P2 AR and
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Ml MR, but not M2MR. As discussed earlier, sequestration of receptors such as 
P2AR and Ml MR is characterised by GRK phosphorylation, parrestin binding and 
then endocytosis via clathrin-coated pits, whereas GPCRs such as ETBR and M2MR 
may internalise via caveolae or GRK-independent pathways respectively (Chini and 
Parenti, 2004; Claing et al., 2000; von Zastrow, 2003). It would be interesting to 
determine whether the involvement of ERM proteins with the endocytosis of specific 
GPCRs does indeed correlate with their GRK dependence, and whether other 
components such as parrestin, dynamin, clathrin and GIT are also involved. Once 
the ERM-dependent GPCRs have been identified, the involvement of the above 
proteins in their internalisation can be determined by expression of Parrestinl V53D 
and parrestinl S412D to inhibit parrestin-dependent pathways; transfection of 
dynamin K44A to inhibit dynamin-dependent endocytosis; over-expression of GIT1 
to inhibit GIT-dependent internalisation; and pre-treatment of cells with the clathrin 
cage stabiliser monodansylcadaverine to block clathrin-mediated endocytosis (Claing 
et al., 2000).
Furthermore, the data presented in Chapter 5.4 indicates that ezrin is required for 
P2AR internalisation, but not trafficking to the plasma membrane. However, 
disruption of the interaction of P2AR with NHERF, or NHERF with ERM proteins 
was shown to cause mis-sorting of the usually recycled receptor to lysosomes (Cao et 
al., 1999). Although I have demonstrated that pERM colocalise with internalised 
p2AR that cannot bind NHERF, the role of ERM proteins in GPCR recycling in my 
system should be further examined. Antibody feeding assays prior to flow cytometry 
could be used to analyse the delivery of internalised P2AR back to the plasma 
membrane in HEKp2 cells in both the absence and presence of N- or C-ezrin.
Both membrane ruffling and receptor-mediated endocytosis are complicated cellular 
pathways that require components of the GPCR desensitisation machinery and actin 
cytoskeleton. Although I have shown that GRK2-mediated phosphorylation of ERM 
proteins is required for these processes, further investigation is required to identify 
the ERM binding partners. The preliminary data in Chapters 3 and 5 suggests that 
GRK2 can associate with ezrin. These data need to be confirmed using in vitro pull­
down assays, and other possible binding partners such as GPCRs or Arf6 identified.
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PKC-a has been shown to colocalise with ezrin at plasma membrane protrusions and 
a complex of PKC, ezrin and the transmembrane adhesion molecule CD44 is 
required for cell motility in response to phorbol esters (Legg et al., 2002; Ng et al., 
2001). It is therefore possible that complexes containing ezrin with kinases, possibly 
including GRK2, and transmembrane proteins, such as GPCRs, may be important for 
kinase-mediated, ERM-dependent cytoskeletal reorganisation events. The formation 
of such a complex can be investigated using in vitro binding assays and cellular 
immunoprecipitation assays following M l MR and P2AR activation.
6.8 Concluding remarks
In conclusion, GRK2 has long been considered to have an involvement in signalling 
pathways downstream of GPCRs besides receptor desensitisation. Here I present 
evidence that a non-receptor substrate of GRK2 has an effector function following 
GPCR activation. I show that ezrin is a novel substrate of GRK2, that ERM proteins 
are activated following receptor stimulation, and that GRK2-mediated ERM protein 
phosphorylation is required for GPCR-mediated cytoskeletal rearrangements as well 
as internalisation of a subset of receptors. In recent years |3arrestins, key regulators 
of GPCR signalling, have been shown to have additional roles as scaffold and 
adaptor proteins in pathways downstream of GPCRs (Ahn et al., 2003). Similarly it 
is becoming clear that GRK2, with its growing list of non-receptor substrates, has a 
more diverse role within the cell than previously appreciated.
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